

Contents

Emergency Protocols.....	10
Triage of Sick Children	11
Paediatric Advanced Life Support.....	12
Adult Cardiac Arrest.....	13
Summary of CPR for Adults, Children and Infants.....	14
Emergency Estimation of Child's Weight.....	15
Standard Vital Signs: Percentiles by Age	16
Resuscitation Medications	19
Use of intra-osseous lines.....	20
Malaria.....	21
Complications	22
Medications	22
Uncomplicated Malaria.....	23
Altered Mental Status	24
Neurological Assessment Scales	25
Ingestions, Anaphylaxis and Bites.....	26
Poisoning/Ingestion	27
Suspected acutely poisoned patient	27
Organophosphate/Carbamate (insecticides)	28
Hydrocarbon Ingestion (kerosene, paraffin).....	29
Paracetamol/Acetaminophen Toxicity.....	31

Alcohol Intoxication	33
Alcohol Withdrawal	34
CIWA-Ar Scale.....	35
Anaphylaxis.....	36
Animal Bite.....	37
Suspected Snake bite.....	38
 Paediatric Protocols	40
Convulsions.....	41
Dehydration.....	42
Diarrhoea Adjunctive Treatment.....	43
Treatment of Sepsis and Septic Shock	44
Pneumonia in children aged 2-59 months	45
Diabetic Ketoacidosis	47
Urinary Tract and Kidney Disorders	48
UTI/Pyelonephritis – Work-Up	49
UTI/Pyelonephritis – Treatment	49
Admission of Wheezing Child	51
Bronchiolitis	51
Acute Asthma.....	52
Meningitis	53
Treatment Rx > 1 month old	54

Pediatric Cardiac Protocols	55
Heart Failure	55
Chronic Medications & Dosages	56
Acute Rheumatic Fever (ARF)	57
Sickle Cell Disease	58
Acute Management.....	59
Stroke.....	60
Acute Chest Syndrome	61
Severe Acute Malnutrition in Children.....	62
Nutritional Assessment.....	62
Classification of acute malnutrition.....	62
Criteria for admission	63
Feeding in Severe Acute Malnutrition.....	65
Epistaxis	66
Ear, Nose and Throat Infections	67
Otitis Media	67
Otitis Externa.....	68
Mastoiditis	68
Pharyngitis	69
Sinusitis	69
Evaluation for Cause of Anemia.....	74
Transfusions	75
When to transfuse	75

Pain Management.....	76
Neonatal Infant Pain Score (NIPS)	76
r-FLACC Scale: 2 months to 7 years old	77
Wong-Baker Faces Scale: 4-12 years old	78
How to Score.....	79
 Neonatal Protocols	80
Newborn Feeding/Fluid Requirements	81
Continuous Positive Airway Pressure (CPAP)	83
Neonatal Sepsis Treatment.....	85
Duration of Treatment.....	86
Neonatal Jaundice	87
 Internal Medicine Protocols	92
Heart Failure	93
Heart Failure Treatment.....	94
Symptoms of TIA/Stroke	95
Stroke Protocol.....	96
Sepsis	98
Convulsions.....	100
Meningitis	101
Management.....	102
Upper GI Bleed	103
Hyperglycemia, DKA and HHS.....	104

Hypertensive Urgency and Emergency	105
Hypertension in Specific Conditions	106
General (Essential) Hypertension	106
Liver Failure Algorithm.....	107
Grading Encephalopathy	109
Modified Child-Turcotte-Pugh Score	109
Chronic Management	109
Children	109
Acute Kidney Injury	110
Severely Agitated or Violent Patient	111
Electrocardiography (ECG).....	113
Findings in Supraventricular Arrhythmias	117
Findings of Ischemia	118
Findings in STEMI	118
Findings in NSTEMI	119
Chest Pain.....	120
HEART Score.....	121
TIMI Risk Score	121
Likelihood of Coronary Artery Disease	121
Treatment of Acute Coronary Syndromes/MI	122
STEMI:	122
NSTEMI	123
Supraventricular Tachycardias (SVT)	124

Adult Common Clinical Complaints.....	125
Syncope.....	125
Epigastric Pain	125
Headache.....	125
COPD and Asthma.....	126
Tuberculosis.....	127
Deep Vein Thrombosis (DVT)	129
Pulmonary Embolism (PE)	130
Sexually Transmitted Diseases	131
Opportunistic Infections in HIV	134
Electrolytes: Na+ & K+ Abnormalities	138
Sodium Abnormalities	139
Potassium Abnormalities	141
Essential Medications	144
Abbreviations	159
References	161
Index	173

A WORD OF WARNING: This book was designed as a tool to assist and guide, not as the final decision maker. It should **never** replace your clinical judgement. However, we do want to continue to improve its contents, so if you have any feedback, positive or negative, any suggestions, questions or comments, please email: jgfaulkenberry@gmail.com. Good luck!

Acknowledgements

I would like to thank those that have helped author and edit sections of this book.

Linda Warren, MD: wrote and edited all neonatal protocols, the protocols for paediatric sepsis, bronchiolitis, asthma, triage, convulsions, along with the neonatal drug formulary and assisted in editing all other paediatric protocols, emergency protocols and the formulary.

Twalib Aliku, MD, MMed: wrote and edited all paediatric protocols for cardiac conditions.

Kyegombe Willy, MBChB: wrote and edited the poisoning protocols, assisted in editing all internal medicine protocols.

Anjali Saxena, MD: assisted in writing and editing the Internal Medicine Heart Failure protocol.

Kendra Van Kirk, MD MAT, Samantha Gonzalez, MD, Theodora Brandon, MD: wrote and edited the paediatric ~~Anjali Shxena~~, CPD/advanced life support algorithms.

Stella Kyoyagala, MBChB, MMed: wrote and edited the malnutrition guideline, and assisted in editing paediatric protocols.

Venice Omona, MBChB, MMed: assisted in editing paediatric protocols.

Oriba Dan Langoya, MBChB: assisted in editing paediatric and internal medicine protocols.

Sam Olum, MBChB, MMed: assisted in editing internal medicine protocols.

Adrian Kayanja, MBChB, MMed: assisted in editing internal medicine protocols.

Abigail Link: wrote and edited all drug interactions.

I also need to thank the Emergency Medicine Kenya Foundation. (<https://www.emergencymedicinekenya.org/>). I have cited their book of protocols throughout this text and borrowed heavily from many of their protocols for the ones developed here.

Thanks also to the WHO and ECGpedia from whom I have reproduced with proper permissions and citations (see references section) images from their publications.

Finally, we would like to thank SEED Global Health for funding the printing of the original edition.



Grey Faulkenberry, MD MPH and
Linda Warren, MD 2018
© 2018 by HSWT LLC

Grey's Quick Reference: Basic Protocols in Paediatrics and Internal Medicine For Resource Limited Settings by Grey Faulkenberry and Linda Warren is licensed under a [Creative Commons Attribution-ShareAlike 4.0 International License](#). You are free to share and adapt this material, as long as you give appropriate credit, and distribute under the same license, a copy of this license may be found at <https://creativecommons.org/licenses/by-sa/4.0/>.

Emergency



Protocols

Paediatric Triage of Sick Children¹

Emergency Signs

Airway and Breathing:

- Obstructed breathing
- Central Cyanosis
- Severe respiratory distress
- Weak / absent breathing

Circulation

Cold Hands with any of:

- Cap refill > 3sec
- Weak + fast pulse
- Slow (<60bpm) or absent pulse

1. Call for help
2. Transfer to emergency bed
3. Give oxygen via nasal cannula
4. Start IV
5. Check Vitals (Weight, HR, RR, BP)
6. Draw blood Hb, Malaria, Type&Cross if pale (red and purple tube)
7. D10% 5ml/kg IV
8. If convulsions: Diazepam IV or PR
9. Keep patient warm

Disability:

- Coma
- Convulsions
- Confusion:
AVPU: 'V', 'P' or 'U'

Severe Diarrhoea with:

- lethargy/unconscious
- unable to drink/drink poorly
- skin pinch goes back slowly
- sunken eyes

Priority Signs (3TPR-MOB)


- Tiny - Sick infant aged < 2 months
- Temperature – very high, very low
- Trauma – major trauma
- Pain – child in severe pain
- Poisoning – mother reports poisoning
- Pallor – severe palmar pallor
- Restless / Irritable / Floppy
- Respiratory distress
- Referral – has an urgent referral letter
- Malnutrition - Visible severe wasting
- Oedema of both feet
- Burns – severe burns

Front of the Queue:

- Clinical review ASAP
- Weigh
- Baseline observations and vital signs


Non-urgent – Children with none of the above signs

Paediatric Advanced Life Support Algorithm^{1,2}



Adult Cardiac Arrest Algorithm³

Safe, Stimulate, Shout for Help! – Rapidly move patient to emergency area
(as long as can be safely moved)



High-Quality CPR

- Compression rate** of at least 100/min
- Compression depth** at least 5cm
- Allow complete chest recoil** after each compression
- Minimize interruptions** in chest compressions to < 10 seconds
- Avoid excessive ventilation** – give just enough volume to produce visible chest rise. Give 2 breaths every 30 compressions or if intubated, 1 breath every 6 seconds

Summary of Steps of CPR for Adults, Children and Infants

Component	Recommendations		
	Adults	Children	Infants
Recognition	Unresponsive (for all ages) No breathing or only gasping No pulse felt within 10 seconds		
CPR Sequence	Newborn: HR < 60		
		Chest compressions, Airway, Breathing (C-A-B)	
		Newborn: Airway, Breathing, Compression (A-B-C)	
Compression Rate	At least 100/min		
Compression Depth	At least 5cm	At least 1/3 AP diameter About 5 cm	At least 1/3 AP diameter About 4 cm
Chest wall recoil	Allow complete recoil between compressions Rotate compressors every 2 minutes Newborns: 2-thumb circling technique preferred		
Compression interruptions	Minimize interruptions in chest compressions Attempt to limit interruptions to < 10 seconds		
Airway	Head tilt- chin lift (suspected trauma: jaw thrust) Newborn: position, suction only if secretions		
Compression: Ventilation ratio (until advanced airway placed)	30:2 1 or 2 rescuers	30:2 (Single rescuer) 15:2 (2 rescuers) 3:1 (only for Newborns)	
Rescue breaths (unresponsive with pulse)	1 breath every 3-5 seconds (12-20 breaths per minute) Newborns (30-50 breath/min)		
Ventilations with advanced airway (intubated)	1 breath every 6-8 seconds (8-10 breaths per minute)		

Paediatric Emergency Estimation of Child's Weight

All neonates, infants and children should have weights measured on admission. Estimate the weight for age **ONLY** if unstable. Check weight as soon as child is stabilized. (NOTE: outside weight measurements may be used in emergencies, but should not be used if weight can be safely measured).

Child looks well nourished, average size for age

Age	Estimated Weight (kg)
1 – 3 weeks	3
4 - 7 weeks	4
2 - 3 months	5
4 - 6 months	7
7 to 9 months	9
10 to 12 months	10
1 to 2 yrs	11
2 to 3 yrs	13
3 to 4 yrs	15
4 to 5 yrs	17

If the child looks obviously underweight use the weight associated with 2 age-categories younger (e.g. underweight 10-month-old, use weight of 4-6 months)

Child looks well nourished, average size for age⁴


Height Range (cm)	Estimated Weight Range (kg)
50-64.99	4-6
65-73.99	7-8
74-80.99	9-10
81-94.99	11-12
95-106.99	13-15
107-120.99	16-19
121-132.99	20-24
133-137.99	25-28
138-150.00	29-36

If the child looks obviously underweight use the weight associated with 1 height-category above (e.g. underweight 100cm, use weight 11-12kg)


If there is severe malnutrition these charts will be inaccurate.

Standard Vital Signs: Percentiles by Age^{143,144}


Respirations per minute




Heart rate per minute



1 to 17 years: Girls BP-for-Stature¹⁴⁵⁻¹⁴⁷



1 to 17 years: Boys BP-for-Stature¹⁴⁵⁻¹⁴⁷
Stature (cm)



Resuscitation Medications

Children

Epinephrine (Adrenaline)	0.1ml/kg 1:10,000 IV (mix 1ml of 1:1,000 in 9mls of normal saline) Flush with 10mL NS
Dextrose 10%	5ml/kg IV (mix 8mL normal saline with 2mL D50% or 4mL of D5% with 1mL of D50%)
Diazepam PR ~2.5mg suppository	1) <10kg: 1 supp (DO NOT USE in neonates) 2) 10-15 kg: 2 supp 3) 15-20 kg: 3 supp 4) 20-25 kg: 4 supp
Diazepam IV	0.3mg/kg slowly over 1 minute <u>Loading dose:</u> 15 mg/kg or 20mg/kg in Neonates IM/IV (if IV, give over 20 mins)
Phenobarbitone/ Phenobarbital	<u>Maintenance dose:</u> 5mg/kg IM/IV/PO OD
Packed Red Blood Cells (PRBCs)	10mL/kg (raise Hgb 1g/dL)
Whole Blood (WB)	20mL/kg (raise Hgb 1g/dL)


Adults

Epinephrine (Adrenaline)	1mg IV in 10mL NS Flush with 20mL NS flush
Dextrose	50mL IV of 50% (1 amp)
Diazepam PR 2.5mg suppository	4 suppositories PR
Diazepam IV	0.15 mg/kg IV slowly over 1 minute <u>Loading dose:</u> 15mg/kg IM/IV (if IV, give over 20 mins)
Phenobarbitone/ Phenobarbital/	<u>Maintenance dose:</u> 5mg/kg IM/IV/PO OD
Packed Red Blood Cells (PRBCs)	1 Unit (raise Hgb 1g/dL)
Whole Blood (WB)	2 Units (raise Hgb 1g/dL)

Use of intra-osseous lines¹

Use IO for all children in shock if no IV access to avoid delays in initiation of fluid therapy


- Use IO or bone marrow needle 15-18G if available or 16-21G hypodermic needle
- Clean after identifying landmarks, use sterile gloves and sterilize site
- Sterility - Use antiseptic and sterile gauze to clean site (alcohol 70% or iodine or chlorhexidine)
- Site – Middle of the antero-medial (flat) surface of tibia at junction of upper and middle thirds – bevel to toes and introduce vertically (90°)- advance slowly with rotating movement
- Stop advancing when there is a ‘sudden give’ – then aspirate with 5mls needle
- Slowly inject 3mls N/Saline looking for any leakage under the skin – if OK attach iv fluid giving set and apply dressings and strap down
- Give fluids as needed – a 20mls / 50mls syringe will be needed for boluses
- Watch for leg / calf muscle swelling
- Replace IO access with iv within 8 hours



Malaria

If blood slide is **positive**, treat, if RDT is **negative**, do not treat^{5,6}

Regardless of testing, if patient has signs or symptoms of severe malaria, treat presumptively and test afterwards to confirm



*Severe malaria may also include SBP < 70 with cold, clammy skin, abnormal bleeding/DIC, renal failure (anuria by history, or Cr > 3 mg/dL), macroscopic hemoglobinuria, hyperbilirubinemia ($>3\text{ mg/dL}$) with B/S MPS +++

**This is treatment for all adults and children, including infants, pregnant women in all trimesters and lactating women

Complications

- a) Coma: maintain airway, place patient on side, exclude other causes (hypoglycemia, meningitis)
- b) Hyperpyrexia – tepid sponging, paracetamol
- c) Convulsions: see general convulsion treatment
- d) Acute kidney injury
 - i) Exclude pre-renal causes,
 - ii) Check fluid balance
 - iii) If decreasing urinary output, add Lasix 1mg/kg/dose every 6 to 12 hours, **the most important part of treatment is to maintain a normal urinary output**
- e) Anemia – if Hgb < 9, start on iron and folic acid for 14 days initially
- f) Treatment Failure
 - i) Consider other causes of illness/co-morbidity
 - ii) A child on PO antimalarials that develops signs of severe malaria should be changed to IV artesunate
 - iii) If a child on PO antimalarials has fever and a **positive blood slide** after 3 days (72 hours), then check compliance with Rx and if treatment failure proceed to second line Rx
- g) Delayed haemolysis
 - i) ~7% of children with hyperparasitemia
 - ii) All children with severe malaria should have control CBC 2 weeks after discharge

Co-infection – no good clinical or laboratory finding to differentiate bacterial infection from malaria^{7,8}, and children with current or recent malaria are at higher risk of invasive bacterial infections and have higher mortality rates^{9–13}

- a) Pneumonia – treat if concern for and meet WHO criteria for pneumonia
- b) Septicemia – treat if concern for and meets SIRS criteria
- c) Meningitis – treat if concern for and meets WHO criteria, get LP before beginning antibiotics

Malaria Medications (all parenteral regimens should be followed by 3 days of oral therapy once tolerating PO)

- a) 1st Line: Artesunate^{14,15}
 - i) 3mg/kg for < 20kg, 2.4mg/kg > 20kg IV/IM at 0, 12 and 24 hours
 - ii) Parenteral Rx for at least 24 hours then daily until tolerating PO then
- b) 2nd Line: Artemeter
 - i) 3.2mg/kg IM on admission
 - ii) 1.6mg/kg IM daily until able to take oral medication then
- c) 3rd Line: Quinine
 - i) Loading dose 20mg/kg - **DANGER:** rapid administration is dangerous, mix with 10mL/kg of 5% dextrose & run over 2-4 hours, DO NOT exceed 5mg/kg/hr followed by
 - ii) 10mg/kg (run over 2 hours) every 8 hours followed by
 - iii) If no improvement in 48H, decrease to 10mg/kg every 12 hours

Uncomplicated Malaria

- a) Relevant investigation:
- i) Blood slide (BS) for malaria parasites
 - ii) +/- Haemoglobin estimation

b) Treatment (Treat as outpatient)

-this is the same regimen that complicated malaria should end with
 -treat infants weighing < 5 kg as children weighing 5 kg¹⁵

i) 1st line Antimalarial: Artemether/Lumefantrine (Coartem®)

Weight (kg)	Regimen for 3 days*	Colour code
5-14	1 tab twice a day	Yellow
15-24	2 tabs twice a day	Blue
25-34	3 tabs twice a day	Brown
>35	4 tabs twice a day	Green

*first two doses would ideally be given 8 hours apart

ii) Alternative antimalarial: Artesunate /Amodiaquine

Weight (kg)	Artesunate + amodiaquine dose (mg) given for 3 days	Colour code
4.5 to < 9	25/67.5mg (Blister - 3 tablets) 1 tab daily	Yellow
9 to < 18	50/135mg (Blister - 3 tablets) 1 tab daily	Blue
18 to < 36	100/270mg (Blister - 3 tablets) 1 tab daily	Brown
>36	100/270mg (Blister - 6 tablets) 2 tabs daily	Green

iii) Alternative antimalarial: **Dihydroartemisinin/Piperaquine**

Weight (kg)	Dihydroartemisinin/Piperaquine Dose (mg) daily x 3 days
5 to <8	20/160
8 to < 11	30/240
11 to <17	40/320
17 to <25	60/480
25 to < 36	80/640
36 to < 60	120/960

High fat meals should be avoided with dihydroartemisinin/Piperaquine

Altered Mental Status and the Neurologic Assessment

- I. Monitor, support the ABCs
- II. Look for life-threatening injuries (if signs of head injury, immobilize cervical spine)
- III. Check vital signs (BP, PR, RR, spO₂, Temp, Weight) – Cushing's Triad: bradycardia, respiratory depression & hypertension is an ominous finding
- IV. Physical Exam (done at the same time as history if possible)
 - a. Neurologic Exam
 - i. Brief and to the point
 - ii. Differentiate structural from non-structural causes (usually suggested by focal findings)
 - iii. Assess: Level of consciousness/responsiveness, Motor responses, Brainstem reflexes
 1. Progressive deterioration +/- focal neuro signs or fixed dilated pupils: request emergent surgical consult
 2. Perform Neurological Assessment Scales (AVPU, BCS or GCS – see next page)
 3. Meningismus / Nuchal Rigidity (meningitis, subarachnoid hemorrhage)
 - a. Brudzinski's sign - Involuntary hip & knee flexion with forced neck flexion
 - b. Kernig's sign - involuntary knee flexion with forced flexion of the hip
 4. Fundoscopy
 - a. Papilledema suggests increased ICP of more than several hours duration.
 - b. Retinal hemorrhages in an infant are a sign of non-accidental trauma
 - c. Unilateral, fixed, dilated pupil: 3rd nerve compression
 - d. Bilateral, fixed, dilated pupils: brainstem pathology
 - e. Bilateral small pupils: opioids, organophosphates, pontine hemorrhage
 - b. Skin exam: bruising may suggest trauma, rashes may suggest infection
 - c. Always consider: anemia, dehydration or malnutrition in children

NEVER assume mental status change is due solely to intoxication until alternatives have been ruled out

History

I. AMPLE History

Allergies

Medications

Past medical history

Last meal

Event – circumstances surrounding, what happened?

- Rapid or gradual?
- Preceding symptoms, neuro, headache?
- Ingestions
- Vague/inconsistent history – non-accidental trauma?

Neurological Assessment Scales

I. AVPU

- A – Alert
- V – responds to Verbal commands
- P – responds to Painful stimulus (press down firmly on the middle fingernail with a pen, rub your knuckles on the sternum)
- U – Unconscious

II. Blantyre Coma Scale (BCS) - if pre-verbal

Best Motor Response	Best Verbal Response	Best Eye Movement	Points
Localizes pain	Cries normally to pain		2
Withdraws from pain	Moans or abnl cry to pain	Watches/follows	1
None or inappropriate	No verbal response	No eye movement	0

III. Glasgow Coma Scale (GCS)

Best Motor Response	Best Verbal Response	Eye Opening	Points
Follows commands			6
Localizes pain	Oriented		5
Withdraws from pain	Confused	Spontaneous	4
Flexor posturing	Inappropriate words	To voice	3
Extensor posturing	Unintelligible sounds	To painful stimuli	2
None	None	None	1

COMA: GCS \leq 8 or BCS \leq 2 – should generally be intubated for airway protection

Ingestions



Anaphylaxis

And Bites

Poisoning/Ingestion Algorithm³

Suspected acutely poisoned patient⁷⁹

1. If ANY concern for residue on skin or clothing – use personal protective equipment (gloves, gowns, masks), remove/bag/discard clothing, wash patient/area thoroughly with soap and water (clothing and PPE hazardous waste, dispose properly)
2. Monitor and support ABCD
3. Check vital signs (BP, PR, RR, sp02, Temp)
4. If sp02 < 94% or ANY concern for respiration, start 100% O2 via facemask
5. Bedside RBS and treat hypoglycemia
6. Place large bore IV line
7. Perform brief, targeted history, physical exam, pay attention to mental status
 - a. What was taken, how long ago, volume/how much, immediate effects
8. Beware occult trauma
9. Obtain labs: CBC, Renal Functions, Electrolytes, Liver Functions
10. 12-lead ECG
11. Seizures are a neurological emergency and should be treated promptly with diazepam.
12. Gastric Lavage: almost NEVER INDICATED⁸⁰⁻⁸⁶
13. Indications for ICU Admission
 - a. Need for ETT and Mechanical Ventilation
 - b. GCS<12/AVPU=U/ status epilepticus
 - c. Toxins with potential of respiratory depression (e.g. Amitraz Poisoning)
 - d. Acid base imbalances
 - e. Unclear/unpredictable clinical course of poisoning (i.e. Poorly studied)
14. Common Toxicodromes and Antidotes:
 - a. See specific protocol for: Organophosphates/Carbamates/Cholinergics, Hydrocarbons/Paraffin/Kerosene, Benzodiazepines/Opiates, Paracetamol, Ethanol
 - b. Adrenergic/Sympathomimetics
 - i. Cocaine, Amphetamines (crystal meth, Adderall), Pseudoephedrine
 - ii. Presentation: HTN, tachycardia, mydriasis, anxiety, delirium, delusions
 - iii. Rx: supportive (IVF, benzodiazepines, ant-hypertensives)
 - c. Anticholinergic/Tricyclic antidepressants (TCA)/antihistamines
 - i. Presentation: Hyperpyrexia, cutaneous vasodilation (flushing), decreased saliva, mydriasis, urinary retention, dysrhythmias
 - ii. Rx:
 1. Physostigmine – avoid in TCA, only if persistent tachyarrhythmias or convulsions. Call anesthetist prior to administering.
 2. NaHCO3 for TCA
 - d. Methanol
 - i. Presentation: delirium, loss of vision
 - ii. Rx: oral by NGT 1.8ml/kg of 43% ethanol or 40ml shots of vodka in a 70kg, maintenance is 0.2-0.4mls/kg/hour of 43% ethanol.

Organophosphate/Carbamate (insecticides/nerve gas)^{87,88}

Children: common accidental ingestion¹⁸²⁻¹⁸⁶

Adults: common purposeful ingestion¹⁸⁷

Diagnosis is on a Clinical Basis

Presentation (SLUDGE-BBB):

Salivation
Lacrimation
Urination
Diarrhoea
Gastric cramping
Emesis

Bronchorrhea
Bronchospasm
Bradycardia

Also; profuse sweating,
convulsions and coma,
fasciculations, constricted pupils

Treatment: Atropine Bolus

Children: 0.02mg/kg IV

Adults: 2mg IV

Double previous dose and repeat every 5 minutes until atropinisation^{88,188}

- Pulmonary secretions dry
 - Improved oxygenation
 - Breathing easier
- Pulse > 80/min
- SBP > 80mm/Hg

Convulsions: Rx Diazepam

Children

- 1) Rectal Diazepam 2.5mg suppository
 - a) <10kg 1 suppository
 - b) 10-15 kg: 2 suppositories
 - c) 15-20 kg: 3 suppositories
 - d) 20-25 kg: 4 suppositories
- 2) IV diazepam 0.2mg/kg

Adults: 10mg IV

Repeat as necessary if convulsions occur

Maintenance after atropinisation:


- mix total amount of atropine used as boluses into NS or D5%, in the following volumes
- For Patients <25kg: use 250mL, run at 50mL/hr
- For Patients >25kg: use 500mL, run at 100mL/hr
- Monitor hourly for signs of recurrent symptoms or over atropinization, and adjust rate accordingly

Over atropinization

- Urinary retention
- Confusion/Delirium
- Hyperthermia

Hydrocarbon Ingestion (kerosene, paraffin)

- More likely in children
- Often asymptomatic presentation
- Kerosene/aliphatic hydrocarbons – Petroleum distillate odor



Benzodiazepine/Opioid Ingestion

Symptoms Generally Associated With	Opioids	Benzos
Anterograde Amnesia	✓	✓✓✓
Ataxia/ incoordination	✓	✓✓✓
Slurred Speech	✓	✓✓✓
Confusion	✓	✓✓✓
Stupor Coma	✓✓✓	✓
Respiratory Depression	✓✓✓	✓
Miosis	✓✓✓	✓
Nausea/Vomiting	✓✓✓	✓

Known or More Likely Opioid Overdose

Known or More Likely Benzodiazepine Overdose

Respirations < 12/min
O₂sat < 90%

No

Yes

Bag-valve Mask
Naloxone

- Children <5yo or < 20kg: 0.1mg/kg IV
- Children > 5yo or > 20kg: 2mg IV
- Adults: 0.4mg IV
- May repeat q2-3 minutes for response
- After reversal may need to repeat 20-60 minutes later
- Admit to ICU

- If respiratory depression: Flumazenil
- Children: 0.01mg/kg IV, max as per adult
- Adults: 0.2 mg IV, may repeat for effect (max 1mg), max 3mg/hour
- Generally lasts ~1 hour, may need repeat dosing

- Supportive Care
- Pay Specific Attention to Respiratory Status
- Duration depends on agent ingested

Paracetamol/Acetaminophen Toxicity

I. Populations

- a. Children: usually accidental ingestion
- b. Older Children/Adolescents/Adults: more likely purposeful ingestion

II. Inappropriate dosing from:

- a. Adult doses given to children
- b. Unclear understanding of liquid dosages
- c. Additional doses when parents feel first dose wasn't effective
- d. Consuming multiple products containing acetaminophen (Tylenol, Panadol, acetaminophen, paracetamol, cough/cold medications - Pyridex, antacids, headache medications)

III. Risk Factors:

- a. <2 years & dose of 90mg/kg/day acetaminophen or multiple adult doses
- b. Chronic alcohol abuse
- c. Co-ingestion with: rifampin, isoniazid, co-trimoxazole, zidovudine, barbiturates, carbamazepine)
- d. Comorbid conditions: prolonged fasting, prolonged vomiting/diarrhea, eating disorders, malnutrition, malignancy, HIV/AIDS

IV. Phases⁸⁹⁻⁹²

- a. Phase 1: ≤ 24-hours after ingestion
 - i. Nonspecific sxs: nausea, vomiting, abdominal pain, anorexia, lethargy, diaphoresis, and malaise
- b. Phase 2: 24-72 hours after ingestion
 - i. Increased hepatotoxic risk if presenting > 24 hrs after ingestion
 - ii. Sxs may improve or disappear
 - iii. Lab abnormalities appear: ↑AST, ALT, bilirubin, PT/INR
 - iv. Possible RUQ pain or hepatomegaly
- c. Phase 3: 72-96 hours after ingestion
 - i. Death of hepatocytes and timing of peak liver injury
 - ii. Nausea and vomiting reappear or worsen
 - iii. Malaise, jaundice, coagulopathy, encephalopathy, & CNS symptoms (for example, confusion, somnolence, coma) may also be present
- d. Phase 4: 96 hours-14 days after ingestion
 - i. May start improving, full recovery within 3 mos
 - ii. May progress to multiorgan failure & death

V. Mental status typically normal in first 48 hrs after overdose, unless affected by co-ingestion

VI. Possibly Toxic Dosages⁹³

0-6 years


>6 years

Acute Single $\geq 200\text{mg/kg}$ in < 8 hrs $\geq 10\text{g}$ or 200mg/kg (whichever is lower) in < 8 hrs
Ingestion

Repeated $\geq 200\text{mg/kg}$ in < 24 hrs $\geq 10\text{g}$ or 200mg/kg (whichever is lower) in < 24 hrs
Supratherapeutic $\geq 150\text{mg/kg/day} \times 48\text{hrs}$

Ingestion (RTSI) $\geq 100\text{mg/kg/day} \times 72\text{ hrs}$ $\geq 6\text{g}$ or 150mg/kg (whichever is lower) per day $\times 48\text{ hrs}$
 $\geq 4\text{g/day}$ or 100mg/kg (whichever is less) with above risk factor

Paracetamol/Acetaminophen Toxicity Management⁹⁴



N-acetylcysteine (NAC) Proper Dosing^{89,*,+:}

Wt	Loading Dose	Maintenance Dose 1	Maintenance Dose 2
<20kg	150mg/kg into 3mL/kg diluent over 1 hr	50mg/kg in 7mL/kg diluent over 4 hrs	100mg/kg in 14mL/kg diluent over 16 hrs
20-40kg	150mg/kg into 100mL diluent over 1 hr	50mg/kg into 250mL diluent over 4 hrs	100mg/kg into 500mL diluent over 16 hrs
>40kg	150mL/kg in 200mL diluent over 1 hr	50mg/kg into 500mL diluent over 4 hrs	100mg/kg into 1L diluent over 16 hrs

*diluent may be DW, ½NS or sterile water, +if wt > 100kg, Rx as per 100kg

Alcohol Intoxication

Always ensure no other causes of alteration before attributing symptoms solely to alcohol (especially trauma or other ingestion)

Diagnostic Criteria for Acute Alcohol Intoxication¹⁹¹

1. Recent alcohol ingestion
2. Maladaptive behavior or psychological changes
 - a. Sexual or aggressive behavior
 - b. Unstable mood
 - c. Impaired judgement
 - d. Impaired social or occupational functioning
3. ≥ 1 of the following during/shortly after ingestion

Slurred speech	Stupor/coma
Unsteady gait	Nystagmus
Lack of Coordination	Impaired attention/memory
Symptoms not caused by other medical conditions or mental disorders	

Management²⁷

1. Monitor, support ABCs
2. Check vital signs (BP, PR, RR, spO₂, Temp, Weight)
3. Assess GCS, hydration status
4. Insert 2 IVs, Start Oxygen if spO₂ < 94%

4. Management
 - a. Lateral position
 - b. Monitor for vomiting/aspiration
 - c. IV hydration if necessary

Concern for more than solely alcohol intoxication?

- Follow altered mental status protocol
- Consider tests for disorders related to alcohol or with a similar presentation
 - Glucose
 - BMP
 - Magnesium
 - Lipase
 - Liver functions

Alcohol Withdrawal


Occurs when a patient stops drinking alcohol after a period of drinking large amounts over a prolonged time

A. Stages (not all patients have all stages, stages may not go in order)

1. Stage 1 – minor symptoms
 - a. 6-12 hours after stopping
 - b. Tremors, agitation, lack of appetite, nausea, vomiting, anxiety, sweating, restlessness
2. Stage 2 – alcoholic hallucinosis
 - a. 12-24 hours after stopping
 - b. Hallucinations may occur
3. Stage 3 – withdrawal seizures
 - a. 24-48 hours after stopping (occasionally sooner)
 - b. Usually tonic-clonic
4. Stage 4 – delirium tremens
 - a. 3-7 days after stopping (up to 14 days after)
 - b. Hallucinations (usually visual), confusion, tachycardia, hypertension, agitation, sweating

Management of Alcohol Withdrawal²⁷

1. Monitor, support ABCs
2. Check vital signs (BP, PR, RR, spO₂, Temp, Weight)
3. Assess GCS, hydration status
4. Insert 2 IVs, Start Oxygen if spO₂ < 94%



CIWA-Ar Scale

HEADACHE	TREMOR
0. not present	0. no tremor
1. very mild	1. not visible, can be felt at fingertips
2. mild	2.
3. moderate	3.
4. moderately severe	4. Moderate when arms extended
5. severe	5.
6. very severe	6.
7. extremely severe	7. severe, even without arms extended
NAUSEA AND VOMITING	ANXIETY
0. no nausea and no vomiting	0. no anxiety, at ease
1.	1.
2.	2.
3.	3.
4. intermittent nausea w/ dry heaves	4. moderately anxious, or guarded
5.	5.
6.	6.
7. constant nausea, frequent dry heaves and vomiting	7. acute panic states similar to severe delirium or acute schizophrenia
PAROXYSMAL SWEATS	ORIENTATION AND CLOUDING OF SENSORIUM
0. no sweat visible	0. oriented and can do serial additions (add by 7s)
1. barely sweating, palms moist	1. cannot do serial additions
2.	2. disoriented for date by \leq 2 calendar days
3.	3. disoriented for date by $>$ 2 days
4. Obvious sweat on forehead	4. disoriented for place and/or person
5.	
6.	
7. Drenching sweats	
AGITATION	AUDITORY DISTURBANCES
0. normal activity	0. not present
1. more than normal activity	1. very mild harshness/ability to frighten
2.	2. mild harshness or ability to frighten
3.	3. moderate harshness/ability to frighten
4. moderately fidgety and restless	4. moderately severe hallucinations
5.	5. severe hallucinations
6.	6. extremely severe hallucinations
7. constantly paces or thrashes about	7. continuous hallucinations
TACTILE DISTURBANCES	VISUAL DISTURBANCES
0. none	0. not present
1. very mild paresthesias	1. very mild photosensitivity
2. mild paresthesias	2. mild photosensitivity
3. moderate paresthesias	3. moderate photosensitivity
4. moderately severe hallucinations	4. moderately severe visual hallucinations
5. severe hallucinations	5. severe visual hallucinations
6. extremely severe hallucinations	6. extremely severe visual hallucinations
7. continuous hallucinations	7. continuous visual hallucinations

Anaphylaxis

I. Common Symptoms

- 1) Mucocutaneous: angioedema, hives, pruritis, flushing
- 2) Respiratory: dyspnea, wheezing, stridor, hypoxia
- 3) GI: nausea/vomiting/diarrhea/abdominal cramping
- 4) End-organ dysfunction: syncope, hypotonia

Criteria 1: Acute skin/mucosal tissue signs + 1 of the following: Respiratory compromise, Hypotension, OR Signs of end-organ dysfunction)

Criteria 2: Rapid onset after likely antigen exposure of 2 of the following: Mucocutaneous signs, Respiratory symptoms, Hypotension, OR GI symptoms

Any of the 3 criteria

Epinephrine (1mg/1ml 1:1000)
0.01mL/kg (max dose 0.3mL)
IM anterolateral thigh
Repeat q5-15 minutes if no improvement

Criteria 3: Hypotension after exposure to known allergen

- Adults SBP < 90
- Children age 11-17: SBP < 90
- Children age 1-10: SBP < (70 + [age x 2])
- Children age 1 month to 1 year: SBP < 70
- Term neonate: SBP < 60

1. Monitor, support ABCs
2. Check vital signs (BP, PR, RR, spO₂, Temp, Weight)
3. Assess GCS, hydration status
4. Insert 2 IVs, Start Oxygen if spO₂ < 94%
5. Draw CBC, malaria, and blood glucose

Wheezing and/or shortness of breath?

Treat as asthma exacerbation

Hypotension?

I. NS or RL

- a. Children: 30mL/kg in first hour
 - b. Adults: 1-2L, 5-10mL/kg in first 5 min
- II. May try recumbent positioning or vasopressors prn

I. Antihistamines

- a. H1 receptor blocker: Diphenhydramine 1mg/kg IV or PO, max dose 50mg or
- b. H2 receptor blocker: Ranitidine 1mg/kg IM/slow IV (max 50mg) or 4mg/kg PO (max 150mg)

II. Steroids: Hydrocortisone 5mg/kg IM/slow IV (max 200mg)

Adjunctive treatment

Animal Bite³

I. Mammalian Bites (not human)

- a. Clean wound with soap and water
- b. Debridement of devitalized tissue
- c. Prophylactic antibiotics are controversial, but generally recommended in the following cases
 - Immunocompromised patients
 - Asplenic patients
 - Advanced liver disease
 - Moderate-severe injury or Crush Injury
 - Oedema at bite site
 - Injuries near hand, close to other bones/joints, especially if penetrating the joint capsule or periosteum

II. Human Bites

- a. Clean wound with soap and water
- b. Debridement of devitalized tissue
- c. All human bites should receive prophylactic antibiotics
- d. Consider post-exposure prophylaxis for HIV, usually low risk, but higher if saliva is contaminated with blood
- e. Hepatitis B vaccine recommended \leq 24 hrs after bite if not previously immunized

III. Prophylactic Treatment

- a. Amoxicillin-Clavulanate x 5 days
 - Pediatric: 25mg/kg/dose PO BD
 - Adult: 1gram PO BD
- b. Alternative: Ciprofloxacin, Azithromycin or Doxycycline
- c. Tetanus

Previous doses of Tetanus Toxoid	Clean and minor wound		All other wounds	
	Tetanus Toxoid	Human tetanus immune globulin	Tetanus Toxoid	Human tetanus immune globulin
< 3 doses or unknown	Yes	No	Yes	Yes
\geq 3 doses	Only if last dose given \geq 10 yrs ago	No	Only if last dose given \geq 5 yrs ago	No

- d. Rabies – assuming not previously vaccinated

Biologic	Schedule
Rabies Immunoglobulin	Total dose: 20 units/kg. Inject as much as possible around the wound, give the rest IM.
Vaccine	Human Ig 20U/kg OR Equine Ig 40U/kg IM (deltoid or anterolateral thigh area), inject once on days 0, 3, 7 and 14*

Suspected Snake bite⁹⁵

Management²⁷

Monitor, support ABCs

Check vital signs (BP, PR, RR, spO₂, Temp)

Start Oxygen if spO₂ < 94%

Perform brief, targeted history, physical exam

↓
Immobilize body part

- DO NOT apply tourniquet
- DO NOT incise wound
- DO NOT administer antivenom outside of hospital
- DO NOTE treat with ice

Consider the follow labs

- CBC, CMP, PT/INR, PTT, FDP/d-dimer, CPK
- Swab bite area, Snake Venom Detection Kit (SVDK) to be used if available and clinical/lab evidence for envenoming

Physical Exam⁹⁵

- Airway – check for hypersalivation and ability to clear secretions
- Breathing – watch for respiratory muscle weakness
- Bleeding – monitor for unusual bleeding (haematuria/oozing from wounds)
- Neuro – full exam including cranial nerves
- Neurovascular status of limb, swelling, necrosis

No skin marks

No symptoms an hour post-bite
Discharge
Instruct to return if symptoms develop

Has envenomation occurred?

No

Suspected

Skin marks BUT no symptoms

- Admit overnight for observation
- Elevate effected limb
- If no new symptoms, discharge next day

Obvious Bite Marks and/or Symptomatic
What Type of Envenomation Syndrome? ^{3,95}
Severe enough to warrant antivenom?

No

Yes

Administration

-Dilute antivenom in NS (no more than 20mL/500mL bag), give slowly over 30 mins or no more than 1-2mL/min

-Polyvalent: titrate to symptoms, assess q30min

-Monovalent: monitor hematologic response, repeat dose if needed

-Epinephrine ready in case of anaphylaxis: Epinephrine (1mg/1ml 1:1000), 0.01mL/kg (max dose 0.3mL), IM anterolateral thigh, Repeat q5-15 minutes if no improvement

-Antihistamine: have available, not routinely recommended

-Monitor Vital Signs

-Never run medications directly into effected limb

Types of Envenomation^{3,95}

I. Neurotoxic

- a. Symptoms: Weakness, paresthesia, ptosis, diplopia, mydriasis, problems swallowing, excessive salivation, difficulty breathing, paralysis and respiratory failure paralysis
- b. Treatment
 - IV placement
 - Monitor oxygenation and breathing
 - Intubation & mechanical ventilation if necessary
- c. Indications for Antivenom (the triad of)
 1. Paraesthesia
 2. Excessive salivation/metallic taste & sweating
 3. Dyspnea in the absence of painful, progressive swelling OR Paresis in the presence of significant swelling
- d. Treatment: Polyvalent Antivenom

II. Cytotoxic

- a. Symptoms: Severe pain, bruising/swelling at site, blisters, severe tissue necrosis, abscess, compartment syndrome, hypotension, shock, rhabdomyolysis, renal failure
- b. Treatment
 - IV placement
 - Analgesia
 - Place limb at heart level
 - IVF for shock/renal failure
 - Supportive care
- c. Indications for Antivenom
 - Progressive swelling $\geq 15\text{cm/hr}$
 - Swelling extending from foot/hand to knee/elbow in 4 hours
 - Entire limb swelling by 8 hours
 - Airway swelling
 - Associated coagulopathy
- d. Treatment: Polyvalent Antivenom

III. Haemotoxic

- a. Symptoms: Bleeding at wound sites (may be minor wounds, lacerations, or puncture sites), Ecchymoses, Haematuria, Renal Failure, DIC
- b. Treatment
 - IV access
 - Blood products as necessary
 - DO NOT give heparin, antifibrinolytics, thrombolytics
- c. Indications for Antivenom
 - Active bleeding
 - Non-clotting blood in clean test tube after 20 minutes
 - Lab evidence of coagulopathy
- d. Treatment: Monovalent Antivenom


Paediatric



Protocols

Treatment of Paediatric convulsions^{1,16}

Convulsions in the 1st month of life should be treated with Phenobarbitone 20mg/kg stat, a further 5-10mg/kg can be given within 24 hrs of the loading dose, maintenance dose is 5mg/kg daily. Do not give Diazepam to neonates.



Paediatric Dehydration Protocol

(EXCLUDING severe malnutrition)^{1,16,17}

> 2 months old with History of diarrhoea/vomiting

CHECK for SHOCK.

All four of

- AVPU < A
- Capillary refill > 3 secs
- Cold hands + Temp gradient
- Weak / absent pulse

If Hb<5g/dl transfuse urgently

Yes

- Ringers 20mls/kg over 15 minutes.
- A second bolus may be given if required before proceeding to PLAN C STEP 2 below
- Treat for hypoglycaemia
- Start ORS 5 mls/kg/hr once able to drink

No

Severe Dehydration (PLAN C)^{149,150}

> 2 of the following signs:

- AVPU < A
- Capillary refill >= 2 seconds
- Unable to drink
- Sunken eyes
- Slow skin pinch >= 2 seconds
- Absent tears AND dry mucus membranes

Yes

PLAN C

STEP 1

- Ringers 30mls/kg over
 - >12 months: 30 minutes
 - < 12 months: 60 minutes
- If no IV access or IVF

STEP 2

- Ringers 70mls/kg over
 - >12 months: 2.5 hours
 - < 12 months: 5 hours
- If no IV access or IVF, use NGT rehydration 100ml/kg ORS
- Reassess Hourly
- After 3-6 hours, reclassify level of dehydration

No

Some Dehydration (PLAN B)

Able to drink but 2 or more of the following signs:

- Restlessness/Irritability
- Sunken eyes
- Slow skin pinch 1-2 seconds
- Dry tongue
- Decreased Tears

Yes

PLAN B

- 1) ORS PO at 75mls/kg over 4 hours
- 2) Continue breast feeding and/or encourage feeding if > 6 months

No

No Significant Dehydration (PLAN A)

Diarrhoea/GE with fewer than 2 of the above signs of

Yes

PLAN A

- 1) ORS PO at 10mls/kg after each loose
- 2) Continue breast feeding and/or encourage feeding if > 6 months

I. Diarrhoea Adjunctive Rx:

- a. All cases to receive Zinc 10-20mg/day x 10-14 days
- b. Diarrhoea > 14 days may be complicated by ORS intolerance (worsening diarrhoea) – if seen, change to IV regimens
- c. Antibiotics ONLY if bloody diarrhoea (dysentery)^{16,18}
 - i. First line: Ciprofloxacin 15mg/kg/dose BD x 3-5 days
 - ii. Second line (or severely ill): Ceftriaxone 50-80mg/kg/day x 3-5 days
 - iii. Alternative: Azithromycin 15mg/kg PO on day 1 then 10mg/kg PO OD days 2-5
 - iv. DO NOT USE: aminoglycosides, amoxicillin, ampicillin, chloramphenicol, cotrimoxazole, 1st or 2nd gen cephalosporins, nalidixic acid, nitrofurans, or tetracycline due to resistance
- d. Antibiotics/Antiprotzozoals ONLY if persistent diarrhoea AND
 - i. proven amoebiasis: Paramomycin, diloxanide, iodoquinol
 - ii. proven giardiasis: Tinidazole, Metronidazole, Nitazoxanide (also albendazole, mebendazole, paramomycin)


Paediatric Treatment of Sepsis and Septic Shock

Sepsis Definition: SIRS criteria + proven or suspected infection¹⁹⁻²²

SIRS Definition: >= 2 of the following abnormal measurements (one must be Temperature or WBC):

Temperature > 37.9 axillary (38.5 core) or < 35.4 axillary (36 axillary)

Age Group	Heart Rate (Beats/Min) ^{21, 23,24}	Respiratory rate (Breaths/ Min) ^{21,23,25}	Leukocyte Count, (leukocytes x $10^3/\text{mm}^3$) ²⁰	SBP (mmHg)
0-1 week	>180/190 (or <100)	>60	>34	<65
1 wk-1mo			>19.5 or <5	<70
1mo – 1 yr	>180 (or <90)	>50	>17.5 or <5	<75
1 – 5 yrs	>140	>40	>15.5 or <6	<74
5 – 10 yrs	>130	>30	>13.5 or <4.5	<83
> 10 yrs	>110	>30	>11 or <4.5	<90



Labs: MRDT, RBS, CBC with diff, Blood Culture

Other Tests: Urinalysis, Urine Culture, electrolytes/Urea/Cr/Calcium, LFTs (AST/ALT [GOT/GPT]/Bili), CSF if indicated, CXR, serologic tests for infections

Ampicillin: 50mg/kg/dose IV/IM

First week of life: every 12 hours

Weeks 2-4: every 8 hours

Over 4 weeks: every 6 hours

Gentamicin:

Low Birth Wt: 3mg/kg IM/IV OD

Nrml Birth Wt & > 1 week of age


(normal renal function): 5mg/kg/OD

IM/IV

Ceftriaxone: 1gm/10mL 100mg/kg/OD IV (can give 50mg/kg/12hrs)

Paediatric Pneumonia protocol for children aged 2-59 months^{1,16}


(refer to HIV exposed/infected, TB, neonatology or Sickle Cell for special cases)



Pediatric Hyperglycemia (RBS > 14mmol/L)^{26,27}

History: Polyuria, Polydipsia, Weight loss, Abdominal pain, Tiredness, Vomiting, Confusion

Clinical findings: deep sighing/Kussmaul respirations, smell of ketones, lethargy, vomiting



Pediatric Diabetic Ketoacidosis

Diabetic Ketoacidosis: Identify and treat precipitating illness, consider: sepsis, pneumonia, gastroenteritis

Fluid Protocol:

Total fluid replacement =
80mL/kg - + 2*maintenance – initial bolus

1. Initial bolus

- Hypovolemic Shock: 10-20mL/kg NS or RL bolus, repeat until BP improves
- Hypovolemic but no Shock: 10-20mL/kg of NS or RL over 1st hr
- DO NOT** give > 40mL/kg in first 4hrs, can cause cerebral edema

2. Replacement fluids: correct the remaining deficit over 48 hours

3. Satisfactory urine output 1-2mL/hr

NEVER alternate D10 & NS/RL
this can cause brain oedema

Insulin Protocol: Start after 1-hour IVF

Soluble Regular Insulin Injection
▪ SC 0.15 IU/kg every 2 hours

Potassium Protocol:

Add 10mEq KCl/500mL bag

DO NOT give potassium if urine output < 1mL/kg/hr (or K > 5.5)

Monitor Neuro Status for:

headache, slowing HR, irritability, incontinence, decreased conscious, focal signs
If any of the above: check/correct hypoglycemia

Not hypoglycemic

Call Senior if neuro changes and concern for increased ICP
Transfer to ICU
Mannitol 0.5-1g/kg or hypertonic saline

When RBS < 14 or RBS drops rapidly, repeat urinalysis

Urine still with ketones

- Keep NPO
- Change IVF to D5 NS/RL
- (50mL D50 + 450mL NS/RL)
- Continue Insulin Regimen until RBS < 14
- Recheck urine for ketones every 4 hours

Urine without ketones

Urine without ketones

- If patient can drink, stop IVF, otherwise continue replacement/maintenance
- Patient is allowed to eat
- Switch to SC Insulin Usual dose: 0.5-1 IU/kg/day
 - Regular sliding scale every 6 hours
 - Mixtard BD (70% AM, 30% PM) 30 minutes before meals

Urinary Tract and Kidney Disorders in Children²⁸

Most Common Presenting Symptoms:

1. Fever
2. Dysuria, frequency, nocturia
3. Abdominal pain/discomfort
4. Hematuria (bloody, dark, tea-colored urine)
5. Oliguria/Anuria
6. Swelling – face and extremities

3-24 months: Fever present?
Verbal child: dysuria, frequency, nocturia, or abdominal symptoms?

Go To Urinary Tract Infection and Pyelonephritis Algorithm

Obtain bedside urine dipstick,

are any of the following present?

1. Hematuria (gross or microscopic)
2. Proteinuria
3. Oliguria/anuria
4. Edema

No

Consider other causes

Yes

Obtain:

1. Renal Functions
2. Electrolytes (Na⁺, K⁺, Cl⁻)
3. Albumin, Protein
4. CBC

Evaluate and Treat other factors:

1. Malaria
2. Sepsis
3. Dehydration
4. Heart Failure
5. Malnutrition

Are all of the following present?

1. Proteinuria
2. Edema
3. Hypoalbuminemia
4. No other diagnosis or history of gross hematuria, or increased Cr

No


Supportive Care:

1. Oliguria/Anuria: **MOST IMPORTANT** if urine output drops (after correcting any prerenal causes), start Lasix 1mg/kg IV/dose BD, and consider IV hydration (1/2-2/3 MIVF, watch for fluid overload)*
2. Hypertension (> 95%¹⁵¹): (if not controlled with Lasix¹⁵²) Amlodipine 2.5mg OD-BD
3. Edema: Lasix 1mg/kg/dose IV OD-BD
4. Monitor UOP/Volume status: may need to place foley catheter (goal UOP: 1mL/kg/hr)
5. Hx of pharyngitis/skin infection: consider Penicillin V 250mg TID for strep eradication
6. Treat infections (avoid gentamicin, ibuprofen, and other nephrotoxic drugs)
7. Treat malaria (consider confirming eradication with control RDT&B/S)

Yes
Treat as Nephrotic Syndrome:
Prednisone
2mg/kg/day x 4 weeks
(will require taper)

REMEMBER: may be intravascularly depleted even with edema

Urinary Tract Infection/Pyelonephritis in Children – Work-Up



Urinary Tract Infection/Pyelonephritis in Children – Treatment

Treatment for lower UTI (7 day course)²⁹

Outpatient treatment (for those non-toxic and able to tolerate):

Nitrofurantoin 6mg/kg PO divided every 6 hours²⁶ (not if < 1 year old)

Amoxicillin/Ampicillin-Clavulanate 50mg/kg PO divided every 12 hours^{16,26,30,31}

Treat for upper UTI (Pyelonephritis) if the following are present:

- I. < 2 years³²
 - a. Age <2 months
 - b. Clinical urosepsis (e.g. toxic appearance, hypotension, poor capillary refill)
 - c. Immunocompromised patient
 - d. Vomiting or inability to tolerate oral medication
 - e. Lack of adequate outpatient follow-up (e.g. no telephone, live far from hospital)
 - f. Failure to respond to outpatient therapy
- II. > 2 years, at least 2 of the following³³: Fever, Chills, Flank Pain

Pyelonephritis Treatment (7-14 days):

Inpatient treatment, Labs: CBC, renal fxn (Bld Cx if concern for sepsis)

IV antibiotics for 48-72 hours until clinical improvement, then switch to PO

Cefotaxime 150mg/kg/day IV/IM divided every 8 hours^{30,34}

Ceftriaxone 75mg/kg IV/IM daily^{30,31}

Ampicillin 50mg/kg IV/IM every 6 hours¹⁶

IV hydration if unable to tolerate PO, monitor urine output

Imaging²⁹

- I. Renal/Bladder Ultrasound: all febrile infants with UTI, within 48 hours if severe, otherwise after resolution of acute illness
- II. VCUG³⁵ for any of: abnormalities on ultrasound, recurrent febrile UTI, Temp > 38 axillary AND a pathogen other than E. Coli, failure to thrive or hypertension

Admission of Wheezing Child^{1,16}

Wheeze + history of cough or difficult breathing:

Likely Bronchiolitis: < 2 year, febrile, crackles

Likely Asthma if: > 2 years, hx of recurrent wheeze, or family atopic hx

DO NOT USE antibiotics for either of the above unless patient ALSO has pneumonia, see pneumonia pathway for guideline

Bronchiolitis Management

- Monitor, support ABCs
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Assess AVPU/GCS, hydration status
- Start Oxygen if spO₂ < 94%, insert IV if needed
- Perform brief, targeted history, physical exam

Consider CBC, CXR in premature
<12 weeks, CHD, immunodeficiency
and chronic neurological disease

Severe Bronchiolitis?

1. spO₂ < 90%
2. apnea
3. Persistently increased respiratory effort
(tachypnea, nasal flaring, subcostal/suprasternal retractions, accessory muscle use, grunting)

Mild Bronchiolitis?

1. No hypoxia
2. No Apnea
3. No respiratory distress

Rx at Home

1. Nasal Saline
2. Oral Hydration
3. Paracetamol for fever
4. **NO Cough or Cold medicine**

Treatment (mostly supportive):

1. Oxygen if spO₂ < 94%
2. Nasal saline and bulb suction
3. PO Hydration or NGT/IVF if not tolerating oral feeds
4. Paracetamol for fever
5. Steroids & Antibiotics ineffective
6. Salbutamol: if over 9 months may give **ONE** nebulization, must examine before and after, stop if no improvement, if notable improvement, may continue every 4 hours

**CPAP trial if
impending
respiratory
failure**

Discharge Criteria:

1. O₂sat > 94% x 12 hours
2. Notably improved respiratory rate
3. Able to take fluids to stay hydrated
4. Caretaker instructed in use of nasal saline
5. Counsel cough may persist 1-2 weeks

Acute Asthma Management

Severe: Wheeze PLUS

- SpO₂ < 90%
- Lower chest wall indrawing
- Inability to breastfeed/drink
- Inability to talk
- Lethargy
- Peak flow < 50%

No

Mild/Moderate: Wheeze PLUS

- Fast breathing
Age 2 – 12 months: RR \geq 50
Age >12 months: RR \geq 40
- Peak flow 50-80%
- Adequate air exchange
- SpO₂ > 90%

Yes
Place on Oxygen

Management

1. Salbutamol every 15 minutes x 3 doses via:

Nebulizer

< 2 years: 2.5mg in 3mL NS

> 2 years: 5mg in 5mL NS

OR MDI+spacer+mask

5-10 kg: 4 puffs

10-20 kg: 6 puffs

> 20 kg: 8 puffs

Oral salbutamol is ineffective

2. Dexamethasone 0.6mg/kg PO or IV (if not drinking)
x 1 dose or Prednisolone 1-2mg/kg PO x 1 dose

Reassess after 30-60 minutes

Was the patient initially mild/moderate and has shown marked improvement?

No

Yes

Admit

- **Severe:** continue oxygen, 1-4 hourly salbutamol, early review
- **Mild/Moderate:** 4 hourly salbutamol
- Prednisolone 1-2mg/kg OD x 3 days
- Ensure adequate hydration, maintenance fluids via NGT/IV if necessary

Discharge Criteria:

1. O₂sat > 92%
2. Able to take fluids to stay hydrated
3. Requires salbutamol no more than every 6hrs

- Give education on use & importance of inhaler, spacer + mask, signs of asthma, danger signs, and avoidance of triggers (smoke, etc.)
- Discharge on Salbutamol MDI every 6 hours for no more than 5 days
- If did NOT receive 3 days of steroids, complete Prednisolone 1-2mg/kg PO OD x 3 days total
- Consider inhaled steroids if recurrent episodes of wheezing

Pediatric Meningitis^{1,16,36}

1. Symptoms are often nonspecific, if unclear treat for Meningitis **AND** other diagnosis (malaria, TB meningitis, etc.) until definitive tests.
2. There is **NO WAY** to rule in or rule out meningitis without a lumbar puncture

Symptoms that **MAY** be present in Infants and Children

Symptom**	Infant	Children
Fever	Neonates: not always (may have hypothermia)	✓
Headache	✓	✓
Neck Stiffness/ Kernig's/Brudzinski's	Less common	✓
Poor feeding/ vomiting/diarrhea	✓	✓
Altered Mental Status	Lethargy/Irritability	Confusion/Lethargy/Irritability
Convulsions	More concerning < 6 months	More concerning > 6 years
Focal Neuro Signs	✓	✓
Respiratory distress/ apnea	✓	uncommon
Bulging Fontanelle	✓	
Photophobia	Unable to confirm	✓
Cushing triad	no	Late and Ominous Sign (HTN, bradycardia, irregular breathing)

**Children with ≥ 1 of: neck stiffness, cyanosis, impaired consciousness, partial convulsions or convulsions older than 6 years old have a much higher rate of meningitis³⁷

- I. If any concern for Tuberculous Meningitis, see Tuberculosis Protocol
- II. If culture reveals meningococcus needs prophylaxis for close contacts
- III. If < 1-month old, see Neonatal Protocols
- IV. Steroids no longer recommended in low-resource countries³⁸⁻⁴¹
- V. If any of the following present, treat with full course of antibiotics
 - a. Lumbar Puncture with either
 - i. Bacteria on Gram Stain, positive CSF culture OR
 - ii. Gram Stain: > 9 WBC (< 3months), >6 WBC (> 3months)
 - b. AVPU = 'P or U'
 - c. Stiff neck/Kernig's/Brudzinski's
 - d. Bulging fontanelle in sick child
 - e. Evidence of partial seizures
 - f. If not, may consider stopping antibiotics at 48 hours if CSF culture negative

Pediatric Meningitis Rx \geq 1 month

Management

- Monitor, support ABCs
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Assess AVPU/GCS, hydration status
- Start Oxygen if spO₂ < 94%, insert IV
- Perform brief, targeted history, physical exam



Does the patient have one of?:

- AVPU = 'P or U'
- Inability to drink / feed
- Stiff neck/Kernig's/Brudzinski's
- Bulging fontanelle
- Convulsions if <6 months or > 6 yrs
- Evidence of partial seizures
- Any altered mental status
(agitation/irritability) AND convulsions

No

Look for other source
of symptoms



Does the patient have any contraindication?:

- Require CPR
- Shock
- Signs of increased ICP (GCS \leq 8, changing mental status, focal or changing neuro signs, pupils unresponsive, papilloedema)
- Skin infection at LP site
- Actively convulsing
- Coagulation abnormalities (known bleeding disorder, platelets < 100)

Yes

NO LP currently

If contraindication resolves < 24-48 hours after starting antibiotics, perform at that time^{153,154}



Perform LP: send for glucose, protein, cell count, gram stain and culture



Treatment (IV Antibiotics x 10 days) – start within 1 hour:
< 3 months:

- Cefotaxime 100mg/kg IV 8hourly (max dose 2g/day)
AND
 - Ampicillin 50mg/kg IV 6hourly (max dose 12g/day)
- > 3 months:
- Ceftriaxone 100mg/kg IV OD



Follow Convulsion Protocol if applicable


Pediatric Cardiac Protocols

I. Heart Failure

- a. Most Common Symptoms
 - i. Infants: difficulty feeding, easy fatigability, failure to thrive
 - ii. Young children: GI sxs, failure to thrive, easy fatigability, recurrent or chronic cough with wheezing (must differentiate from asthma)
 - iii. Older children: exercise intolerance, anorexia, abdominal pain, wheezing, dyspnea, edema, palpitations, chest pain or syncope⁴²
- b. Physical exam findings⁴³
 - i. Tachycardia, gallop rhythm
 - ii. Poor perfusion – cool/mottled extremities, decreased cap refill, decreased peripheral pulses, lowered systemic BP
 - iii. Pulmonary findings – tachypnea, retractions, accessory respiratory muscle use, grunting/nasal flaring in infants, wheezes and rales (more in older children)
 - iv. Systemic congestion – hepatomegaly, jugular venous distension (rare in infants and young children), peripheral edema
 - v. Hypertension in upper extremities or weak pulses in lower extremities
 - vi. Grade III+ murmur, precordial thrill or heave
 - vii. Neonatal screening (>24 hrs old): check preductal (R. hand) & post-ductal (either foot) SpO₂: positive screen if a) SpO₂ differs by >3% btw upper and lower extremities on 3 measurements separated by an hour each, b) SpO₂ <90% any extremity, or c) SpO₂ <95% in upper and lower extremities on 3 measurements separated by an hour each

c. Acute Management

Monitor, support ABCs, ensure patient is seated
Check vital signs (BP, PR, RR, spO₂, Temp, Weight)
Assess GCS, hydration status
Start Oxygen if spO₂ < 94%, insert IV as needed
Draw CBC, malaria, RFTs, electrolytes
Perform brief, targeted history, physical exam
Consider ECG if available



II. Chronic Medications & Dosages⁴⁴

- a. Diuretics
 - i. Furosemide 1mg/kg/dose OD or BD
 - ii. Spironolactone 1mg/kg/day divided OD-BD up to 3.3-6mg/kg/day divided OD-BD (not to exceed 100mg/day)
- b. ACE Inhibitors/ARBs
 - i. Captopril 0.3-2.5mg/kg divided BD, titrate up as needed, max dose 6mg/kg/day
 - ii. Lisinopril/enalapril 0.1mg/kg OD
 - iii. Losartan 0.5mg/kg/day (not to exceed 12.5-25mg/day), up to 1.4mg/kg/day (not to exceed 150mg/day)
- c. Digitalis/Digoxin 5-15mcg/kg/day divided BD up to 20-30mcg/kg/day divided BD
 - i. Especially useful in the setting of atrial arrhythmias
- d. Beta Blockers
 - i. Propranolol 1-3mg/kg/dose BD-TID
 - ii. Carvedilol 0.1mg/kg/day divided BD (not to exceed 3.125mg/day), up to 0.8-1mg/kg/day divided BD (not to exceed 25mg BD)
- e. Generally recommended order of medications in left ventricular dysfunction
 - 1. Furosemide – for patients with or history of fluid retention
 - 2. ACEI/ARBs – everyone without specific contraindication, especially with valvular (notably regurgitant mitral or aortic valvular) disease

WARNING! Before starting either of the following medications, must have ECHO, potassium level and have consulted with senior

- 3. Spironolactone – for patients on Furosemide that continue with fluid retention, especially in patients that are more symptomatic
- 4. Digoxin – for those with low ejection fraction

III. Rx for Specified Conditions

- a. Acyanotic Congenital Heart Disease: Left to Right Shunts (VSD/PDA most common) – standard order of medications
- b. Cyanotic Congenital Heart Disease: Tetralogy of Fallot
 - i. Heart failure symptoms rare
 - ii. Treat Tet Spell
 - 1) Knee-chest position
 - 2) Oxygen
 - 3) Morphine 0.1 mg/kg/dose IV
 - 4) Normal Saline 10-20mL/kg IV slow bolus
 - 5) Propranolol 0.1mg/kg/dose IV or 0.5mg/kg/dose PO
- c. Dilated Cardiomyopathy
 - i. Order of Rx: standard
 - ii. Digoxin (especially in the setting of atrial arrhythmias)

Acute Rheumatic Fever (ARF)

- I. Diagnosis Initial ARF: (evidence of preceding group A Streptococcus infection) + (2 major) or (1 major + 2 minor criteria)
- II. Diagnosis Recurrent ARF: (h/o ARF) + (2 major) or (1 major + 2 minor) or (3 minor criteria)
- III. 2015 Jones criteria for the diagnosis of rheumatic fever for moderate to high-risk populations⁴⁵⁻⁵⁰
 - a. Clinical Manifestations for Major Criteria
 - Carditis and valvulitis (clinical and/or subclinical)
 - Manifestations: fever, new murmur, chest discomfort or pleuritic chest pain, malaise, tachycardia, heart failure
 - Arthritis
 - Manifestations: fever, migratory polyarthritis affecting large joints (knees, elbows, ankles, wrists) but also monoarthritis or polyarthralgia, lower extremity affected first, more in adolescents, asymmetric
 - Central nervous system involvement (e.g. Sydenham Chorea)
 - Manifestations: fever, grimacing, fidgeting, clumsiness, emotional lability, difficulty with handwriting), gait imbalance, may resolve while sleeping
 - Subcutaneous nodules
 - Erythema marginatum
 - b. Clinical Manifestations for Minor Criteria
 - Monoarthralgia or polyarthralgia
 - Fever ($\geq 37.5^{\circ}\text{C}$ axillary)
 - $\uparrow\uparrow$ ESR ($\geq 30 \text{ mm/hr}$) and/or $\uparrow\uparrow$ CRP ($\geq 3.0 \text{ mg/dL}$)
 - Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)

IV. Evaluation

- a. CBC and ESR/CRP when available
- b. ECHO, ECG if available

V. Treatment


- a. Streptococcal Pharyngitis antibiotic regimen (regardless of whether patient currently has pharyngitis)
- b. Arthritis: Aspirin 20-25mg/kg/dose q6hrs
- c. Secondary prophylaxis
 1. Benzathine Penicillin G (BPG) IM qmonth
 - a. $\leq 27\text{kg} = 600,000 \text{ IU}$
 - b. $>27\text{kg} = 1.2 \text{ million IU}$
 2. Penicillin V 250mg PO BD
 3. Erythromycin 250mg PO BD
 - a. Only if PCN allergic

Sickle Cell Disease

- I. Admit any child with a diagnosis of Sickle Cell Disease and any of the following conditions:
 - a. Pain: moderate to severe
 - b. Severe pallor, Hgb < 5, symptomatic with Hgb < 7 or 2+ drop in Hgb from baseline
 - c. Fever with tachycardia, tachypnea, hypotension or >38.0 C
 - d. Chest pain, difficulty breathing
 - e. Acute (0-7 days) abnormal CNS signs (e.g. headache, drowsiness, paralysis or limb weakness)
 - f. Priapism (>4 hours)
 - g. RDT or B/S + for Malaria
 - h. Diarrhea and/or vomiting with abdominal pain, distension or inability to drink enough to stay hydrated
 - i. Neutropenia (granulocytes < 1000) and fever
- II. Home Medications at time of Discharge²⁶
 - a. Folic Acid 5mg PO QD
 - b. Penicillin VK
 - 1.<3yo: 125mg PO BD
 - 2.3-5yo: 250mg PO BD
 - c. Malaria Prophylaxis
 - 1.Sulphadoxinepyrimethamine
 - a) 2-5yo: ½ tab monthly
 - b) 5-10yo: 1 tab monthly
 - c) 10-15yo: 2 tabs monthly
 - d) >15yo: 3 tabs monthly
 2. Sulfur allergy: Consider erythromycin 250mg PO q12hrs
 - d. Hydroxyurea
 1. Should ideally be managed by specialized treatment centre
 2. Indications
 - a) Frequent crises: > 5/year
 - b) Abnormal Transcranial Doppler (TCD) Ultrasonography velocity >200cm/s
 - c) H/o of Acute Chest Syndrome
 - d) H/o Stroke
 3. Likely beneficial in all children with Sickle Cell Disease, although larger studies are still pending⁵¹
 4. Start after 9 months old
 5. Starting Dose: 20mg/kg PO QD

Sickle Cell Acute Management

- Monitor, support ABCs
- Check VS (BP, PR, RR, spO₂, Temp, Wt)
- Assess GCS, hydration status
- Insert IV, Start Oxygen if spO₂ < 94%
- Draw CBC, retic count, malaria, Tbili/Dbili if jaundiced
- Perform brief, targeted history, physical exam



Sickle Cell Stroke

New Neurologic Findings: hemiparesis, focal neurologic deficit, speech disorder
OR
High Clinical Suspicion

Monitor, support ABCs
Check vital signs (BP, PR, RR, spO₂, Temp, Weight)
Start Oxygen if spO₂ < 94%
Assess GCS
Assess hydration status
Insert IV, Draw CBC, malaria, RBS
Perform brief, targeted history, physical exam

Does the patient have any contraindication?:

	Children	Adults
Fever: Paracetamol	15mg/kg PO q6hrs	650mg PO q6hrs
Hypoglycemia	Dextrose 10% 5ml/kg (mix 8ml NS with 2ml Dextrose 50%)	1 amp (50ml) of Dextrose 50%
Convulsions	See Convulsion Protocol	
Anemia: Transfusion	Simple transfusion, PRBCs, to Hgb > 9 ^{156,162}	
Infection: Antibiotics	Cefotaxime IV 50mg/kg every 8 hours (max dose 2g) May substitute Ceftriaxone 80mg/kg IV daily (max dose 2g)	
Hydration	Dehydrated: see dehydration recommendations MIVF if hydrated ^{163,164} Encourage feeding	

Monitoring

1. Daily neuro checks
2. Physiotherapy as soon as acute issues resolved

Discharge Plan

1. Hydroxyurea
2. F/U in Sickle Cell Clinic

Sickle Cell Acute Chest Syndrome

Meets criteria for pneumonia OR has moderate to severe chest pain

Monitor, support ABCs
Check vital signs (BP, PR, RR, spO₂, Temp, Weight)
Assess GCS, hydration status
Start Oxygen if spO₂ < 94%
Insert IV, Draw CBC, malaria, transfuse for Hgb<9
Perform brief, targeted history, physical exam

Clinical Respiratory Score¹⁶⁵

	0	1	2
RR (>12mo)	<30	30-40	>40
Auscultation	Good air mvmt, minimal wheezing/creps	Decreased air mvmt, insp&exp wheezing	Severely diminished/absent sounds, severe wheezing
Retractions or nasal flaring	Mild	Moderate	Severe
Mental Status	Normal/mildly irritable	Irritable, restless	Lethargic
O₂sat	>95%	90-95%	<90%
Color	Normal	Pale	Cyanotic, dusky

If available, consider ICU admission for CRS >=6

Start Antibiotics¹⁶³⁻¹⁶⁵

1. Cefotaxime IV 50mg/kg every 8 hours (max dose 2g)
 - a. May substitute Ceftriaxone 80mg/kg IV daily (max dose 2g)
2. Azithromycin
 - a. Day 1: 10mg/kg (max/adult dose 500mg)
 - b. Day 2-5: 5mg/kg (max/adult dose 250mg)

General Supportive Care:

1. Aggressive pain management
2. Encourage feeding, IVF if not eating (but TOTAL fluid intake should be no more than maintenance)

Discharge Criteria¹⁶⁵

1. Improved symptoms
2. Afebrile x 24hrs
3. Good PO intake
2. pO₂ >94% on room air
4. Hgb > 5
5. Pain controlled without morphine

Severe Acute Malnutrition in Children

Nutritional Assessment

- **Mid upper arm circumference (MUAC) in cm.**
 - Measures wasting/muscle mass in children older than 6 months
 - Correlates significantly with risk for death
 - Easy screening tool in the community
 - Used in very ill patients who cannot have weight/length measured
- **Body weight** (in kg to the nearest 0.1 kg)
 - weigh as soon as arrival to hospital
 - take one hour before or after a meal
 - remove clothes, jewelry, diapers, etc.
 - keep child warm with a blanket as you wait to measure
- **Length/height**
 - Length (child laying down): <2yrs, or < 87cm if age unknown
 - Height (child standing up): \geq 2yrs, or \geq 87cm if age not known
 - If \geq 2yrs & can't stand, take length and subtract 0.7 cm
 - Child should be barefoot, no head gear
 - Shoulders, buttocks and heels should touch the board
 - Measure to the nearest 0.1 cm.

Making sense of the measurements

- Use Weight-for-Length/Height (WFL/WFH) if <6 years (59 months)
- Use BMI/age if \geq 6 years
- Plot measurements (use growth charts) and obtain Z-score
- Classify the degree of malnutrition

Classification of acute malnutrition

Age category	Nutritional indicator	Moderate Acute Malnutrition (MAM)	Severe Acute Malnutrition (SAM)
< 6 months	WFL	\geq -3SD & $<$ -2SD	$<$ -3SD
	Oedema	Absent	Present
6 to 59 months	WFL/WFH	\geq -3SD & $<$ -2SD	$<$ -3SD
	Oedema	Absent	Present
	MUAC	\geq 11.5 cm & $<$ 12.5cm	$<$ 11.5cm (red)
5 to 19 years	BMI/ age	\geq -3SD & $<$ -2SD	$<$ -3SD
	Oedema	Absent	Present
5 to < 10 yrs	MUAC	\geq 13.5 & $<$ 14.5cm	$<$ 13.5 cm
10 to < 15 yrs	MUAC	\geq 16.0 & $<$ 18.0 cm	$<$ 16.0 cm
15 to 19	MUAC	\geq 16.5 & $<$ 21.0 cm	$<$ 18.5 cm

Complicated SAM includes any of the following: hypoglycemia, hypothermia, infections, severe dehydration, shock, Hgb < 4, cardiac failure, corneal ulceration, severe dermatoses, or IMCI danger signs like anorexia, intractable vomiting, convulsions, lethargy/LOC, inability to feed or breast feed, fever $>$ 39.

Criteria for admission with Severe Acute Malnutrition (any)

- Patients with SAM & severe oedema
- Children < 6 months with SAM
- Patients with complicated SAM

Uncomplicated SAM (no admission criteria) manage from outpatient therapeutic care (OTC) with ready to use therapeutic feeds (RUTF)

Check for all of the following after admission

1. **Hypoglycemia:** blood glucose < 3mmol/L, 54mg/dL, treatment:
 - a. Can drink: 50mls of 10% dextrose or sugar water (1 spoon of sugar + 50mls of water)
 - b. Can't drink: Dextrose 10% IV 5mls/kg, followed by Dextrose 10% 50mLs or sugar water by NGT
2. **Hypothermia:** < Axillary temperature <35 or rectal < 35.5, treatment:
 - a. Actively warm (kangaroo, cover head, no water bottles as skin is already fragile, away from windows or draughts, keep room warm, change wet clothes, keep covered all time & at night)
 - b. Must also treat for hypoglycemia and infection
3. **Shock:**

Both AVPU < A AND cold extremities
 plus one of
 Capillary refill >3 secs OR weak/fast/absent pulse

 - a. Oxygen
 - b. Keep warm
 - c. IV fluids: 15mls/kg/hour (may repeat once)
 - d. Choice of fluids: RL+D5% or ½NS+D5%, add 20mmol/L KCL
 - e. If no improvement after first bolus, assume septic shock, give whole blood 10mL/kg
4. **Dehydration:**

> 2 of the following signs

AVPU < A	Absent tears
Capillary refill >= 2 seconds	Dry mucus membranes
Unable to drink	Recent/frequent diarrhea
Sunken eyes	Vomiting
Slow skin pinch >= 2 seconds	

- a. Use rehydration solution for malnutrition (ReSoMal)
 - i. 5mls/kg PO q30min x 2 hrs THEN
 - ii. 5-10mls/kg/hr, alternate ReSoMal one hour then F-75 the next x 10 hrs
 - iii. Monitor for improvement or over hydration
 - iv. If improved, give ReSoMal only after each loose stool

5. Severe Anemia

Hgb < 4g/dl, <6g/dl with heart failure, or (if no Hgb), pallor with heart failure symptoms (tachypnea, tachycardia, engorged neck veins, cold extremities, cyanosis of fingertips or tongue)

- a. Stop all oral feeds and IV fluids for 24 hours, check for heart failure
- b. No heart failure: 10mls/kg whole blood over 3hrs
- c. Heart failure: 5-7mls/kg of packed RBCS

6. Cardiac Failure

Common causes: over hydration, overfeeding, blood transfusion, high sodium diet, severe anemia, severe pneumonia.

Signs: deterioration with weight gain, reappearance of edema, sudden DIB, prominent neck veins, cold extremities, tender liver, cyanosis.

- a. Oxygen
- b. Stop all IV fluids & feeds
- c. Lasix 1mg/kg IV
- d. Do not use digoxin in newborns

7. Eye signs of Vitamin A deficiency/Corneal ulceration/purulent ocular discharge, treatment:

- a. Vitamin A on day 1, 2 and 15
- b. 1% atropine to relax the eye
- c. Gentamycin or chloramphenical eyedrops

8. Severe dermatosis: Peeling with cracking and ulceration of the skin

- a. Sponge affected areas with 0.01% potassium permanganate or gentian violet.

9. Infection Control (for complicated SAM), treatment:

- a. Ampicillin 50mg/kg IV q6hrs x 2 days
- b. Switch ampicillin to amoxicillin if there is improved after 2 days
- c. Gentamicin 5mg/kg/day x 7 days
- d. Check mom for HIV if < 18 months, otherwise check patient

10. Micronutrient deficiency

- a. No supplements necessary (all micronutrients already included in F-75, F-100)
- b. Add CMV (Combined mineral and vitamin) mix to the milk if making own feeds.
- c. If no formula feeds or CMV, then supplement with multivitamin drops for all the stages of management. However, start iron in the rehabilitation phase.

Feeding in Severe Acute Malnutrition

Stabilization

- Use F-75 only
- If oedema: 100mls/kg/day
- If no oedema: 130mls/kg/day
- Do not change the total daily volume of milk, even when they lose or gain weight.
- Initially 2 hourly feeds for at least 48 hrs.
- If stable, then go to 3 hourly, or 4 hourly feeds.
- Child should complete at least 80% of the feeds offered.
- Use NGT if not finishing at least 80% of the feeds on 2-3 consecutive feeds
- **Vomiting:** reduce feeds to 1 hourly or estimate the vomited milk and offer it again.

When to transition?

- Return of appetite
- Reduced edema or minimal edema
- Child may smile at this point
- Resolved medical complications
- Passes acceptance/appetite test (eats a third of the 92g packet of plumpy nut).
- NB. Can transition to ready to use therapeutic feeds (RUTF/Plumpy nuts) or F-100.

Transitioning to RUTF

- Offer the RUTF in a hygienic and Playful environment
- Provide the RUTF with plenty of safe water to drink.
- If not completing but finishing > half of the RUTF, then supplement with F-75.
- If taking < a half, go back to stabilization F-75

Transitioning to F-100

- For the first 2 days, give the same volume as F-75.
- On day 3, add 10mls/feed to a maximum of 220ml/kg/day or until the child is unable to finish
- Start iron supplementation on day 3 of transition

When to switch back to stabilization

- Re-occurrence of medical complications
- Loss of appetite (taking < 80% of feeds consecutively)
- Development/increasing of edema
- Deteriorating medical condition
- Signs of fluid overload
- Re-feeding diarrhea

Epistaxis*

Management

- Monitor, support ABCs
- Have patient lean forward, pinch nose closed (**DO NOT** tilt head back)
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Assess AVPU/GCS, hydration status
- Start Oxygen if spO₂ < 94%, insert IV if needed
- Perform brief, targeted history, physical exam
 - Nasal Trauma (nose picking) most common cause (especially in children)
- Continue pinching the nose closed for **15 MINUTES**
- **Do not order coagulation labs during this time**
- **Do not use packing during this time**

No After 15 minutes of
nose pinching, has
bleeding stopped?

Yes

Insert into bleeding nostril, a cotton plegget soaked in the following, in order, each for **10 minutes**, stop at any point if bleeding is controlled (note, this is **NOT PACKING**):

- 1) Injectable tranexamic acid (500mg in 5mL NS)
- 2) Epinephrine/adrenaline (1mg in 5mL)

Bleeding continues

Perform the following in order, stop at any point if bleeding is controlled:

- 1) Pack the bleeding nostril with a tampon or gauze that has been soaked in bacitracin or K-Y jelly
- 2) Pack the contralateral nostril with a tampon or gauze that has been soaked in bacitracin or K-Y jelly
- 3) Pass a lubricated foley catheter through the bleeding nostril into the nasopharynx, fill with NS and pull forward, placing light traction against the posterior nasal choana
- 4) Pack the bleeding nostril around the foley catheter with a tampon or gauze that has been soaked in bacitracin or K-Y jelly

Bleeding has stopped

- Repeat vital signs (PR, RR, spO₂, Temp)
- Repeat GCS
- Remove any packing
- Monitor for at least 60 minutes
- Education about cause
- Vaseline/Petroleum Jelly should be applied TID for 7-10 days

Bleeding
has
stopped

Repeat vital signs (PR, RR, spO₂, Temp, BP)
Repeat GCS
IV access
Labs: CBC, LFTs, Coagulation Studies
Consider keeping packing in place for 12-24 hours

Ear, Nose and Throat Infections

I. Otitis Media

a. Presentation

- i. **Most common parental complaints:** restless sleep, irritability, ear rubbing (appears to be the most useful symptoms to aid diagnosis), ear pain, severe or prolonged rhinitis or cough, fever
- ii. Acute onset, possibly preceded by upper respiratory symptoms
- iii. More likely if smoking at home or formula feeding


b. Examination

- i. Perform Otoscopy (examine Tympanic membrane with otoscope – ideally with an insufflator bulb)
- ii. Remove cerumen if necessary for visualization

c. **Diagnosis: Any of the following on exam**^{16,52}


- i. Moderate-to-severe bulging of tympanic membrane (TM)
 - ii. Mild bulging of TM & < 48 hrs of ear pain or intense erythema of TM
 - iii. TM is red, bulging and opaque
 - iv. New otorrhea not due to Otitis Externa
 - v. TM is perforated with discharge
- d. Treatment (max/adult dose for below is 875mg/dose PO BD)
- i. 1st line: Amoxicillin 45mg/dose PO BD
 - ii. 2nd line: Amoxicillin/Clavulanic Acid 45mg/dose PO BD
- iii. Duration: 10 days if < 2 years old, 7 days > 2 years old

Normal TM



53


Acute Otitis Media



53



54




55

II. Otitis Externa

- a. Presentation
 - i. Otalgia, pruritus, pressure/fullness of ear canal, hearing loss, jaw pain, discharge, redness/erythema, swelling/edema
- b. Examination (need to perform otoscopy as well)^{56,57}
 - i. Pain with tragus/pinna movement
 - ii. Erythema/edema of ear canal
 - iii. Cellulitis
 - iv. Discharge from canal
 - v. *Generally, manipulation of external ear is painful in Otitis Externa but not in Otitis Media*
- c. Treatment
 - i. Topical Antibiotic
 1. Neomycin/Polymyxin B/Hydrocortisone (Cortisporin Otic) 3-4 drops to affected ear 8 hourly x 7-10 days
 2. Educate about keeping ear dry

III. Mastoiditis

- a. Presentation/Examination findings^{58,59}
 - i. Risk factor is current or recent diagnosis of acute otitis media
 - ii. Signs of local inflammation over mastoid
 - 1. Protruding ear
 - 2. Postauricular erythema, swelling or pain
 - 3. Systemic signs, fever or malaise
- b. Treatment
 - i. Children
 - 1. Ampicillin-Sulbactam IV 50mg/kg 8 hourly
 - 2. Cloxacillin or Flucloxacillin IV 50mg/kg 6 hourly
 - 3. If no response within 48 hours or child deteriorates, refer to a surgical specialist to consider incision and drainage
 - ii. Adults
 - 1. Ceftriaxone 2g IV BD or Cefotaxime 2g IV 8 hourly
 - 2. With intracranial complications
- a. Ceftriaxone 2g IV BD or 8 hourly plus Vancomycin 2g in 2-4 divided doses



53

IV. Pharyngitis

- a. Strep pharyngitis usually presents with sore throat, fever, headache or stomach ache, but **NOT** with viral sxs like cough, coryza, conjunctivitis
- b. Remember, ONLY Streptococcal Pharyngitis should be treated with antibiotics, all others should only be treated with supportive care
- c. Streptococcal Pharyngitis Diagnosis (Modified Centor Score)

Criteria	Points	Criteria	Points
Age Range		Tonsillar Exudates	+1
3-14 years	+1	Tender/swollen anterior lymph nodes	+1
15-44 years	0	Febrile	+1
>= 45 years	-1	Cough absent	+1

- d. Scoring

Child Scoring	0-1 points	2 points	3+ points
	No treatment required	Ideally rapid test/culture, may use clinical judgement to start Rx	Start Rx presumptively
Adult Scoring	0-2 points		3+ points
	No Treatment Required		Start Treatment Presumptively

- e. Treatment

Drug	Paediatric Dose ($\leq 27\text{kg}$)	Adult Dose ($> 27\text{kg}$)
Penicillin VK PO	250mg PO BD x 10 days	500mg PO BD x 10 days
Benzathine Penicillin G IM	600,000 IU	1.2 million IU
Amoxicillin PO	25mg/kg/dose (max 1g) BD x 10 days	
Clindamycin PO	7mg/kg (max 300mg) 8 hourly x 10 days	

V. Sinusitis

- a. DOES NOT require antibiotics unless bacterial
- b. Diagnosis of Acute Sinusitis: 2 major or 1 major & 2+ minor symptoms⁶⁰

Major Symptoms	Minor Criteria
Nasal congestion or obstruction	Headache
Purulent nasal discharge	Ear pain, pressure or fullness
Hyposmia or anosmia	Halitosis
Facial congestion or fullness	Dental pain
Facial pain or pressure	Cough
Fever	Fatigue

c. Diagnosis of **BACTERIAL SINUSITIS**^{60,61}

- i. Signs/symptoms above lasting ≥ 10 days
- ii. Worsening or new onset of signs/symptoms following initial improvement, typically after 5-6 days (double sickening)
- iii. Severe symptoms with concurrent fever (>38.5 axillary) & purulent nasal discharge or facial pain lasting ≥ 3 days
- d. Treatment for **BACTERIAL SINUSITIS** (must meet above criteria)
 - i. Amoxicillin 45mg/kg/dose BD⁶²⁻⁶⁵ x 7 days if > 2 years, mild-moderate, uncomplicated disease
 - ii. Amoxicillin/Clavulanic Acid 45mg/kg/dose BD x 7 days if < 2 years, moderate-severe illness, attending daycare, or antibiotic exposure in last 4 weeks
 - iii. If no improvement in 72 hours, consider changing antibiotics

Paediatric Tuberculosis

VII. Consider Tuberculosis with the following

- a. Chronic cough
- b. Chronic fever
- c. Pneumonia not improving on treatment
- d. Wasting
- e. Lymphadenopathy
- f. Ascites
- g. Heart failure/pericardial effusion
- h. Refusal to bend a painful joint
- i. Irritability, meningeal signs
- j. Haematuria, sterile pyuria

VIII. General considerations making tuberculosis more likely

- a. Prolonged course of cough, fever, sweats
- b. Patient's disease symptoms don't improve with expected treatment
- c. Weight loss/malnutrition, especially if no improvement after 4 weeks
- d. Large, painless lymphadenopathy
- e. Close contact with someone with tuberculosis within last 2 years

IX. Diagnosis

- a. In children especially difficult, <5yo cannot produce sputum
- b. <5yo or cannot produce sputum, Gastric Aspirate
 - i. perform on different days, 3 times total, early morning prior to the child eating or ambulating (ideally would wake patient up after sleeping prone all night)

X. Scoring Systems – Systemic Tuberculosis

Keith Edwards Score for Diagnosis of Tuberculosis in Children⁶⁶⁻⁶⁸

Feature/score	0	1	2	3	4
Length of illness (weeks)	<2	2-4	-	>4	-
Nutrition (% wt for age)	>80	60-80	-	<60	-
Family h/o TB	None	Reported	-	Proven	-
Unexplained fever not responding to malaria drugs	-	-	Positive	-	-
Tuberculin test	-	-	-	Positive	-
Painless lymphadenopathy with or without sinus	-	-	-	Positive	-
Malnutrition not improved after four weeks	-	-	-	Positive	-
Joint/bone swelling, sinuses	-	-	-	Positive	-
Unexplained abdominal mass or ascites	-	-	-	Positive	-
CNS: changes in temperament, fits or coma	-	-	-	Positive	-
Angle deformity of spine	-	-	-	-	Positive

Scores of ≥ 7 indicative of tuberculosis

XI. Scoring Systems – Pulmonary Tuberculosis

8-point Risk Score for children in contact with infected persons⁶⁹

Feature/score	0	1	2	3	4
Tuberculin Test (mm of induration)	<10		10-14	15-19	≥20
Smear positive source case		Present			
Source case lives in high incident area*			Present		
Source case is female		Present			

*in initial study this incidence was 277/100,000, if unsure of your local incidence, may assume high if in Africa or South-East Asia⁷⁰

New modified Edwards' score⁶⁶⁻⁶⁸


Feature/score	0	1	2	3
Duration of illness/weeks	<2	2-4	-	>4
Nutrition (% wt-for-lt)	>80	60-80	-	<60
Family h/o TB	None	Reported by family	-	Proved sputum +ve
Tuberculin test	-	-	-	Positive
Malnutrition	-	-	-	Not improved after 4 weeks
Unexplained fever (>2 weeks)	-	-	No response to treatment	-

Scores of ≥7 indicative of tuberculosis

Brazilian Ministry of Health Scoring System ^{68,71}	Points
Clinical Symptoms	
Fever or sxs such as cough, fatigue, wt loss, sweating for > 2 weeks	+15
Asymptomatic or symptomatic < 2 weeks	0
Improvement in respiratory infection w/o antibiotics or with antibiotics for common germs	-10
Radiologic Findings	
CXR with hilar lymph node enlargement, military pattern, condensation or infiltrate for > 2 wks, with worsening sxs or lack of improvement with antibiotics for common germs	+15
Condensation or infiltrate < 2 weeks	+5
Normal CXR	-5
Contact with Adult TB patient	
Close contact within last 2 years	+10
Occasional or negative	0
Tuberculin skin test	
> 10mm in child given BCG > 2 years ago or never vaccinated	+15
>15mm in children given BCG vaccine within last 2 years	+15
≥ 5mm and ≤ 9mm	+5
< 5mm	0
Nutritional Status	
Weight < 10 th percentile	+5
Wt ≥ 10 th percentile	0

Points - ≥40: highly likely ≤39 and ≥ 30: possible ≤ 29: unlikely

Treatment for Pediatric Tuberculosis*



*Throughout treatment patient should receive Pyridoxine

Weight (kg)	Number of tablets pyridoxine (50mg)
5-7	Quarter tablet daily
8-14	Half tablet daily
≥ 15	One full tablet daily

**If liver tenderness, hepatomegaly or jaundice recheck LFTs. Do not change regimen unless LFTs > 5 x upper limit of normal

Anaemia

History: Sleepiness, anorexia, dysphagia, fatigue, dyspnea on exertion, syncope

Clinical findings: pallor, tachycardia, stomatitis, koilonychia, angular

stomatitis, glossitis, esophageal/pharyngeal webs, heart failure symptoms

Management²⁷

12. Monitor, support ABCs
13. Check vital signs (BP, PR, RR, spO₂, Temp, **Weight**)
14. Assess GCS, hydration status
15. Insert 2 IVs, Start Oxygen if spO₂ < 94%
16. Draw CBC, malaria, consider blood cultures if concern for sepsis
17. Type and cross if tachycardic, tachypneic, or severe pallor
18. Perform brief, targeted history, physical exam

Is there a possibility of bleeding?

- Ask about recent trauma
- Clinically significant GI bleeding should be visible as hematemesis, coffee ground emesis, melena, or hematochezia
- 4 locations in body may hide active bleeding: thorax, abdomen, retroperitoneum/pelvis, thigh

Consider empirically treating for Malaria and Sepsis if appropriate, remember there is NO way to clinically differentiate between malaria and sepsis

Transfuse in the following cases


High Malaria Areas:

- Low blood supply
 - <4g/dL or <5g/dL and unstable
- Good blood supply
 - <5g/dL
- Low Malaria Areas:
 - <7g/dL or <10g/dL and unstable

Evaluate for Cause of anemia

Evaluation for Cause of Anemia⁷²

Workup after stabilization (and rule-out of malaria & sepsis), using labs: CBC, LDH, bilirubin, haptoglobin, reticulocyte index (RI)



I. Iron supplementation

- Children: 1-2mg/kg/dose PO q8hrs of elemental iron
- Adults: 50mg/dose PO q8hrs of elemental iron

II. Folate (Folic Acid) supplementation

- Children: 1mg PO daily
- Adults: 1-5mg PO daily (depending on severity)

III. B12 (Cyanocobalamin)

- Children: 1mg PO daily
- Adults: 1-2mg PO daily

Transfusions^{15,16,73}

A. When to transfuse

a. High Malaria Areas

- i. Low blood supply: <4g/dL or <5g/dL and unstable
- ii. Good blood supply: <5g/dL

b. Low Malaria Areas

- i. <7g/dL or <10g/dL and unstable

B. General considerations about transfusions

- a. 10mL PRBCs = 20mLs WB
- b. If in shock, give WB for extra volume
- c. If no shock and concern for volume overload (malnourished, heart failure, give PRBCs)
- d. 10-15mL/kg PRBCs raises child's Hgb an average of 2-3g/dL
- e. Usual range for children 10-20mL/kg
- f. 1 Unit PRBCs raises adults Hgb average 1g/dL
- g. Normal volume for adults 1-2 units
- h. Usually run 10mL/kg / 1 Unit over 3-4 hours

C. Calculate Transfusion Volume

a. Paediatric:

- i. <1yo: 10mL/kg PRBCs or 15mL/kg WB
- ii. >1yo: 10mL/kg PRBCs or 20mL/kg WB
- iii. Malnourished: 5mL/kg PRBCs or 10mL/kg WB (do not repeat transfusion)
- iv. Adult: 1-2 units PRBCs

D. Complications

- a. Acute hemolytic transfusion reaction (AHTR) – w/in 24hrs
 - i. Sxs: fevers, chills, rigors, pain at infusion site, chest/back/abdominal pain, low BP, shortness of breath
 - ii. Treatment: stop transfusion, send back to lab to recheck compatibility, aggressive IVF hydration, maintain UOP with Lasix and/or dopamine
- b. Febrile nonhemolytic – w/in 6 hrs
 - i. Sxs: fevers, chills, tachypnea, headache, vomiting, BP change
 - ii. Treatment: stop transfusion, send back to lab to recheck compatibility (important to differentiate Hemolytic from Nonhemolytic), draw blood cultures, give Acetaminophen (may consider meperidine)
- c. Delayed Hemolytic Reaction – w/in 5-7 days
 - i. Sxs: fever, anemia, mild jaundice
 - ii. Treatment: screen for new antibodies, no specific treatment
- d. Allergic/urticarial/anaphylaxis
 - i. Sxs: bronchospasm, laryngeal edema, hypotension
 - ii. Treatment: Urticaria: diphenhydramine, Anaphylaxis (see protocol): epinephrine, diphenhydramine, H2-blocker, glucocorticoids
- e. Transfusion-related lung injury (TRALI)
 - i. Often w/in 1-2 hours, sxs w/in 6 hrs, usu. improves 48-96 hrs
 - ii. Sxs: fever, bilateral pulmonary edema, hypoxemia, respiratory failure, hypotension
- iii. Treatment: supplemental oxygen & respiratory support, CXR, evaluate for possible volume overload (presents with similar features)

Pain Management

Evaluation based on age, use appropriate scoring system

Neonatal Infant Pain Score (NIPS)^{74,75} - < 1 year old

Variable	Finding	Points
Facial expression	Relaxed (Restful face, neutral expression)	0
	Grimace (Tight muscles, furrowed brow/chin/ jaw)	1
Cry	No cry (Quiet, not crying)	0
	Whimper (Mild moaning, intermittent)	1
	Vigorous crying (Loud scream, shrill, continuous). If intubated, score silent cry based on facial movement.	2
Breathing pattern	Relaxed (Usual pattern for this infant)	0
	Change in breathing (Irregular, faster than usual, gagging, breath holding)	1
Arms	Relaxed (No muscular rigidity, occasional random movements of arms)	0
	Flexed/extended (Tense, straight arms, rigid and/or rapid extension, flexion)	1
Legs	Relaxed (No rigidity, occasional random movements)	0
	Flexed/Extended (Tense, straight legs, rigid and/or rapid extension, flexion)	1
State of Arousal	Sleeping/Awake (Quiet/peaceful/sleeping or alert and settled)	0
	Fussy (Alert, restless and thrashing)	1
Heart Rate	Within 10% of baseline	0
	11-20% of baseline	1
	>20% of baseline	2
O2 Saturation	No additional O2 needed to maintain O2 saturation	0
	Additional O2 required to maintain O2 saturation	1

How to Score

0-3 Mild Non Pharmacologic (primary method)

-Pacifiers, sucrose, hand-to-mouth, non-nutritive sucking

-Swaddling, nesting, holding

-Position changes, correct positioning for procedures

-Decrease environmental stimuli (light, noise, abrupt movements)

-Decreased handling with rest periods between procedures

-Comfort measures noted to be effective with individual neonate

-Soothing vocalizations, recorded intrauterine sounds

Pharmacologic -Acetaminophen (Tylenol™)

4-6 Moderate

Non Pharmacologic

-See above Pharmacologic: (primary method) -Narcotic bolus

7-10 Severe


Pharmacologic: (primary method) -Narcotic intermittent bolus

-Consider narcotic drip

r-FLACC Scale (Revised Face, Legs, Activity, Cry, Consolability)^{76,77}
 – 2 months to 7 years old


Variable	Finding	Points
Face	No particular expression or smile	0
	Occasional grimace or frown, withdrawn or disinterested; appears sad or worried	1
	Consistent grimace or frown; frequent/constant quivering chin; clenched jaw; distressed-looking face; expression of fright or panic	2
Legs	Normal position or relaxed; usual tone & motion to limbs	0
	Uneasy, restless, tense; occasional tremors	1
	Kicking, or legs drawn up; marked increase in spasticity, constant tremors or jerking	2
Activity	Lying quietly, normal position, moves easily, regular & rhythmic respirations	0
	Squirming, shifting back/forth, tense or guarded movements, mildly agitated, shallow splinting respirations, intermittent sighs	1
	Arched, rigid or jerking, severe agitation, head banging, shivering, breath holding, gasping or sharp intake of breaths, severe splinting	2
Cry	No cry/verbalization	0
	Moans or whimpers, occasional complaint, occasional verbal outburst or grunt	1
	Crying steadily, screams or sobs, frequent complaints, repeated outbursts, constant grunting	2
Consolability	Content or relaxed	0
	Reassured by occasional touching, hugging or being talked to, distractible	1
	Difficult to console or comfort, pushing away caregiver, resisting care or comfort measures	2

Wong-Baker Faces Scale: 4 – 12 years old (can be used up to 18)^{178–180}



0	2	4	6	8	10
No Hurt	Hurts a Little Bit	Hurts Little More	Hurts Even More	Hurts Whole Lot	Hurts Worst


Jerry Cans for Scoring if Unable to Understand Faces¹⁷⁷



0	2	4	6	8	10
No Pain	Mild Pain	More Pain	Moderate Pain	Severe Pain	Overwhelming Pain

Adults and Children Able to Understand Numeric Scores

PAIN SCORE 0–10 NUMERICAL RATING



How to Score – All of the above scales have outcomes graded the same

0: relaxed and comfortable

1 – 3: mild discomfort

4 – 6: moderate pain

7 – 10: severe pain

Treatment: WHO Analgesic Ladder – graduated approach to pain control

Step 1: Pain score 0-3

Non-opioid

Paracetamol 10-15mg/kg q4-6hrs (adults 650mg PO q4-6hrs)

Ibuprofen 10mg/kg q6-8hrs (adults 400-800mg PO q6-8hrs)

If alternate paracetamol & ibuprofen can give patient one or the other pain medication every 3 hours (e.g. paracetamol now, ibuprofen in 3 hours, paracetamol 3 hours after that, etc.)

Step 2: Pain score 4-6

Oral Opioids preferred

Morphine preferred over Codeine if available

Children: Morphine 0.2-0.5 mg/kg/dose PO q4-6hrs prn

Adults: Morphine 2-10mg/kg/dose PO q2-4hrs prn

Step 3: Pain score 7-10

Intravenous Opioids preferred

Children: Morphine 0.1-0.2 mg/kg/dose IV q2-4hrs prn

Adults: Morphine 1-2 mg/dose IV q2-4hrs prn

Notes

It is often beneficial to use non-opiates with opiates

When beginning opioids, use high enough dose to control pain and monitor respirations q1hr to avoid respiratory depression

Neonatal



Protocols

Newborn Feeding/Fluid Requirements

	<1500g	>1500g
D1 (D10%)	80	60
D2 (D10%)	100	80
D3 (MRL)	120	100
D4 (MRL)	140	120
D5 (MRL)	160	140
D6 (MRL)	180	160
D7+ (MRL)	180	160-180

Total Fluids Calculations:

- Day 1 refers to 1st day of life – there is no day 0. The total volume of fluids is calculated for 24 hours and is composed of both enteral (PO/NG) and IV fluids.
- Use Birth Weight for calculations until BW exceeded. Or use highest weight.
- If IV fluids given, use D10% for days 1 & 2. Change to MRL on Day 3. Maximum IVF 150ml/kg/d. Give via paediatric infusion set (1 ml=60 drops) and replace fluid bag every 24 hours.
- Perinatal asphyxia: NPO for 24 hours after birth and IVF at 50ml/kg/day
- Occasionally VLBW babies need 200-220 ml/kg/d to gain weight.
- Monitor weight daily for all infants in newborn nursery.

Well baby >34 weeks gestation and/or >1500 g:

- LBW infants who are able to breastfeed should be put to the breast as soon as possible after birth when they are clinically stable.
- Feed on demand, at least every 3 hours (at least 8 feeds per day). In babies >1500 g who are not sick and are breastfeeding, it is not necessary to perform fluid calculations.
- If sick and not able to breastfeed, start EBM using enteral feed calculations below

Newborn Feeding/Fluid Requirements

Enteral feeding:

- Neonates < 32-34 weeks or <1500 g often have trouble coordinating suck and swallow. Expressed breast milk should be obtained and given to infant by cup, spoon or oral/nasal-gastric tube. Bottle feed not recommended.
- Feed EBM every 2 hours (12 feeds per day). May put to breast after EBM.
- Neonates unable to BF should be kept NPO for day 1. On day 2 start EBM at 10ml/kg/day, with the remaining fluid requirement met by intravenous fluids.
- Increase EBM by 30ml/kg/day every 24 hours and decrease IV fluids to keep within daily fluid requirement until IVF stopped. Monitor carefully for feeding intolerance (vomiting, apnea, gastric residuals).
- When enteral feeding volume reaches 100ml/kg/day and baby tolerating enteral feeds, the IV infusion may be stopped. Aim to stop IVF by day 7-8 of life to reduce risk of infection.
- Newborns lose weight the first week of life but should not lose more than 10% body weight.
- Newborns should be back to birthweight by 2 weeks of age. After infant regains BW, the goal is to gain 20-30 grams a day during the first 6-8 weeks of life

Indications for OGT or NGT:


- All neonates <1300 grams until gaining weight steadily.
- Premature or VLBW (<32-34 wks or <1500 g) with poor suck, ineffective suck/swallow coordination (coughs or vomits with feed), fatigues easily.
- Respiratory distress –risk aspiration. All newborns on CPAP.
- Sick newborns (asphyxia, meningitis, seizures) – poor suck
- Poor/no weight gain for 1 week on EMB/BF alone.

VLBW infants (<1500g) Vitamin supplementation (when tolerating full feeds):

- Vitamin D supplements at a 400 I.U. per day until 6 months of age.
- Iron supplementation 2-4 mg/kg per day starting at 2 weeks until 6 months of age

Continuous Positive Airway Pressure (CPAP)⁷⁸

(For maximum benefit start as soon as symptoms are identified)



Silverman-Anderson Score

Feature	Score 0	Score 1	Score 2
Chest Movement	Equal	Respiratory Lag	Seesaw Respiration
Intercostal Retraction	None	Minimal	Marked
Xiphoid Retraction	None	Minimal	Marked
Nasal Flaring	None	Minimal	Marked
Espiratory Grunt	None	Audible with Stethoscope	Audible


Score of >6 initiate CPAP as you prepare for transfer for mechanical ventilation

Early Onset Neonatal Sepsis (<7 days)

Risk Factors:

- Prolonged rupture of membranes (>18 hours)
- Prolonged labour
- Maternal fever ($\geq 38^{\circ}\text{C}$) or other evidence of infection
- Foul smelling amniotic fluid or malodourous baby
- Prematurity (< 37 weeks)
- Low birth weight ($<2000\text{g}$)
- Birth outside health facility
- Some traditional practices (such as application of cow dung to cord)
- 5-minute APGAR score < 6

Prevention (in settings without laboratory)¹⁹²



Neonatal Sepsis (<28 days) Treatment

Clinical Signs of sepsis?

- Lethargy
- Bulging fontanelle
- History of convulsions
- Feeding Difficulty
- Temperature >38 or <35.5
- Respiratory rate >60 bpm
- Severe chest wall indrawing, grunting, apnea or cyanosis
- PROM >18 hrs if aged <7 d

Yes

- 1)Blood cultures
- 2)Do LP if meningitis suspected
- 3)Check for hypoglycaemia, treat if unable to measure glucose
- 4)Give oxygen if cyanosed / respiratory rate >60 bpm
- 5)Give Vitamin K and Tetracycline Eye Ointment (TEO) if born at home or not given at maternity
- 6)Keep warm
- 7)Maintain feeding by mouth or ng, use iv fluids only if respiratory distress or severe abdominal

No`

Is there

- Pus from the eye;
- Pus from the ear;
- Pus from umbilicus and redness of abdominal skin; or
- Few **large**, pus-filled blisters / septic spots.

DECIDE - does the baby need fluids, feeds or blood

- Any of the following symptoms?
- Jaundice
 - Capillary refill
 - Severe pallor
 - Localized severe infection - joints, abdominal distension
 - Weight loss

1)Antibiotic Treatment*

- a. Ampicillin 50mg/kg q8hr (q12hr if in 1st week) PLUS Gentamicin 5mg/kg OD (3mg/kg OD if <2 kg in 1st week or birth asphyxia)
- b. If concern for soft tissue infection: Cloxacillin PLUS Gentamicin (same dosing as above)
- c. If concern for meningitis: Ampicillin 100mg/kg q8hr (q12hr if in 1st week) PLUS Cefotaxime* 50mg/kg q8hr (q12hr if in 1st week)
*may substitute Ceftriaxone (but risk for jaundice)

Where appropriate:

- 1)Treat for neonatal ophthalmia
- 2)Treat with oral antibiotic – one that covers Staph aureus if large, pus-filled septic spots
- 3)Give mother and advice and arrange review

Duration of Treatment for Neonatal Sepsis


Problem	Days of Treatment
Signs of severe neonatal sepsis	<ul style="list-style-type: none">• Blood culture should be done• IV/IM antibiotics should be continued for a minimum of 7 days or until completely well if the LP is clear.
Mild signs of neonatal infection or R/O sepsis in child with risk factors – ONLY if blood culture done	<ul style="list-style-type: none">• Antibiotics could be stopped after 48 hours if all signs of possible sepsis have resolved, child feeding well and LP, if done is negative. Blood Culture negative.
Neonatal Meningitis or Severe Neonatal Sepsis with LP	<ul style="list-style-type: none">• Blood culture should be done if not able to do LP• IV/IM antibiotics should be continued for a minimum of 14 days• IV/IM antibiotics for a minimum of 3 weeks, if gram negative meningitis is suspected
Clinical or radiological pneumonia	<ul style="list-style-type: none">• IV/IM antibiotics should be continued for a minimum of 5 days or until completely well for 24 hrs• For positive LP see meningitis
Skin infection with signs of generalized illness such as poor feeding	<ul style="list-style-type: none">• IV / IM antibiotics could be stopped after 72 hours if the child is feeding well without fever and has no other problem and LP, if done, is normal. Blood Culture negative• Oral antibiotics should be continued for a further 5 days.

Neonatal Jaundice

- Assess for jaundice in bright, natural light if possible. Check eyes, under tongue, palms and soles
- Always measure serum bilirubin if <24 hours and if clinically moderate or severe jaundice. Treat according to <https://bilitool.org/> or infant age in days per WHO guidelines below
- **Any jaundice <24 hours needs further evaluation and urgent treatment with phototherapy or exchange transfusion**
- If unable to measure bilirubin start phototherapy:
 - In well baby with jaundice easily visible sole of foot during first week of life
 - In a preterm baby (<2000 gm) with ANY visible jaundice
 - In a sick baby with poor feeding, irritability and moderate to severe jaundice. Evaluate and treat for sepsis
- Babies over 2 weeks of age need evaluation for obstructive causes of jaundice such as biliary atresia. They do not usually require phototherapy.
- Phototherapy will not treat indirect hyperbilirubinemia

Phototherapy and Supportive Care: Checklist

- **Shield the eyes with eye patch or hat.** Remove periodically during feeds
- **Keep the baby naked**
- **Place the baby close to the light source** – 45 cm distance is often recommended but closer OK if baby not overheating. May use white cloth around light to reflect light back to bay. Learn recommended distance for your equipment
- **Do not place anything on phototherapy devices.** Lights and baby need to keep cool so do not block air vents. Also keep device clean – dust can carry bacteria and reduce light emitted
- **Promote frequent breastfeeding.** Unless baby dehydrated, supplements or IV fluids are unnecessary. Phototherapy can be interrupted for feeds and to allow maternal bonding
- **Periodically change position from supine to prone.** Expose the maximum surface area of baby. Reposition after each feed
- **Monitor temperature** every 2 hours and weight every 24 hours
- **Periodic (12-24 hours) plasma/serum bilirubin test required.** Visual testing for jaundice is unreliable
- **Make sure light source is working** and emitting light. Fluorescent tubes should be replaced if more than 6 months in use, tube ends have blackened or lights flicker.



Dermal Zone	Indirect Bilirubin (mg/100 mL)		
	Mean ± SD	Range	Observations
1	5.9 ± 0.3	4.3 – 7.9	13
2	8.9 ± 1.7	5.4 – 12.2	49
3	11.8 ± 1.8	8.1 – 16.5	52
4	15.0 ± 1.7	11.1 – 18.3	45
5		> 15	29

While can be used if no other method available, remember that visual inspection for jaundice is unreliable.

Treatment of jaundice based on serum bilirubin level

⁵³

Age	Phototherapy		Exchange transfusion ^a	
	Healthy infant ≥ 35 weeks	Preterm infant < 35 weeks' gestation or any risk factors ^b	Healthy infant ≥ 35 weeks	Preterm infant < 35 weeks' gestation or any risk factors
Day 1	Any visible jaundice ^c		260 µmol/l (15 mg/dl)	220 µmol/l (10 mg/dl)
Day 2	260 µmol/l (15 mg/dl)	170 µmol/l (10 mg/dl)	425 µmol/l (25 mg/dl)	260 µmol/l (15 mg/dl)
Day ≥ 3	310 µmol/l (18 mg/dl)	250 µmol/l (15 mg/dl)	425 µmol/l (25 mg/dl)	340 µmol/l (20 mg/dl)

^a Exchange transfusion is not described in this *Pocket book*. The serum bilirubin levels are included in case exchange transfusion is possible or if the infant can be transferred quickly and safely to another facility where exchange transfusion can be performed.

^b Risk factors include small size (< 2.5 kg at birth or born before 37 weeks' gestation), haemolysis and sepsis.

^c Visible jaundice anywhere on the body on day 1.




Ballard Score

SIGN

-1 0 1 2 3 4 5

Posture






Square
Window



NEUROMUSCULAR MATURITY SCORE







Arm Recoil

Popliteal
Angle



Scarf Sign

Heel to Ear



SIGN

PHYSICAL MATURITY SCORE

	-1	0	1	2	3	4	5
Skin	Sticky, friable, transparent	gelatinous, red, translucent	smooth pink, visible veins	superficial peeling &/or rash, few veins	cracking, pale areas, rare veins	parchment, deep cracking, no vessels	Leathery, cracked, and wrinkled
Lanugo	none	sparse	abundant	thinning	bald areas	mostly bald	
Plantar Surface	heel-toe 40-50mm: -1 <40mm: -2	>50 mm no crease	faint red marks	anterior transverse crease only	creases ant. 2/3	creases over entire sole	
Breast	imperceptible	barely perceptible	flat areola no bud	stippled areola 1-2mm bud	raised areola 3-4 mm bud	full areola 5-10mm bud	
Eye / Ear	lids fused loosely: -1 tightly: -2	lids open pinna flat stays folded	sl. curved pinna; soft; slow recoil	well-curved pinna; soft but ready recoil	formed & firm instant recoil	thick cartilage ear stiff	
Genitals Male	scrotum flat, smooth	scrotum empty, faint rugae	testes in upper canal, rare rugae	testes descending, few rugae	testes down, good rugae	testes pendulous, deep rugae	
Genitals Female	clitoris prominent & labia flat	clitoris & small minora	prominent clitoris & enlarging minora	majora & minora equally prominent	majora large, minora small	majora cover clitoris & minora	

90

MATURITY RATING

Total Score
(Neuromuscular + Physical)

Weeks

20

22

24

26

28

30

32

34

36

38

40

42


44

46

48

50

Internal Medicine



Protocols

Adult Heart Failure Algorithm

Common Presenting Complaints

- Paroxysmal Nocturnal Dyspnea (PND)
- Orthopnea
- Dyspnea on Exertion (DOE)
- fatigue and weight gain
- cough
- exercise intolerance
- increasing abdominal girth
- lower extremity edema
- shortness of breath when bending forward ("bendopnea")

Risk Factors

- known history of heart failure, coronary artery disease, myocardial infarction or hypertension
- diabetes mellitus or dyslipidemia
- chronic obstructive pulmonary disease (COPD) or other lung disease
- cardiac valve disease
- pulmonary embolism or pulmonary hypertension
- sleep apnea
- infection
- recent surgery or trauma
- family history heart disease
- significant smoking/alcohol use

- Monitor, support ABCs
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Start Oxygen if spO₂ < 94%
- Place large bore IV
- Assess AVPU/GCS, hydration status
- Perform brief, targeted history, physical exam
- 12-lead ECG

Classify based on your physical exam

Congestion

Low Perfusion

Yes

- Cold & Wet**
SBP<90/narrow pulse pressure
Cool/pale extremities
Decreased UOP
Yes Elevated JVP
Crackles in lung bases
+Peripheral edema
Hepatomegaly/ascites

No

- Cold & Dry**
SBP<90/narrow pulse pressure
Cool/pale extremities
Decreased UOP
Normal/low JVP
Clear Lungs
Minimal peripheral edema

Warm & Wet

- SBP > 90
Good peripheral pulse

- No** Normal UOP
Elevated JVP
Crackles in lung bases
+Peripheral edema
Hepatomegaly/ascites

Warm & Dry

- SBP > 90
Good peripheral pulse

- Normal UOP
Normal JVP
Clear Lungs
Minimal peripheral edema

Adult Heart Failure Treatment⁷³

For all exacerbations:

- Monitor intake/output, consider foley, get daily weights
- Consider electrolytes, BUN, Cr
- ECHO if new Dx, repeat once stable if possible worsening baseline disease

Cold & Wet

- I. Dopamine: 3-10 mcg/kg/minute to maintain SBP > 90
- II. Furosemide
 - a. Start once BP is sustained
 - b. 40-80mg IV 2 hrly according to clinical evaluation
- III. Digoxin
 - a. **ONLY IF PROVEN**
supraventricular tachycardia (atrial fibrillation, atrial flutter, etc.)
 - b. Loading dose: 0.25-0.5mg IV
 - c. Maintenance dose: 0.25mg 6-8 hrly / 24 hours prn

Warm & Wet

- I. Furosemide
 - a. Initial IV dose should equal or exceed chronic daily PO dose OR 40-80mg IV bolus, double dose if no effect in 30 minutes
 - b. Consider 2nd diuretic if no response
 - c. Continue 2 hrly as needed
- II. Morphine: 5-10 mg PO if distressed, restless or anxious
- III. If hypertensive: ACE-inhibitor
- IV. Continue home dose of Beta-blocker or ACEI if hemodynamically stable, but do not titrate until exacerbation is resolved

Cold & Dry

- I. Dopamine: 3-10 mcg/kg/minute to maintain SBP > 90
- II. Digoxin
 - a. **ONLY IF PROVEN**
supraventricular tachycardia (atrial fibrillation, atrial flutter, etc.)
 - b. Loading dose: 0.25-0.5mg IV
 - c. Maintenance dose: 0.25mg 6-8 hrly / 24 hours prn

Warm & Dry (Stable, chronic heart failure, Rx should also be started in the hospital after an acute exacerbation is stabilized, prior to discharge)

- I. Ace-inhibitor
 - a. titrate to highest dose tolerated
 - b. periodically monitor Cr and K+
- II. Beta-blocker – start low dose, titrate up every two weeks to maximum dosage tolerable
- III. Furosemide: for chronic volume overload
- IV. Spironolactone
 - a. For NYHA class II-IV
 - b. Serum Cr < 2.5/2 (men/women)
 - c. Potassium < 5

New York Heart Association (NYHA) Classes⁹⁶

- I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath)
- II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
- III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
- IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

TIA/Stroke²⁷ (check or give glucose prior to initiating stroke evaluation)

Symptoms of TIA/Stroke

- Transient symptoms in TIA
- focal neurologic deficit
- unilateral motor dysfunction of extremities, face (weakness, clumsiness, paralysis)
- vision change: loss of vision in one eye, diplopia
- homonymous hemianopia
- speech disturbances (aphasia, dysarthria)
- unilateral sensory deficit (numbness, sensory loss)
- Vertigo, ataxia of gait, trunk, extremities
- Loss of consciousness, syncope convulsion

Management²⁷

1. Monitor, support ABCs
2. Check vital signs (BP, PR, RR, spO₂, Temp)
3. Start Oxygen if spO₂ < 94%
4. Maintain glucose between 7.7 (140)-10 (180)
5. Obtain labs: CBC, RFT, electrolytes, coagulation studies, urinalysis for proteinuria
6. 12-lead ECG
7. Perform brief, targeted history, physical exam

ECG positive for arrhythmia or infarction

Prioritize Cardiac Stabilization (see protocol)

Symptoms Ongoing?

No

Yes

Evaluate and treat mimics:

- Hypo/hyperglycemia
- Convulsion
- (Complicated) Migraine
- Brain lesion (tumor/aneurysm)
- Infection (e.g. meningitis)
- Cardiac Disorders
- Syncope
- Delirium
- Psychiatric disorder
- Acute vestibular syndrome
- Peripheral Nerve Condition

ROSIER Criteria¹⁹³

Loss of consciousness or syncope	-1
Seizure activity	-1
Asymmetrical facial weakness*	+1
Asymmetrical arm weakness*	+1
Asymmetrical leg weakness*	+1
Speech disturbance	+1
Visual field defect	+1


Total < 1:
Look for other causes

No mimics found (TIA Rx is same as stroke at this point)

Total >= 1

Stroke Protocol

Stroke Protocol




National Institute of Health Stroke Scale⁹⁷

1a. Level of consciousness (LOC)	0 = Alert; keenly responsive 1 = Not alert, but arousable by minor stimulation 2 = Not alert; requires repeated stimulation 3 = Unresponsive or responds only with reflex
1b. LOC Questions: What is the month? What is your age?	0 = Both answers correct 1 = Answers one question correctly 2 = Answers both questions incorrectly
1c. LOC Commands	0 = Performs both tasks correctly 1 = Performs one task correctly 2 = Performs neither task correctly
2. Best Gaze	0 = Normal 1 = Partial gaze palsy 2 = Forced deviation
3. Visual	0 = No visual loss 1 = Partial hemianopia 2 = Complete hemianopia 3 = Bilateral hemianopia
4. Facial palsy	0 = Normal symmetric movements 1 = Minor paralysis 2 = Partial paralysis 3 = Complete paralysis of one or both sides
5. Motor arm 5a. Left arm 5b. Right arm	0 = No drift 1 = Drift 2 = Some effort against gravity 3 = No effort against gravity; limb falls 4 = No movement
6. Motor leg 6a. Left leg 6b. Right leg	0 = No drift 1 = Drift 2 = Some effort against gravity 3 = No effort against gravity; limb falls 4 = No movement
7. Limb ataxia	0 = Absent 1 = Present in one limb 2 = Present in two limbs
8. Sensory	0 = Normal, no sensory loss 1 = Mild-to-moderate sensory loss 2 = Severe to total sensor loss
9. Best language	0 = No aphasia; normal 1 = Mild to moderate aphasia 2 = Severe aphasia 3 = Mute, global aphasia
10. Dysarthria	0 = Normal 1 = Mild to moderate dysarthria 2 = Severe dysarthria
11. Extinction and inattention	0 = No abnormality 1 = Visual/tactile/auditory/spatial/personal inattention 2 = Profound hemi-inattention or extinction

Adult Sepsis

Definitions

1. Sepsis (no more Severe Sepsis): Life-threatening Organ Dysfunction Caused by Dysregulated Host Response to Infection
2. Organ Dysfunction: acute change in Sequential Organ Failure Assessment (SOFA) score ≥ 2 points secondary to infection
3. Septic Shock
 - a. sepsis with severe circulatory/cellular/metabolic abnormalities substantially increasing mortality (hospital mortality $\geq 40\%$)
 - b. Clinical definition: persistent hypotension requiring vasopressors to maintain MAP ≥ 65 & serum lactate $\leq 2 \text{ mmol/L}$ (18mg/dL) after adequate volume resuscitation



REMINDER:
This protocol can be used during hospitalization, not just at admission!

≥ 2 increase in SOFA score from baseline? (assume a score of 0 if no known preexisting organ dysfunction)

Don't treat for Sepsis! ← No → **Treat Sepsis**

Estimate of PaO₂ using O₂Sat⁹⁸

PaO ₂	O ₂ sat	PaO ₂	O ₂ sat	PaO ₂	O ₂ sat
21	35%	36	69%	51	86%
22	37%	37	71%	52	86%
23	40%	38	72%	53	87%
24	43%	39	74%	54-55	88%
25	45%	40	75%	56-57	89%
26	48%	41	76%	58-59	90%
27	50%	42	77%	60-62	91%
28	53%	43	79%	63-65	92%
29	55%	44	80%	66-68	93%
30	57%	45	81%	69-73	94%
31	60%	46	82%	74-78	95%
32	62%	47	83%	79-85	96%
33	64%	48	83%	86-96	97%
34	65%	49	84%	97-114	98%
35	67%	50	85%	>=115	99%


Estimate of Oxygen Flow Rates

Nasal Cannula	
Oxygen Flow Rate	FiO ₂ (%)
Room Air	21
1L	24
2L	28
3L	32
4L	36
5L	40
6L	44

Therapeutic management

- I. Cardiovascular: monitor HR, BP, UOP, and capillary refill for signs of hypoperfusion
 - a. **Initial Bolus: 30mL/kg LR/NS in first 3 hours**⁹⁹
 - b. Further Bolus: additional 500mL-1L LR/NS as needed
 - c. Vasopressor: begin if MAP < 65 after fluid resuscitation
 - i. Dopamine 5mcg/kg/minute, titrate to effect
- II. Respiratory: Oxygen as necessary to keep O₂sat > 90%
- III. Labs to draw
 - a. **CBC, malaria, Blood Culture**
 - b. Renal Functions, electrolytes
 - c. Liver functions, amylase, lipase
 - d. PT/INR, PTT
 - e. Urine Culture
- IV. Choice of Antibiotics^{99,100,109,101-108}
 - a. dual therapy ONLY for those in shock
 - b. 2nd line or additional antibiotic based on clinical suspicion of source
 - i. **1st line: Ceftriaxone 2g IV daily**
 - ii. Gram Negatives
 1. Gentamycin IV 5mg/kg/day (also for MRSA)
 2. Meropenem 1g IV 8 hourly (also gram+ but NOT MRSA)
 - iii. Gram Positives (including MRSA)
 1. Clindamycin 600mg IV 8 hourly (also anaerobes)
 2. Vancomycin 15mg/kg IV 8 hourly (consult pharmacy)
- V. Transfuse: Hgb < 5
- VI. Glucose Control: insulin to keep glucose under 12
- VII. DVT Prophylaxis: generally recommended
- VIII. GI Prophylaxis¹¹⁰: only recommended if mechanically ventilated or coagulopathy present, may consider in severely ill with multiple comorbidities, may use H2-blocker or PPI
- IX. Nutrition: begin enteral feeding early in the disease course

Adult Convulsions²⁷



Adult Meningitis^{1,111}

1. Symptoms are often nonspecific, if unclear treat for Meningitis **AND** other diagnosis (malaria, TB meningitis, etc.) until definitive tests.
2. There is **NO WAY** to rule in or rule out meningitis without a lumbar puncture

Symptoms that MAY be present	Warning Signs/Red Flags (indicate more critical illness)
Fever* ⁺	Rapidly Progressive Rash
Headache*	Poor Peripheral Perfusion: CR > 4 sec, oliguria, SBP < 90
Neck Stiffness or Kernig's/Brudzinski's* ⁺	Respiratory Rate: < 8, > 30
Altered Mental Status – Confusion, Obtundation* ⁺	Pulse: > 140, < 40
*If < 2 of these symptoms, strongly consider alternate diagnosis ^{112,113}	WBC < 4
⁺ If none of these, should not consider meningitis ¹¹⁴	GCS < 12
Convulsions Photophobia	Poor response to initial resuscitation Focal Neurological Signs Cushing's Triad: <u>Late and Ominous Sign</u> (HTN, bradycardia, irregular breathing)

3. If culture reveals meningococcus, must treat close-contacts


- a. Close-contacts:
 - i. Household members, roommates, dorm members,
 - ii. On same flight/bus > 8 hours
 - iii. Exposed to oral secretions (intimate kissing, mouth-to-mouth resuscitation, intubation or ET-tube management)
- b. Rx:
 - i. > 15 years old: Ciprofloxacin 500mg PO stat
 - ii. < 15 years old: Ceftriaxone 125mg IM stat^{115,116}

4. TB see tuberculosis section

5. Steroids no longer recommended³⁸⁻⁴¹

Management of Meningitis

- Monitor, support ABCs
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Assess AVPU/GCS, hydration status
- Start Oxygen if spO₂ < 94%, insert IV if needed
- Perform brief, targeted history, physical exam



Upper GI Bleed


I. Common Presentations²⁷

- Melena: dark, tarry stools, stained with blood. Requires 50mL of blood from UGI.
- Haematemesis: bright red blood in vomitus, usually source is above ligament of Treitz.
- Coffee-ground emesis: vomitus containing dark, altered blood with stomach contents.
- Haematochezia: bloody faeces.

II. Factors effecting likelihood of UGI bleed¹¹⁷

- More likely: history of melena, melenic stool on exam, coffee grounds on lavage, Urea/Cr > 30
- Severe bleeding more likely: red blood detected during lavage, tachycardia, Hgb < 8
- Less likely: blood clots in stool

III. Management



Adult Hyperglycemia, DKA and HHS (RBS > 14mmol/L)^{26,27}

Management

Monitor, support ABCs

Check vital signs (BP, PR, RR, spO₂, Temp)


Start Oxygen if spO₂ < 94%

IV access, draw renal functions, potassium urinalysis

12-lead ECG (adults)

Perform brief, targeted history, physical exam

DO NOT GIVE INSULIN



Uncomplicated Hyperglycemia

Known Diabetic

- Medication compliance?
 - No: restart regimen
 - Yes: change dose
- Keep log of RBS
- Clinic f/u in 5 days

Newly Diagnosed Diabetic

- Start Metformin
- 500mg BD with meals
- Titrate qweek if no GI sxs
- If GI sxs, decrease to previous dose until resolution
- Max dose is 1000mg BD or sometimes 850mg TID

All Patients

- Lifestyle modification advice

Insulin Protocol (start after 1 hr of hydration):

1. Soluble insulin Injection
 - a. IM 0.1 IU/kg/hr
 - b. SC 0.15 IU/kg every 2 hours
2. Soluble insulin infusion
 - a. 0.14 IU/kg/hr

Potassium Protocol:

Add 5mEq KCl/500mL bag

DO NOT give potassium if urine output < 1mL/kg/hr (or K > 5.5)

Monitor Neuro Status for: headache, slowing HR, irritability, incontinence, decreased conscious, focal signs

1. Check/correct hypoglycemia
2. Call senior, transfer ICU
3. Mannitol 0.5-1g/kg

When RBS < 14, recheck Urinalysis


1. Ketones still present
 - a. Change IVF to 5% Dextrose ½ NS at 150-200mL/hr
 - b. Insulin 0.02-0.05 IU/kg/hr infusion (IM/SC maintain regimen)
2. No ketones, switch to SC insulin with meals, sliding scale, or Mixtard BD
 - a. Usual dose: 0.5-1 IU/kg/day

Fluid Protocol:

1. Initial bolus
 - a. Hypovolemic Shock: 15-20mL/kg NS or RL bolus, repeat until BP improves
 - b. Hypovolemic but no Shock: 15-20mL/kg of NS or RL over 1st hr
 - c. **DO NOT** give > 50mL/kg in first 4hrs, can cause cerebral edema
2. IF CORRECTED Na is < 135, continue NS or LR @ 250-500mL/hr
3. IF CORRECTED Na is > 135, continue with ½ NS @ 250-500mL/hr
4. Satisfactory urine output is 1-2 mL/kg/hr

NEVER alternate D10 & NS/RL this can cause brain oedema

Hypertensive Urgency and Emergency³



Management³

19. Monitor, support ABCs
20. Check vital signs (PR, RR, spO₂, Temp)
21. Repeat and **VERIFY** BP
22. Start Oxygen if spO₂ < 94%
23. IV access, 12-lead ECG
24. Labs: RBS, CBC, renal functions, urinalysis for proteinuria
25. Perform brief, targeted history, physical exam

Hypertensive, go to Hypertension Protocol

REMEMBER
Headache alone is **NEVER** an emergency.

Evidence of end-organ dysfunction²⁰⁴

1. Chest Pain/Angina/ACS/Heart Failure
2. Shortness of breath or Pulmonary Edema
3. Stroke/Numbness/weakness/changes in vision/difficulty speaking
4. Encephalopathy
5. Acute Kidney Injury
6. Aortic dissection
7. Eclampsia

Yes No

Hypertensive Emergency

Hypertensive Urgency

Rx with any of the following²⁰⁵:

1. Nicardipine: initial 5mg/H, increase 2.5mg/hr q5min to max of 15mg/H
2. Sodium nitroprusside: 0.3-0.5 mcg/kg/min, increase 0.5 mcg/kg/minute every few minutes to max 10mcg/kg/min
3. Labetalol: 10-20 mg IV, then bolus of 20-80 mg q10min until BP at target or 300mg total dose

Rx with any of the following:

1. Nicardipine 20-40mg PO q8-12H
2. Captopril 25mg PO q8-12H
3. Labetalol 200mg PO, then 200-400mg q6-12H prn

Must be admitted for management
Goal²⁰⁶: 20-25% decrease in BP in 1st hour, then <160/110 in next 2-6 hours

No specific goal BP acutely
If still no evidence of end-organ dysfunction at 6 hours, may discharge home with follow-up in a **few days**


Hypertension in Specific Conditions

1. Acute aortic dissection
 - a. Goal: SBP < 120 in 5-10 minutes
 - b. Recommended Rx is beta-blocker and vasodilator
 - i. Esmolol/metoprolol & nicardipine, nitroprusside, fenoldapam
2. Acute stroke – see stroke pathway
3. Hypertensive Encephalopathy
 - a. Goal: lower SBP by no more than 20-25% or DBP 100-110 in first hour
 - b. Rx options: labetalol, nicardipine (DO NOT USE: nitroprusside)
4. Acute myocardial ischemia (also see Acute Coronary Syndrome protocol)
 - a. Goal: SBP < 160, DBP < 100
 - b. Rx recommended: Nitroglycerin (unless phosphodiesterase inhibitor use in last 48 hours – sildenafil, tadalafil)
 - c. Alternatives: labetalol, esmolol, nicardipine
5. Acute Heart Failure (also see Heart Failure protocol)
 - a. Rx recommended: IV or SL nitroglycerine
6. Acute postoperative hypertension
 - a. Usually starts <2H after operation, Usually requires Rx < 6 hours
 - b. Goal in cardiac surgery patients: BP < 140/90 or MAP < 105
 - c. Rx options: esmolol, nicardipine, labetalol, nitroprusside
7. Acute pulmonary edema
8. Acute renal failure – see renal failure algorithm
9. Preeclampsia/eclampsia – consult OBGYN

General (Essential) Hypertension (confirmed on >1 occasion) Treatment¹¹⁸

Lifestyle Interventions

Set blood pressure goal and choose medication based on age, diabetes (DM) and chronic kidney disease (CKD)



Liver Failure Algorithm⁷²


If no known history, suspect liver disease with:

- | | |
|---|---------------------------|
| Elevated liver function tests | Jaundice |
| Peripheral edema/ascites | Cutaneous telangiectasias |
| Abdominal distension | Spider angiomas |
| Gastrointestinal bleeding (hematemesis/melena) | Palmar erythema |
| Abdominal wall collaterals (caput medusa) | Digital clubbing |
| Encephalopathy (confusion, change in sleep pattern) | Peripheral Neuropathy |
| Gynecomastia/testicular atrophy | Asterixis |


Notes on Lab Results

1. ↓albumin, ↑PT/INR/PTT in liver failure
2. ALT more liver specific than AST
3. ALT > AST: viral hepatitis, fatty liver/nonalcoholic steatohepatitis (pre-cirrhotic)
4. AST > 2 x ALT: alcoholic hepatitis, cirrhosis (non-hepatic source)
5. Jaundice: seen when bilirubin > 2.5mg/dL, ↑ in urine bili if conjugated

- Monitor, support ABCs
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Start Oxygen if spO₂ < 94%, Place large bore IV
- Assess AVPU/GCS, hydration status
- Perform brief, targeted history, physical exam
- 12-lead ECG in adults
- **Rule Out:** Malaria (RDT, B/S), Sepsis (CBC, blood Cx)
- Other Labs: LFTs (AST, ALT, T&D bili, albumin), renal functions, electrolytes, consider PT/INR/PTT



Diagnostic Workup⁷²



Grading Encephalopathy

Stage I = Altered/depressed mental status, not acting like their usual self

Stage II = Lethargy, Confusion, sleep reversal

Stage III = Stupor, somnolence, combativeness

Stage IV = Coma

Modified Child-Turcotte-Pugh Score

Points Scored			
	1	2	3
Ascites	None	Easily Controlled	Poorly Controlled
Encephalopathy	None	Grade 1 or 2	Grade 3 or 4
Bilirubin (mg/dL)	< 2	2-3	> 3
Albumin (g/dL)	> 3.5	2.8-3.5	< 2.8
PT (sec > control)	< 4	4-6	> 6
Or INR	< 1.7	1.8-2.3	> 2.3
Classification			
	A	B	C
Total points	5-6	7-9	10-15
1-year survival	100%	80%	45%


Chronic Management

1. Vaccinate for Hepatitis A & B if not done already
2. Educate about avoiding EtOH, paracetamol, and other hepatotoxic drugs
3. Variceal Bleeding
 - a. Start prophylaxis 1 week after bleeding if hemodynamically stable
 - b. Propranolol 20mg PO BD or Carvedilol 3.125mg PO BD
 - c. Titrate to 1 of the following criteria¹¹⁹
 - i. Resting HR 55 beats/minute
 - ii. HR reduction 25% from baseline rate
 - iii. Development of side effects
4. If all of the following, start Co-trimoxazole 160/800mg PO 5 days/week or Norfloxacin 400mg PO daily¹²⁰⁻¹²²
 - a. Spontaneous bacterial peritonitis
 - b. Ascitic fluid protein < 1.5g/dL
 - c. Impaired renal function (Cr > 1.2, BUN > 25 or Na < 130)
 - d. Child-Turcotte-Pugh Score > 9 & bilirubin > 3
5. Ascites Rx
 - a. Education: reduce salt, reduce fluid intake if low Na and hypervolemic
 - b. Diuretics (both if blood pressure can tolerate)
 - i. Spironolactone 100mg/day (max 400mg/day)
 - ii. Furosemide 40mg/day (max 160mg/day)
 - c. If refractory, consider therapeutic paracentesis

Children

1. Almost always secondary (almost never intrinsic hepatic disease)
2. If intrinsic disease, hepatitis A most common, but screen for Hepatitis B/C
3. If cholelithiasis/choledocholithiasis, must rule-out sickle cell disease


Acute Kidney Injury in Adults



Severely Agitated or Violent Patient¹²³

- I. Prevention is always better than treatment when possible
- II. Factors making violence more likely
 - a. Male gender
 - b. A history of violence
 - c. Drug or alcohol abuse
- III. Signs of impending violence
 - a. Provocative behavior
 - b. Angry demeanor
 - c. Loud, aggressive speech
 - d. Tense posturing (eg, clenched fists)
 - e. Frequently moving or changing body position, pacing
 - f. Aggressive acts (eg, pounding walls, throwing objects, hitting oneself)
- IV. 10 elements for verbal de-escalation
 - a. Respect personal space (2 arms lengths)
 - b. Do not be provocative (remain calm)
 - c. Establish verbal contact (first person to contact leads discussion)
 - d. Use concise, simple language
 - e. Identify feelings & desired (“What are you hoping for”)
 - f. Listen closely (repeat back to patient to ensure accuracy)
 - g. Agree, be clear, agree to disagree if necessary
 - h. Set clear limits and boundaries (explain violence/abuse is not tolerated)
 - i. Offer choices, stay positive
 - j. Debrief the patient and staff
- V. DO NOT
 - a. Argue
 - b. Threaten
 - c. Condescend
 - d. Command


Management of Severely Agitated or Violent Patient²⁷



Electrocardiography (ECG)¹²⁴

Placement

- LA/RA: Placed mid-arm, lateral bicep, immediately below V4 horizontal line
- LL/RL: Limb (abdominal) leads, placed 7.5cm below umbilicus, 5cm on either side of the umbilical vertical line.
- V1: 4th ICS, just right of sternum
- V2: 4th ICS, just left of sternum
- V3: midway between V2 & V4
- V4: midclavicular line, 5th ICS
- V5: anterior axillary line, lateral V4
- V6: midaxillary line, lateral V4 & V5




Properly mounted?

- R waves in lead II should be sum of R waves in lead I and lead III
- Sum of waves in aVR, aVL & aVF should equal zero

Basic Parts of ECG

- P wave - atrial depolarization (activation)
- QRS complex - ventricular depolarization (activation)
- ST segment, T wave, and U wave - ventricular repolarization (recovery)




1 large box

1 Large Box = 5mm = 0.20 seconds


1 small box = 1mm = 0.04 seconds

5 small boxes = 1 large box

0.04 sec




Proper calibration, 10mm tall, represents 1-mV (10 small boxes, 2 large boxes). This is ensured with a standardization mark at the beginning of the ECG, as on the right.




Approach (a systematic approach is vital)

1. Rate (? tachy, brady): $300 \div \text{R-R interval} (\# \text{ large boxes}) = \text{beats per minute}$
2. Rhythm (? relationship between P and QRS): sinus is P before every QRS, QRS after every P, and P up in II and down in aVR
3. Intervals
 - o PR 0.12-0.2 sec (3-5 small boxes)
 - o QRS < 0.1-0.11 sec (3 small boxes)
 - o QT/QTc ($\text{QTc} = 0.33-0.44/0.45 \text{ sec}$)
 - o Easily Confused Points
 - RR interval is really the QRS-QRS interval
 - PR interval is really start of P to start of QRS
 - QT interval is really onset of QRS to end of T
 - Not every QRS has all 3
4. Mean QRS Axis (? LAD or RAD)
 - o Midway between two extremity leads with tall R waves of equal height
 - o Points at 90° (right angle) to any extremity lead with biphasic QRS complex (Q=R or R=S)
 - o Normal between -30° and 100°
 - o If QRS positive in I & II, axis is normal
 - o If QRS positive in I & negative in II, LAD is present
 - o If QRS positive in II & negative in I, RAD is present




5. Atrial/Ventricular enlargement (all findings suggestive but not diagnostic)


- Right atrial enlargement (RAA)
 - P wave > 2.5mm in II, III, or aVF but < 0.12 sec
 - Usually with R. ventricular enlargement
 - Often with pulmonary disease or congenital heart disease
- Left atrial enlargement (LAA)
 - P wave > 0.12 sec
 - P wave with double humped or notched appearance in extremity leads
 - P wave biphasic in V1 – negative deflection > 0.04 sec or >1 mm
 - If particularly notable, indicates increased risk for afib



- Right ventricular hypertrophy (RVH)
 - Tall R wave in V1
 - R wave > S wave in V1
 - Right axis deviation
 - T-wave inversions in V1-V3
 - Often in congenital heart disease
 - RAA is often present




- Left ventricular hypertrophy (LVH)
 - Deep S waves in right chest leads
 - Tall, positive R waves in left chest leads
 - S wave height in V1 plus R wave height in either V5 or V6 > 35mm
 - Cornell Voltage Criteria: S wave height in V3 + R wave Height in aVL, men > 28mm, women > 20mm
 - R wave in aVL > 12mm
 - LAA is often present
 - 2 most common causes: Hypertension and aortic stenosis



6. Conduction Abnormalities

- Right Bundle Branch Block (RBBB)

- rSR' pattern in V1 (small initial r wave, followed by a normal size S wave, and then another large positive deflection)
- Complete RBB: QRS > 0.12 seconds with above pattern
- Incomplete RBB: QRS 0.10-0.12 seconds with above pattern



- Left Bundle Branch Block (LBBB)

- Loss of initial r wave in V1 & q wave in V6
- QS pattern in V1 (just downward deflecting, may be notched)
- R pattern in V6 (just upward deflecting, may be notched)
- Complete LBBB: QRS 0.10-0.12 seconds with above pattern
- Incomplete LBBB: QRS 0.10-0.12 seconds with above pattern

7. EKG findings in Supraventricular Arrhythmias

- Atrial flutter


1. Typically ~300 cycles/minute, ventricular rate 150/min
2. Classic F waves negative in II, III, aVF, positive in V1
3. Aflutter (sawtooth or coarse)^h

II





- Atrial Fibrillation

1. Atrial wave irregular
2. Pattern irregularly irregular
3. Atrial Fibrillation



4. Atrial Fibrillation with Rapid Ventricular Response



8. EKG findings of Ischemia

I. Usually the result of blockage of one of the 3 main arteries



- Right coronary artery (RCA) supplies inferior wall
- Left anterior descending (LAD) supplies anterior
- Left Circumflex (LCx) supplies lateral
- Note: Left main supplies both anterior and lateral

ii. Localization is sometimes possible via the EKG

Anatomic Area	ECG leads	Coronary Artery
Septal	V1-V2	Proximal LAD
Anterior	V3-V4	LAD
Apical	V5-V6	Distal LAD, LCx or RCA
Lateral	I, aVL	LCx
Inferior	II, III, aVF	RCA (85%), LCx (15%)
RV	V1-V2 & V4R	Proximal RCA
Posterior	ST depression V1-V2	RCA or LCx

iii. ST-Elevation Myocardial Infarction (ST-Elevation MI or STEMI)^j

- Transmural ischemia – entire thickness
- ST segment elevation at J point in 2 contiguous leads
 - a. Leads V2-V3
 - 2mm elevation in men ≥ 40 years old
 - 2.5mm elevation in men < 40 years old
 - 1.5mm elevation in women
 - b. 1mm elevation in all other leads
 - c.
- Examples of ST segment elevation^{k,l,m,n}



- Examples of ST segment elevation with Left Bundle Branch Block^{o,p}



iv. Non-STEMI (NSTEMI)

- Subendocardial ischemia
- Abnormal ST segment
 - a. Present in 2 contiguous leads
 - b. Horizontal or downward ST depression
 - c. 1 mm or more
 - d. Lasting at least 0.08 seconds
- NOTE: ST depressions < 1mm (or only J point) with a rapid rise of ST segment are considered normal
- Examples of ST segment depression^{q,r,s,t}




Chest Pain

I. Wide differential should be considered

I. Most dangerous usually: acute coronary syndrome, aortic dissection, pulmonary embolism, tension pneumothorax, pericardial tamponade, mediastinitis (from things like esophageal rupture)

II. Management – chest discomfort suggestive of ischemia


- Monitor, support ABCs
- Obtain/Review EKG
- Check vital signs (PR, RR, spO₂, Temp, Weight)
- Assess AVPU/GCS, hydration status
- Start Oxygen if spO₂ < 94%, insert IV if needed
- Perform brief, targeted history, physical exam
- Aspirin 300/325mg PO x 1 dose
- Nitroglycerin sublingual spray or tablet 0.4mg every 5 minutes x 3 doses maximum, until symptoms resolved
- IV morphine/fentanyl if available for pain control



No

Risk Stratification

- I. If Troponin is available: use HEART Score
- II. If Troponin or CK-MB is available:
 - a. use TIMI score, high risk treat as NSTEMI
- III. If no labs are available:
 1. Use TIMI score without labs
 - a. high risk, treat as NSTEMI
 - b. low risk, use Types of Anginal Chest pain



A. HEART Score^{125–131} (≤ 3 – Low Risk, 4-6 Intermediate Risk, ≥ 7 High Risk)

Characteristic		Points
History	Highly suspicious	2
	Moderately suspicious	1
ECG	Significant ST depression	2
	Nonspecific repolarization abnormality	1
Age	65 or older	2
	45-65	1
Risk Factors	diabetes, > 90 days smoker, hyperlipidemia, hypertension, FHx of CAD, BMI > 30, history of atherosclerotic disease	
	3 or more	2
	1-2	1
Troponin	> 3 times normal limit	2
	1-3 times normal limit	1

B. TIMI Risk Score (TRS) for NSTEMI (≥ 3 High Risk)

Characteristic	Point
<i>Historical</i>	
Age ≥ 65	1
≥ 3 Risk factors for CAD (Hypertension, hypercholesterolemia, diabetes, family history of CAD, current smoker)	1
Known CAD (stenosis $\geq 50\%$)	1
Aspirin use in the last 7 days	1
<i>Presentation</i>	
Severe angina (≥ 2 episodes in last 24 hours)	1
ST deviation ≥ 0.5 mm	1
+ cardiac biomarkers (troponin, CK-MB)	1

C. Types of Anginal Chest Pain

Substernal chest pain or discomfort Provoked by exertion/exercise/emotional stress Relieved by rest and/or nitroglycerin	<ul style="list-style-type: none"> Typical Angina has all 3 components Atypical Angina has 2 of 3 Non-anginal chest pain has < 2 components
--	---

Likelihood of Coronary Artery Disease

Age	Gender	Typical Angina	Atypical Angina	Non-Anginal Chest Pain
30-39	Men	Intermediate	Intermediate	Low
	Women	Intermediate	Very Low	Very Low
40-49	Men	High	Intermediate	Intermediate
	Women	Intermediate	Low	Very Low
50-59	Men	High	Intermediate	Intermediate
	Women	Intermediate	Intermediate	Low
60-69	Men	High	Intermediate	Intermediate
	Women	High	Intermediate	Intermediate

Treatment of Acute Coronary Syndromes/Myocardial Infarctions

I. STEMI¹³²:

1. Anti-platelet:
 - a. Aspirin 325mg PO x 1 dose if not already given
 - b. Clopidogrel 300mg PO x 1 dose
2. Nitroglycerin sublingual spray or tablet (if not already given)
 - a. 0.4mg every 5 minutes x 3 doses maximum, until symptoms resolved
3. Anticoagulant:
 - a. Unfractionated Heparin
 - i. 60 units/kg IV bolus, maximum 4,000 units
 - ii. 12 units/kg/hr IV infusion, maximum 1,000 units/hr
 - b. Enoxaparin
 - i. 30mg IV bolus followed 15 minutes later by
 - ii. 1mg/kg subcutaneously q12hrs (maximum 100mg/dose for first 2 doses)
 - iii. Should not be given if creatinine clearance < 30
4. Thrombolytics
 - a. Ideally within first 24 hours of chest pain
 - b. Patient should be connected to defibrillator if possible
 - c. Contraindications

Absolute Contraindications	Relative Contraindications
<ul style="list-style-type: none">• History of intracranial hemorrhage• Known structural cerebrovascular lesion (such as arteriovenous malformation)• Known intracranial malignant neoplasm• Ischaemic stroke within 3 months (EXCEPT ischaemic stroke within 3 hours)• Suspected aortic dissection• Active bleeding• Significant head/facial trauma within 3 months• Intracranial/intraspinal surgery within 2 months	<ul style="list-style-type: none">• History of chronic, severe, poorly controlled hypertension• Uncontrolled hypertension (>180/110)• Ischemic stroke > 3 months• Dementia• Known intracranial pathology that is not an absolute contraindication• CPR > 10min or traumatic• Major surgery within 3 weeks• Pregnancy• Active peptic ulcer• Oral anticoagulant therapy

d. Dosages²⁷

- i. Tenecteplase, mix 50mg vial in 10mL sterile water (5mg/mL), administered as an IV bolus over 5 seconds
 - < 60kg: 30mg (6mL)
 - 60-69kg: 35mg (7mL)
 - 70-79kg: 40mg (8mL)
 - 80-89kg: 45mg (9mL)
 - ≥90kg: 50mg (10mL)

ii. Streptokinase

- 1.5 million units in 50mL of D5W IV given over 60 minutes

e. Monitor vital signs every 15 minutes during infusions

f. Monitor patient for 30 minutes after infusion

5. Transfer patient to ICU whether or not they have received infusion

II. NSTEMI

1. Recheck EKG in 6 hours
2. Anti-platelet:
 - a. Aspirin 325mg PO x 1 dose if not already given
 - b. Clopidogrel 300mg PO x 1 dose
3. Nitroglycerin sublingual spray or tablet (if not already given)
 - a. 0.4mg every 5 minutes x 3 doses maximum, until symptoms resolved
4. Anticoagulant:
 - a. Unfractionated Heparin
 - i. 60 units/kg IV bolus, maximum 4,000 units
 - ii. 12 units/kg/hr IV infusion, maximum 1,000 units/hr
 - b. Enoxaparin
 - i. 30mg IV bolus followed 15 minutes later by
 - ii. 1mg/kg subcutaneously q12hrs (maximum 100mg/dose for first 2 doses)
 - iii. Should not be given if creatinine clearance < 30
5. Oral Beta Blocker within first 24 hours
 - a. Preferred Metoprolol Succinate or Carvedilol
 - b. Metoprolol Succinate (Metoprolol ER) 25mg PO daily
 - c. Carvedilol 6.25mg PO BD
 - d. Metoprolol Tartrate 25mg PO BD
 - e. Labetalol 100mg PO BD
 - f. Atenolol 50mg PO daily
6. Oral ACE inhibitor with first 24 hours
 - a. Captopril 12.5mg PO BD
 - b. Lisinopril 5mg PO daily
 - c. May use ARB if no ACE inhibitors available
 - i. Losartan 50mg PO daily

III. Intermediate risk category


1. Anti-platelet:
 - a. Aspirin 325mg PO x 1 dose if not already given
2. Nitroglycerin sublingual spray or tablet (if not already given)
 - a. 0.4mg every 5 minutes x 3 doses maximum, until symptoms resolved
3. Prophylactic anticoagulant
 - a. Heparin 5,000 units subcutaneously q12hrs¹³³
 - b. Enoxaparin 40mg subcutaneously daily

IV. Low/Very low risk categories: Look for other causes

Supraventricular Tachycardias (SVT)

1. Tachycardias arising above the AV node
2. Narrow QRS indicates SVT

3. Evaluation of SVT



Adult Common Clinical Complaints

- 1) Syncope
 - a) Good and complete history and physical
 - i) Include circumstances: changes in medication, dehydration, defecation, urination, coughing, pain, heat exposure, standing outside for long periods of time, head rotation, pressure on carotid sinus (such as shaving), exercise, shortness of breath
 - b) Check RBS, CBC, Pregnancy Test
 - c) Consider convulsions (but remember shaking alone does not mean convulsion, non-convulsive shaking common after syncope)
 - d) 12-lead ECG, ECHO if concerning murmur or if syncope occurred during exercise or associated with chest pain
 - e) Electrolytes **ONLY** in patients with high likelihood of abnormalities
 - f) If above are all WNL, including VS, may be safely discharged home
 - 2) Epigastric Pain
 - a) Good and complete history and physical
 - i) VS and SPO₂
 - ii) Consider: ACS, pancreatitis, DKA, cholecystitis, Ulcer, Pre-eclampsia/Eclampsia, HELLP, ectopic pregnancy
 - iii) Tests to consider: 12-lead ECG, CXR
 - iv) Labs to consider: CBC, RFTs, amylase/lipase, LFTs, glucose, pregnancy test
 - v) Signs requiring immediate surgical consult: unstable VS or signs of peritonitis (severe abdominal pain on palpation or rebound tenderness)
 - vi) Indications for Oesophagogastroduodenoscopy: >55yo, bleeding/bloody stools/bloody vomitus/anemia, early satiety, unexplained/unintended weight loss (>10% body weight), progressive dysphagia, odynophagia, persistent n/v, PMHx or FHx of gastrointestinal cancer, previous ulcer, abdominal mass
 - vii) Helicobacter Pylori:
 - (1) ≤ 55yo, test for H. Pylori if possible, treat if positive
 - (2) >55yo, consider OGD, if negative, test for H. pylori, Rx if positive

 - 3) Headache
 - a) Good and complete history and physical
 - b) Danger signs (“red flags”) for space-occupying or vascular lesion, infection, metabolic disturbance, systemic condition^{134,135}
 - i) Systemic symptoms or condition (e.g. fever, ↓wt, pregnancy, HIV)
 - ii) Neuro sxs (e.g. confusion, decreased consciousness, focal signs, vision changes, meningismus, convulsions, papilledema)
 - iii) New onset (especially if > 40yo) or sudden (“thunderclap”)
 - iv) H/O head trauma, illicit drug use, toxic exposure
 - v) HA awakens from sleep, worse with Valsalva, cough, exertion or sexual activity, or worse in a specific position
 - vi) H/O HA with change in features: frequency, severity, associated features

Adult COPD and Asthma

VI. History

- a. CC: almost always shortness of breath
- b. COPD: often chronic and progressive symptoms
 - a. Cough, wheezing
 - b. Sputum production (3 or more months in the last 2 yrs)
 - c. Dyspnea on exertion, usually worse w/ upper body activity, lower body activity better tolerated
 - d. Smoking History
- c. Asthma: may also have cough, chest tightness, wheezing

VII. Physical Exam/Study Findings

- a. Prolonged expiratory phase
- b. Expiratory Wheezing
- c. Use of accessory respiratory muscles
- d. Hypoxia
- e. NOT finger clubbing (if present, other dx needs to be considered)
- f. CXR: hyperinflation, flat diaphragm

Management

- Monitor, support ABCs
- Check VS (PR, RR, spO₂, Temp, Weight)
- Assess AVPU/GCS
- Assess hydration status, IV if needed
- Perform brief, targeted history, physical exam

IMPORTANT NOTE ON OXYGEN!

If patient has known or suspected COPD, aim for spO₂ of 90-92% not higher

- Evaluate for other causes of SOB
1. Heart Failure
 2. Pneumonia
 3. Pulmonary TB

Albuterol/Ipratropium q20min x 3 doses
Nebulizer (5mg/0.5mg) / MDI 8 puffs

- Caution using albuterol with cardiac disease
- Evaluate after first Rx and after first 3 Rx, if symptoms dramatically improve, more likely to be asthma

Prednisolone 40mg/d x 5 days

- More sputum, change in color to yellow/green, or increased breathlessness, fever, tachypnea? Suspect COPD and Rx:
- Amoxicillin/Clavulanate: 875mg BD x 5 days
 - Doxycycline 100mg BD x 10 days
 - Azithromycin 500mg once daily x 3 days

Adult Tuberculosis


I. Consider Tuberculosis with the following

- a. Chronic cough (> 2-3 weeks)
- b. Chronic fever (>2-3 weeks)
- c. Pneumonia not improving on treatment
- d. Wasting
- e. Lymphadenopathy (large, painless)
- f. Ascites
- g. Heart failure/pericardial effusion
- h. Refusal to bend a painful joint
- i. Irritability, meningeal signs
- j. Haematuria, sterile pyuria
- k. Close contact with someone with TB in last 2 years


II. Diagnosis^{136,137}

Are any of the following present?

- Cough > 2 weeks
- Other unexplained respiratory sxs > 2 weeks
- Community acquired pneumonia not responding after 7 days of treatment
- High clinical suspicion based on history or physical



Treatment for Adult Tuberculosis^{207,208}



*If liver tenderness, hepatomegaly or jaundice recheck LFTs. Do not change regimen unless LFTs > 5 x upper limit of normal

Deep Vein Thrombosis (DVT)


I. Common Presenting Complaints

- a. Leg swelling, pain, unilateral leg tenderness
- b. Iliofemoral thrombosis may present with
 - i. Pain in buttocks/groin, swelling in thigh, collateral superficial veins

II. Risk Factors^{138,139}

- a. Prolonged bed rest, immobilization, air or bus travel
- b. Age > 40 years
- c. Obesity
- d. HIV or Tuberculosis

Well Prediction Score ²¹⁰	
Finding	Points
Previous DVT/PE	1
Paralysis/immobilization of lower extremity	1
Bedridden >3 days or major surgery within 4 weeks	1
Local tenderness	1
Swelling of entire leg	1
Calf difference \geq 3cm	1
Pitting edema ONLY in symptomatic leg	1
Collateral superficial veins	1
Alternative diagnosis more likely than DVT	-2



III. Management Recommendations

- a. Low Risk: can rule out with doppler ultrasound of lower extremities or D-dimer if concerned, otherwise no treatment
- b. Moderate Risk
 - i. Doppler ultrasound of lower extremities or D-dimer to rule out
 - ii. Wait until results to begin treatment
- c. High Risk
 - i. Begin treatment
 - ii. Order Doppler ultrasound of lower extremities for confirmation

IV. Treatment Options for DVT or PE

- a. Acute
 - i. Enoxaparin 1mg/kg subcutaneously q12hrs
 - ii. Unfractionated Heparin IV 80 units/kg (5000 units max), then 18 units/kg/hr (1000 units max)

V. Chronic: Warfarin 10mg PO daily x 2 days, then base on INR (goal 2-3)

Pulmonary Embolism (PE)¹⁴⁰

I. Common Presenting Complaints (usually with rapid onset)

- a. Dyspnea
- b. Tachypnea
- c. Pleuritic chest pain
- d. Cough
- e. Fever
- f. Tachycardia

II. Risk Factors

- a. Same as DVT

ALSO

- b. Medications: hormonal contraceptives, hormonal replacement therapy, antipsychotics, fibrates

Pulmonary Embolism Rule-Out (PERC)²¹²

Does the patient meet all of these?

- 1. Age < 50 years
- 2. Pulse < 100
- 3. SpO₂ > 94%
- 4. No unilateral leg swelling
- 5. No hemoptysis
- 6. No surgery or trauma within 4 weeks
- 7. No previous DVT/PE
- 8. No oral hormone use

Yes

Do not treat for Pulmonary Embolism

No

Positive for DVT

Evaluate for DVT

Treat for DVT/PE

Well Clinical Decision Rule²¹¹

Finding	Points
Previous DVT/PE	1.5
Immobilization > 3 days or surgery in previous 4 weeks	1.5
Malignancy in last 6 months	1
Leg swelling/pain with palpation of deep veins (clinical signs of DVT)	3
Hemoptysis	1
Pulmonary Embolism most likely diagnosis	3
Heart rate > 100	1.5

- I. Score 2: Low Risk
- II. Score 2-6: Intermediate Risk
- III. Score > 6: High Risk


III. Treatment Based on Risk



- a. Low Risk: no treatment
- b. Intermediate risk: discuss with senior if treatment is appropriate
- c. High Risk: may start empiric treatment, discuss with senior if treatment should be continued

Sexually Transmitted Infections/Diseases (STI/STDs)⁷³

I. Common Presenting Complaints

- Dysuria
- Dyspareunia
- Lower Abdominal Pain
- Urethral/Vaginal Discharge
- Vulvar/Vaginal itching/burning
- Penile/scrotal itching/burning
- Blisters/sores/warts/growths in genital/anal area





II. While beyond the scope of this text, these symptoms in any children are sexual abuse until proven otherwise

III. Always consider sexual assault

IV. Partner Treatment - All sexual partner of patient should be treated even if no symptoms (except herpes and candidiasis)

V. Treatment Regimens

a. Upper Genital Tract Infections

- i. Admit to hospital if the following are present
 1. Concern for severe infection (sepsis), toxic appearance, clinical concern that outpatient regimen is unsuitable
 2. Concern for complicated infection (peritonitis, abscess)
 3. Unclear etiology
 4. Unable to tolerate PO
 5. No improvement/worsening in first 48hrs of outpatient treatment
- ii. Inpatient Treatment
 1. Ceftriaxone 250mg IM daily
 2. Doxycycline 100mg/dose PO BID x 14 days
 3. Metronidazole 500mg PO/IV BID x 14 days
- iii. Ambulatory Treatment
 1. Ceftriaxone 250mg IM x 1 dose
 - a. Alternative: Cefixime 400mg PO 1 dose
 2. Doxycycline 100mg/dose PO BID x 14 days
 3. Metronidazole 500mg PO BID x 14 days

b. Gonorrhea

- i. Ceftriaxone 250mg IM x 1 dose
 1. Alternative: Cefixime 400mg PO x 1 dose

c. Chlamydia

- i. Azithromycin 1g PO x 1 dose
 1. Alternative for non-pregnant Women/Men: Doxycycline 100mg/dose q12hrs x 7 days
 2. Alternative for pregnant women: Erythromycin 1g/dose q12hrs x 7 days

d. Bacterial Vaginosis

- i. Tinidazole 2g PO x 1 dose
- ii. Alternative: Metronidazole 2g PO x 1 dose

e. Trichomoniasis (using vaginal tablets)

- i. Clotrimazole 500mg inserted vaginally at bedtime x 1 dose
- ii. Alternative: Clotrimazole 100mg inserted vaginally at bedtime x 6 days
- iii. Alternative: Nystatin 100,000 IU

f. Herpes

- i. Initial outbreak
 1. Ineffective if given started after 5 days from onset
 2. Acyclovir 400mg/dose PO q8hrs x 7 days

ii. Recurrence

1. Ineffective if given after 24 hours from onset
2. Acyclovir 400mg/dose PO q8hrs x 5 days

g. Syphilis

- i. Benzathine Penicillin 1.2 million IU IM in each buttock
 1. If < 2 years of infection, 1 dose
 2. If > 2 years or unknown, 1 dose weekly x 3 weeks

h. Chancroid

- i. Azithromycin 1g PO x 1 dose
- ii. Alternative: Ceftriaxone 250mg IM x 1 dose

Opportunistic Infections in HIV^{26,141,142}

IV. Prophylaxis

When to give to Prevent Infection	Regimen
CD4 < 200 OR % CD4 < 14%	Preferred: TMP-SMX Child < 5kg: 120mg PO QD Child 5-14.9 kg: 240mg PO QD Child 15-29.9 kg: 480mg PO QD Child > 30kg and adult: 1 DS tab PO QD
Pneumocystis jiroveci pneumonia (PCP)	
CD4 < 100 and toxoplasma IgG positive	Alternative: Dapsone Child < 12yo: 2mg/kg PO QD Child > 12yo and adults: 100mg PO QD
Toxoplasma gondii encephalitis	
CD4 < 50 and ruling out disseminated active MAC	Preferred: Child Azithromycin 20mg/kg PO once weekly <u>OR</u> Clarithromycin 7.5mg/kg PO BD <u>OR</u> Azithromycin 5mg/kg/day PO Alternative: Rifabutin 5mg/kg PO daily
Disseminated Mycobacterium avium complex (MAC)	Adult Azithromycin 1200mg PO once weekly <u>OR</u> Clarithromycin 500mg PO BD <u>OR</u> Azithromycin 600mg PO twice weekly Alternative: Rifabutin 300mg PO daily

V. Candida (oropharyngeal and oesophageal)

- CD4: usually < 200
- Symptoms: cotton feeling in the mouth, loss of taste, varying degrees of pain with swallowing
- Diagnosis: Physical exam reveals pseudomembranous white plaques
- Treatment
 - Oropharyngeal (treat 7-14 days)
 - Fluconazole
 - Child: 3-6mg/kg/dose PO daily
 - Adult: 100mg PO QD
 - Nystatin
 - if suspension, swish in mouth as long as possible prior to swallowing
 - Child < 5yo: 100,000 IU (1mL) q6hrs PO
 - Child 5-12 years: 200,000 IU (2mL) q6hrs PO
 - >12yo and adult: 400,000-600,000 IU (4-6mL) q6hrs PO
 - Oesophageal (treat 14-21 days)
 - Fluconazole
 - Child: 6mg/kg/dose PO x 1, then 3-6mg/kg/dose PO daily
 - Adult 400mg PO x 1, then 150-200mg PO QD

VI. Toxoplasmosis

- a. CD4: usually < 200
- b. Symptoms: often neurological/encephalitis (headache, confusion), may also have fever, can have pneumonitis (present similarly to PCP)
- c. Diagnosis: usually presumptive based on clinical picture, can also diagnose with positive Ig test
- d. Treatment (Pyrimethamine, Sulfadiazine and Leucovorin):
 - Children
 - a. Pyrimethamine 0.5mg/kg/dose BD x 2-4 days followed by 0.25mg/kg/dose x 4 weeks PLUS
 - b. Sulfadiazine 40mg/kg/dose 4 times daily
 - c. Leucovorin 5mg PO QD once every 3 days
 - Adults
 - a. Pyrimethamine 200mg PO once follow by
 - i. Wt \leq 60kg: 50mg PO QD; Wt $>$ 60kg: 75mg PO QD
 - b. Sulfadiazine 1.5g PO q6hrs
 - c. Leucovorin 10-25mg PO QD
 - d. Alternative: TMP-SMX 5mg/kg/dose & 25mg/kg/dose PO BD

VII. Cryptococcal meningitis

- a. CD4: usually < 100
- b. Symptoms: typical meningoencephalitis symptoms, fever, headache, meningismus, photophobia and vomiting
- c. Diagnosis: LP - CSF analysis (india ink stain, Ag testing, fungal culture)
- d. Treatment:
 - Induction phase (2 weeks) – one of the following, first option preferred:
 - a. (Preferred) Liposomal amphotericin B 4 mg/kg/day IV plus flucytosine 25 gm/kg/dose PO 4 times daily x 2 weeks
 - b. Amphotericin B deoxycholate 1 mg/kg/day IV plus flucytosine 25 mg/kg/dose PO 4 times daily
 - c. Fluconazole 800mg/day (12mg/kg/day in children < 19kg) plus flucytosine 25 mg/kg/dose PO 4 times daily
 - Consolidation phase (8 weeks):
 - a. Fluconazole 400mg/day (10mg/kg/day in children <19kg)

VIII. Pneumocystis jiroveci pneumonia (PCP)

- a. CD4: usually < 200
- b. Symptoms: progressive dyspnea on exertion, nonproductive cough, fever, chest discomfort, may be severely hypoxic
- c. Diagnosis: CXR with bilateral infiltrates, elevated LDH
- d. Treatment options (21 days) – first option preferred:
 - TMP-SMX: 5mg/kg/dose & SMX 25 mg/kg/dose IV or PO q6hrs
 - Pentamidine 4mg/kg IV QD
 - If initial O₂ sat on room air is < 90: add Prednisone/Prednisolone
 - a. Days 1-5: 1mg/kg/dose BID (max 40mg/dose)
 - b. Days 6-10: 1mg/kg/dose QD (max 40mg/dose)
 - c. Days 11-21: 0.5mg/kg/dose QD (max 20mg/dose)

IX. Mycobacterium Avium Complex (MAC)

- a. CD4: usually < 50
- b. Symptoms: typically nonspecific, including fevers, night sweats, abdominal pain and diarrhea, but can also cause lymphadenitis
- c. Diagnosis: AFB smear from blood, bone marrow, stool, sputum, bronchial washings, gastric aspirate, or biopsy/FNA
- d. Treatment (at least 2 drugs)
 - Children
 - a. Clarithromycin 10mg/kg/dose BD
 - b. Ethambutol 20mg/kg PO QD
 - c. Azithromycin (in place of Clarithromycin) 10mg/kg QD
 - d. If CD4 < 50 consider adding Rifabutin 15mg/kg PO QD
 - Adults
 - a. Clarithromycin 500mg PO BD
 - b. Ethambutol 15mg/kg PO QD
 - c. Azithromycin (in place of Clarithromycin) 500mg PO QD

X. Cryptosporidiosis

- a. CD4: usually < 100
- b. Symptoms: varying degrees of diarrheal illness, from mild to severe enteritis, can be profuse and life threatening
- c. Diagnosis: clinical presentation, stool microscopy, PCR
- d. Treatment
 - Primary treatment is to start ART, difficult to clear infection while severely immunocompromised
 - May attempt direct treatment
 - a. Nitazoxanide: 1-3yo 100mg PO BD, 4-11yo 200mg PO BD, ≥12yo 500-1000mg PO BD w/ food x 14 days
 - b. Alternative: Paramomycin 500mg PO QID x 14-21 days

XI. Histoplasmosis

- a. CD4: usually < 150
- b. Symptoms: nonspecific, may include fever, chills, sweats, malaise, fatigue, muscle ache, weight loss, often may have pulmonary involvement and can be mistaken for TB. May have hepatosplenomegaly.
- c. Diagnosis: Often only by history (exposure to soil contaminated with bat and bird feces). Difficult to make , cultures may take 6 wks, Ag (in blood or urine) more rapid, Ig may take 4-6 weeks after initial exposure to appear
- d. Treatment:
 - Induction, one of the two below (first option preferred):
 - i. Liposomal amphotericin B 3mg/kg IV QD (children 3-5mg/kg)
 - ii. Amphotericin B deoxycholate 1 mg/kg/day IV
 - Maintenance
 - i. Children: Itraconazole 2-5mg/kg/dose TID x 3 days then BID
 - ii. Adults: Itraconazole 200mg PO TID
 - If CD4 < 50, consider adding Rifabutin 300mg PO QD

XII. Herpes Simplex Virus (HSV) types 1 & 2

- a. CD4: no specific level, generally more severe as CD4 drops
- b. Symptoms: often prodrome of pruritis, followed by eruption of painful vesicles and ulcerations, may be multiple or single, unable to determine 1 vs 2 from clinical presentation alone
- c. Diagnosis: Often clinical, ideally viral culture, Ag detection or PCR for HSV DNA if available (especially because if immunocompromised multiple disease may present with ulcers)
- d. Treatment:
 - Valacyclovir 1g PO BD (Children and Adults)
 - Acyclovir
 - a. Children < 12yo: 20mg/kg/dose PO TID
 - b. Children > 12yo & adults: 400mg PO TID

XIII. Varicella Zoster Virus (VZV) – “Shingles”

- a. CD4: no specific level, generally more severe as CD4 drops
- b. Symptoms: erythematous papules, progress to vesicals or bullae, generally distributed along a single dermatome (although more likely to affect greater area with more severe immunosuppression)
- c. Diagnosis: usually clinical, based on history, vesicular/dermatomal rash
- d. Treatment:

Valacyclovir	Acyclovir
1. Children: 20mg/kg/dose PO TID	1. Children: 20mg/kg/dose PO QID
2. Adults: 1g PO TID	2. Adults: 1g PO TID

Severe cutaneous, visceral or disseminated disease in children and adults:
Acyclovir 10-15 mg/kg/dose IV q8hrs until improvement


e. Prevention – Vaccination

- Give in Pts w/ CD4 > 200, no prior vaccination, no prior outbreaks, and seronegative for VZV
- Primary varicella vaccination: 0.5mL SQ x 2 doses \geq 3 months apart


XIV. Cytomegalovirus (CMV)

- a. CD4: usually < 50
- b. Symptoms: Retinitis most common (80-90%), causes blurring, blind spots, floaters, or flashing lights, usually unilaterally. Can also effect GI track, presenting with nonspecific GI complaints that usually include pain. Rarely can effect nervous system, symptoms of encephalitis or peripheral nerve involvement.
- c. Diagnosis: Generally made by ophthalmologist, Serum PCR and Serologies are not normally helpful, but if found in CSF on LP high likelihood of brain involvement
- d. Treatment:
 - Induction (one of the following)
 - a. Adults: Valgancyclovir 900mg PO BD
 - b. Alternatives for Adults and Children
 - i. Ganciclovir 5mg/kg/dose IV q12hrs
 - ii. Foscarnet 90mg/kg/dose IV q12hrs

Electrolytes:



&



Abnormalities

Electrolyte Abnormalities

Sodium Abnormalities

I. Calculations with Sodium

a. $TBW \text{ (Total Body Water)} = \text{Weight (kg)} \times \text{fraction of water}$

b. Fraction of water =

Children: $0.65 < 6 \text{ yo}, 0.6 \text{ until adulthood}$

Adult: 0.5 for females, 0.6 for males

Elderly: 0.45 for females, 0.5 for males

c. Change $[Na]_{\text{serum}}$ per L infusate = $\frac{[Na]_{\text{infusate}} - [Na]_{\text{serum}}}{TBW + 1}$

d. Rate of IVF infusion to increase Na by 0.5 mEq/L/h = $\frac{1000}{2 \times [Na]_{\text{serum}}}$

e. Free H₂O Deficit (L) = $\frac{[Na]_{\text{serum}} - 140}{140} \times TBW$

f. FENa (fractional excretion of sodium) = $100 \times \frac{Na_{\text{urine}} \times Cr_{\text{serum}}}{Na_{\text{serum}} \times Cr_{\text{urine}}}$

II. Hyponatremia (Na < 135)

a. Emergent Management

Monitor, support ABCs

Check vital signs (BP, PR, RR, spO₂, Temp, Wt)


Start Oxygen if spO₂ < 94%

Serum labs: CBC, RFT, electrolytes


Urine labs: creatinine, sodium, osmolarity

12-lead ECG

Perform brief, targeted history, physical exam



b. Hyponatremia Evaluation and Management



III. Hypernatremia (Na > 145)

- Most common renal causes: osmotic diuresis, loop diuretics, diabetes insipidus
- Most common extrarenal causes: vomiting, diarrhea
- Treatment
 - Restore access to PO water (>1 L/day)
 - Correct Na no faster than 10mEq/L/day and 0.5 mEq/L/hr
- Assess if clinically logical, if not, consider confirming before managing
- Unless reason to suspect otherwise (extremely elevated glucose, mannitol, high serum protein levels – e.g. cancer), assume hypotonic hyponatremia

Potassium Abnormalities

Hypokalemia (main Rx is treating cause)

- I. Risk Factors: diarrhea, vomiting, diuretics, refeeding syndrome, inadequate dietary intake (malnutrition, chronic alcoholic)
- II. Potassium Replacement
 - a. < 3: even if asymptomatic
 - b. < 4: in heart failure, HTN or arrhythmias
- III. IV Potassium
 - a. Indications: K < 2.5, symptomatic, or a nonfunctioning GI tract
 - b. 40mEq in 1L NS, (children: 0.5-1mEq/kg/hr, adult: 10mEq/hr infusion)
 - c. NEVER BOLUS
- IV. PO Potassium
 - a. 40-100 mEq/day (max adult 200mEq/day, max children 3mEq/kg/day)
 - b. Divide into doses every 6 hours
- V. Magnesium (often accompanies hypokalemia)
 - a. Rx unstable or symptomatic & Magnesium < 1: magnesium sulfate 2g in 50mL 5% dextrose, given over 30 minutes 6 hourly, (children 25-50mg/kg)
 - b. Stable, asymptomatic, Magnesium <2 but > 1: oral supplementation

Hyperkalemia

Presentation¹⁶⁹

- MAJORITY ARE ASYMPTOMATIC¹⁷⁰
- Muscle Weakness/paralysis
- Cardiac Arrhythmias/Palpitations
- Decreased bowel motility
- Neuro: Paresthesia, confusion, convulsion

Common Risk Factors¹⁶⁷

- Acute and chronic kidney disease
- Medications: (ACEI and ARBS, Beta Blockers, Digoxin, NSAIDs, Spironolactone, Co-trimoxazole¹⁶⁸)
- Highly aggressive tumours with tumour lysis syndrome
- Tissue damage (rhabdomyolysis, burns or trauma)

Monitor, support ABCs

Check vital signs (BP, PR, RR, spO₂, Temp, Wt)

Start Oxygen if spO₂ < 94%

Serum labs: CBC, RFT, electrolytes

12-lead ECG

Perform brief, targeted history, physical exam

K+ ≥ 5.5 = Hyperkalemia
Recheck to confirm result
Stop all K+ supplementation

Any of the following?

1. K+ > 6.5¹⁷³
2. Weakness, frank muscle paralysis, palpitations, paraesthesia
3. ECG changes? - tall tented T-waves, PR prolongation, AV-block, widening QRS (may eventually begin to merge with T-wave)

Yes

- Cardiac monitoring
- 10% Calcium Gluconate IV^{169–172}
 - Children: 0.5mL/kg
 - Adults 10mL
 - give over 2-3 minutes
 - repeat every 5min until ECG improves
 - lasts 30-60 min
- Furosemide IV
 - Children: 1mg/kg
 - Adults: 20-40mg
- Dialysis: Urgently if unstable, consider for asymptomatic patients with ESRD

No

Yes

Insulin/glucose^{170,174,175}

Adults: IV bolus Insulin 10IU+Glucose 40-60g
Children: Insulin IV 0.05 IU/kg/hr + Glucose IV 0.5g/kg/hr for RBS < 180

No

Consider no Rx

Salbutamol q1-2hr^{172,174–176}

Nebulizer MDI+spacer+mask

< 25kg: 2.5mg in 3mL NS 5-10 kg: 4 puffs

> 25kg: 5mg in 5mL NS 10-20 kg: 6 puffs

(Adults 10-20mg max) > 20 kg: 8 puffs

Resonium q6hr PO PR

Children 1g/kg 1g/kg

Adults 15g 30-50g

Essential Medications



Formulary¹⁴⁸

Note on age designations

Neonates: ≤ 28 days old

Infants: ≤ 1-year old, and includes neonates unless specified

Children: ≤ 12 years old, includes infants & neonates unless specified

Adult: >12 years old

Note on dosing regimens

When written “dose BD”, this indicates that dose is given twice daily, not divided

When written “dose ÷ BD”, this indicates the dose is the total for the day and it is to be divided into two separate and equal doses

Note on dosages

We have tried to include the most common dosing regimens for the most commonly encountered conditions, but the specific patient or condition you are treating may require different dosing

<u>Medications</u>	<u>Dose and Route</u>	<u>Notes/ Contraindications</u>
Acyclovir	<p>Children:</p> <ul style="list-style-type: none"> HSV: 20mg/kg/dose PO TID VZV: 20mg/kg/dose PO QID <p>Adults:</p> <ul style="list-style-type: none"> HSV: 400mg PO TID VZV: 1g PO TID 	
Albendazole	<p>Age < 2yrs: 200mg PO x 1 dose</p> <p>Age ≥ 2yr: 400mg PO x 1 dose</p>	
Aminophylline	<p>Infants (only <32weeks or 1.5kg with apnea of prematurity):</p> <ul style="list-style-type: none"> Loading: 6mg/kg IV/PO over 1hr Maintenance dose: (IV or oral) <ul style="list-style-type: none"> Age ≤ 6 days: 2.5mg/kg 12hrly Age 7-28 days: 4mg/kg 12hrly 	<p>Not compatible with phenobarbital</p> <p>IV infusion: give over 20- 30 minutes</p> <p>Oral Preparation: Mix 10 ml aminophylline (250 mg vial) with 40 ml sterile water = 5mg/1ml</p>
Amoxicillin/ Amoxiclav (Amoxicillin- Clavulanic acid)	<p>Children:</p> <ul style="list-style-type: none"> 25mg/kg/dose BD for simple infections 40-45mg/kg/dose BD for pneumonia/otitis media <p>Adults: 875mg PO BD</p>	
Amlodipine	<p>Children: 0.05mg/kg/dose OD</p> <p>Adults: 5-10mg/dose PO daily</p>	Max dose 5mg/dose, 10mg/24hr

Amphotericin	Children/Adults: Liposomal Amphotericin B: 4mg/kg/day IV Amphotericin B deoxycholate: 1mg/kg/day IV	Used with flucytosine
Ampicillin	Neonate: 50mg/kg/dose IV or IM <ul style="list-style-type: none"> • \leq 7 days: 12 hourly • 8-28 days: 8 hourly Infants/Children: 50mg/kg/dose (Max 500mg) 6 hourly IV/ IM Adults: 2g 6 hourly IV/IM	DO NOT MIX WITH GENTAMICIN. <i>Flush line or burette if given at same time as Gentamicin.</i> IV Push: over 3-5 min IV infusion: over 15-30 min.
Artesunate	<5 kg: treat as though 5 kg < 20 kg: 3mg/kg IV/IM at 0, 12 & 24 hrs > 20 kg: 2.4mg/kg IV/IM at 0, 12 & 24 hrs	
Azithromycin	Infants/Children: 10mg/kg PO x 1 day, then 5mg/kg PO x 4 days Adults: 500mg PO x 1 day, then 250mg PO x 4 days	MAC: first day dose is continued as maintenance dose
Benzyl Penicillin (Crystalline Penicillin, PenG)	< 7 days: 50,000 IU/kg/dose q12hrs IV/IM \geq 7 days: 50,000 IU/kg/dose q6hrs IV/IM Group A Streptococcal Pharyngitis \leq 27kg: 600,000 IU IM single dose >27kg: 1.2 million IU IM single dose	
Calcium	Children: <ul style="list-style-type: none"> • Replacement: 10mg/kg/day • Tetany/convulsions: 0.6-1 mL/kg of 10% solution via slow push Adults: <ul style="list-style-type: none"> • Tetany/convulsions: 2g IV calcium gluconate • Replacement: 10mg/kg/day 	20mg = 1 mEq 100mg Ca Carbonate = 40mg elemental Ca = 2 mEq Ca Ca Gluconate 10% Max dose: 20 mL/kg Max dose: 2g
Captopril	Neonate: <ul style="list-style-type: none"> • 0.01-0.05mg/kg/dose PO Q8-12hr Infants < 6mo: <ul style="list-style-type: none"> • 0.01-0.5mg/kg/dose PO BID-TID Children: <ul style="list-style-type: none"> • 0.3-0.5mg/kg/dose PO BID-TID Adults: <ul style="list-style-type: none"> • 12.5-25mg PO BID-TID • Titrate qweek by 25mg/dose 	• Max dose 450mg/24hr

	Carbamazepine < 12 years:	<i>Avoid abrupt withdrawal and watch carefully for side effects</i>
	<ul style="list-style-type: none"> Initial: 10-20 mg/kg/24hr PO ÷ q12hr Titrate qweek 	
	> 12 yr:	
	<ul style="list-style-type: none"> Initial: 200mg PO BD Titrate qweek by 200mg/24hr 	
		Max Dose
		<ul style="list-style-type: none"> <12 yrs: 1g/day, 35mg/kg/day, 100mg/dose BD, 12-15yrs: 1g/24hr > 15yrs: 1.2g/24hr Adult: 1.6-2.4g/24hr
Carvedilol	Infants/Children: 0.025 mg/kg/dose PO q12hr Adults: 3.125mg PO q12hr, max 25mg PO q12hr	Titrate every 2 weeks
Cefotaxime	Neonates: <ul style="list-style-type: none"> ≤ 7 days: 50mg/kg/dose IV/IM 12 hourly 8-28 days: 50mg/kg/dose IV/IM 8 hourly Infants/Children: <ul style="list-style-type: none"> 50mg/kg/dose q8hr Meningitis: 50mg/kg/dose q6hr Max: 2000mg/dose Adults: <ul style="list-style-type: none"> Meningitis/Sepsis: 2g IV 6hrly Other: 1g IV 12hrly 	<i>Flush line or burette well if given at same time as Gentamicin</i> IV push: over 5 minutes IV infusion: over 30 min
Ceftriaxone	Infants: <ul style="list-style-type: none"> Meningitis 100mg/kg IV OD Sepsis/Pneumonia 80mg/kg IV OD Children: <ul style="list-style-type: none"> 50mg/kg/dose IV/IM q24hr Meningitis: 100mg/kg/dose q24hr Max: 2g/dose Adults: <ul style="list-style-type: none"> Meningitis: 2g IV q12hr Other: 2g IV q23hr 	<i>Contraindicated in neonates if severe jaundice. Do not mix with RL.</i> IV push: 10 minutes IV infusion: Give over 30-60 minutes
Ciprofloxacin	Children: <ul style="list-style-type: none"> 10-15mg/kg/dose PO BD Max: 1000mg/dose Adults: <ul style="list-style-type: none"> Mild/Moderate infection: 500mg PO BD Severe Infection: 750mg PO BD UTI (uncomplicated): 250mg PO BD x 3 days 	

Clarithromycin	Children: 10mg/kg/dose BD Adults: 500mg PO BD	
Clotrimazole	Children: paint for oral thrush, apply BD-TID until cleared Children/Adults: apply to infected area BD-TID until cleared	
Cloxacillin	Neonates: 25-50mg/kg/dose <ul style="list-style-type: none">• ≤ 7 days: every 12hours<ul style="list-style-type: none">• 8-28 days: every 8 hours Infants/Children: <ul style="list-style-type: none">• 25-50mg/kg/dose IV/IM q6hr Adults: <ul style="list-style-type: none">• 2g IV/IM• Mild/Moderate Infection: q6hr• Severe Infection: q4hr5	Flush line or burette will if given at same time as Gentamicin
Co-trimoxazole (Trimethoprim – Sulfamethoxazole) TMP-SMX	Children: <ul style="list-style-type: none">• Dosage: 4mg/kg/dose TMP + 20mg/kg/dose SMZ/dose BD• For interstitial pneumonia in children with HIV give 8mg/kg/dose + SMZ/40mg/kg/dose TMP TID x 21 days Adults: <ul style="list-style-type: none">• TMP 160 mg/ SMX 800 mg PO every 12 hrs• PCP Pneumonia: TMP 15-20 mg/kg/day SMX 75-100mg/kg/day Divided in 4 equal doses	Syrup: 40mg TMP/ 200mg SMZ per 5mL Paediatric Tab: 20mg TMP/100mg SMZ Max dose: TMP 160 mg/ SMX 800mg PO q12hrs <u>Tablets</u> Single Strength (SS): TMP 80mg/ SMX 400mg Double Strength (DS): TMP 160mg/SMX 800mg
Dapsone	Prophylaxis CD4 < 200 Children: 2mg/kg PO QD Adults: 100mg PO QD	
Dexamethasone	Children: <ul style="list-style-type: none">• Extubation/upper airway swelling: 0.25-0.5mg/kg/dose IV q6hr (Max: 8mg/dose)• Asthma/Croup: 0.6mg/kg/dose IV/IM/PO x 1 dose Adults: <ul style="list-style-type: none">• Cerebral Edema: 2mg PO TID	

Dextrose/ Glucose	Neonates/Infants/Children: • D10% 5ml/kg IV push (if no D10 immediately available use D5) Adults: 25-50mL D50 IV push	How to make D10: 1mL of D50% + 9mL D5% OR 2mL of D50% + 8mL NS
Diazepam	Rectal Diazepam 2.5mg suppository • <10kg 1 suppository • 10-15 kg: 2 suppositories • 15-20 kg: 3 suppositories • 20-25 kg: 4 suppositories	Do not give to neonate Do not give IM
	IV Diazepam: 0.3mg/kg slowly over 1 minute	
Digoxin	Age 2-5 yrs: • Loading: 35mcg/kg ÷ TID x 24hr • Maintenance: 5mcg/kg/dose BD Age 5-10 yrs: • Loading: 25mcg/kg ÷ TID x 24hr • Maintenance: 3mcg/kg/dose BD Age 10-12 yrs: • Loading: 0.75-1.5mg ÷ TID x 24hr • Maintenance 30-125mcg BD Adults:	Titrate maintenance dose every 2 weeks
Enoxaparin	Children/Adults: • DVT/PE Treatment: 1mg/kg SC q12hrs Adults: • DVT prophylaxis: 40mg SC OD • Acute Coronary Syndrome treatment: 1mg/kg SC q12hrs	Should not be given if CrCl < 30 For ACS: 30mg IV bolus is given 15 minutes before starting SC
Epinephrine (Adrenaline)	Resuscitation Children: 0.1ml/kg IV of 1:10,000 Adults: 1mg or 10mL 1:10,000 Viral Croup Children: 2mL of 1:1000 nebulized, may repeat if effective	To make 1:10,000: mix 1mL of 1:1000 epinephrine in 9mls NS

Ethambutol	Children: 20mg/kg/dose PO QD Adults: 15mg/kg/dose PO QD	
Erythromycin (Estolate)	Infants/Children: <ul style="list-style-type: none">• 50mg/kg/day PO ÷ q6-8hrs• 20mg/kg/day IV ÷ q6hrs Adults: 500mg PO q6hr	
Fluconazole	<u>Oropharyngeal Candidiasis</u> Children: 3-6mg/kg/dose daily x 7-14 days Adult: 100mg PO QD x 7-14 days	
	<u>Oesophageal Candidiasis</u> Children: 6mg/kg/dose PO x 1, then 3-6mg/kg/dose PO daily x 14-21 days Adult: 400mg PO x 1, then 150-200mg PO QD x 14-21 days	
Folic Acid/ Folate	Infants/Children Maintenance <ul style="list-style-type: none">• Infant: 0.1mg PO/day• < 4 years: 0.3mg PO/day• ≥ 4 years: 0.4mg PO/day Adults <ul style="list-style-type: none">• Deficiency: 1mg PO/day• Maintenance: 0.4mg PO/day Pregnant Women <ul style="list-style-type: none">• 0.8mg PO/day	Megaloblastic/ Macrocytic anemia all receive 1mg PO/IM/IV daily regardless of age
Foscarnet	Everyone: 90mg/kg/dose IV q12hrs	<u>NEVER LESS THAN 0.1 MG PO/DAY IN PREGNANCY</u>
Furosemide/ Lasix	Children: 1-2mg/kg IV/PO q12hrs Adults: <ul style="list-style-type: none">• Heart failure exacerbation: 40mg IV/IM (or double maintenance dose) q2hrs• Heart failure maintenance: 20-40mg PO OD-BD• Other: 20-40mg IV/IM/PO	Not compatible with Gentamicin IV Push: max rate 0.5mg/kg/min IV Infusion: 10-15 min
Gancyclovir	Everyone: 5mg/kg/dose IV q12hrs	See heart failure protocol for specific details
Gentamicin	Neonates (if LBW <2.5kg and Term with Birth Asphyxia): <ul style="list-style-type: none">○ ≤ 7 days: 3mg/kg/day OD○ 8-28 days: 5mg/kg/day OD Term Neonates/Children/Adults: 5-7.5mg/kg/day OD	Do not mix with Ampicillin. <i>Flush line or burette well if given at same time as Ampicillin</i> IV push: no IV infusion: Give over 30 minutes. Flush line well.

Heparin (unfractionated)	Children: <ul style="list-style-type: none">• DVT/PE Treatment:<ul style="list-style-type: none">◦ 75 units/kg IV bolus◦ 20 units/kg/hr IV infusion Adults: <ul style="list-style-type: none">• DVT prophylaxis: 5000 units SC q12hrs• DVT/PE Treatment:<ul style="list-style-type: none">◦ 80 units/kg IV bolus◦ 18 units/kg/hr IV infusion• Acute Coronary Syndrome<ul style="list-style-type: none">◦ 60 units/kg IV bolus◦ 12 units/kg/hr IV infusion	Treatment is given as an IV bolus followed by a continuous IV infusion
		Maximum bolus for DVT/PE: 5,000 units
		Maximum bolus for ACS: 4,000 units
		Maximum infusion rate: 1,000 units/hr
HCTZ (hydrochlorothiazide)	Children: 0.5-1mg/kg/dose OD or BD Adults: 12.5-50mg OD	Max Dose: <2 years: 37.5mg OD 2-12 years: 100mg OD >12 years: 200mg OD
Hydroxyurea	Child 2-12 years initially 20mg/kg once daily, increased every 12 weeks in steps of 2.5 - 5 mg/kg daily according to response; usual dose 20 - 30 mg/kg daily (max. 35 mg/kg daily)	For use in SCD with stroke, admission for acute chest syndrome, >3 admissions/yr for pain, require ≥2 transfusions yearly
Ibuprofen	Neonates (PDA Closure): <ul style="list-style-type: none">• Dose 1 at 0 hours: 10mg/kg PO• Dose 2 & 3: 5mg/kg PO at 24 & 48 hours Children: 10mg/kg PO q6hrs Adults: 400-800mg PO q6-8hrs	Max: <ul style="list-style-type: none">• 800mg/dose• 2400mg/day Do not give in cases of renal disease Give with food when possible
Iron	Pre-term Infant: 2-4mg elemental Fe/kg/day	Max dose: 15mg elemental Fe/kg/day
	Iron Deficiency Children: 3-6mg elemental Fe/kg/day Adults: 60-120mg elemental iron daily	Hemaforte syrup: 5 mg elemental iron/ml
Isoniazid	Children: 10mg/kg PO QD Adults: 5mg/kg PO QD	325mg Ferrous Sulfate tablet contains 65mg elemental Iron
Lactulose	Infants (hepatic encephalopathy): 2.5-10mL ÷ TID-QID Children: 1-3mL/kg/day ÷ q8-12hrs Adults: 30mL PO q6hr	Children Max dose: 60mL/day Formulation: 10g/15mL Goal: at least 3-4 soft stools daily

Leucovorin	Children: 5mg PO QD Adults: 10-25mg PO QD	
Lisinopril	Infants/Children: 0.1mg/kg PO OD Adults: 5mg PO OD	Max Dose: Children: 0.6mg/kg/day or adult dose Adults: 40mg/day
Lorazepam	Adults/Children (>12yr): <ul style="list-style-type: none"> Anxiety (acute): 2mg PO q8hr Agitation: 0.5-2mg IV 12-4hrs Infants/Children: <ul style="list-style-type: none"> Initial: 0.5mg/kg/day Maintenance: up to 1.4mg/kg/day Adults: 25mg PO daily	Use with caution in elderly
Losartan	Infants/Children: <ul style="list-style-type: none"> Initial: 0.5mg/kg/day Maintenance: up to 1.4mg/kg/day Adults: 25mg PO daily	Infants/Children Max: Initial: 12.5mg/day Maintenance: 150mg/day Adult Max: 150mg/day
Metronidazole	Neonates: 7.5mg/kg/dose IV <u>First week of life</u> <ul style="list-style-type: none"> <1.2 kg: every 48 hours 1.2-2kg: every 24 hours >2 kg: every 12 hours <u>Weeks 2-4</u> <ul style="list-style-type: none"> <1.2kg: every 24 hours >1.2kg: every 12 hours Mild Infections Infants/Children: 7.5mg/kg/dose PO q8hrs Adults: 500mg PO q6hrs Moderate-Severe Infections Infants/Children: 10mg/kg/dose IV q8hrs Adults: 500mg IV q6hrs	Not compatible with phenobarbital or Ringers Lactate <i>Administer separately.</i> <i>Discontinue primary IV.</i> IV push: no IV infusion: Give over 60 minutes in D10 or NS.
Morphine	Neonate: 0.05-0.2 mg/kg/dose IM/ SC/slow IV q4hr prn Children: <ul style="list-style-type: none"> 0.1-0.2 mg/kg/dose IV q2-4hrs prn 0.2-0.5 mg/kg/dose PO q4-6hrs prn Adults: <ul style="list-style-type: none"> 1-2 mg/dose IV q2-4hrs prn 2-10mg/kg/dose PO q2-4hrs prn 	Ensure high enough dose for pain control, just remember to monitor frequently (at least q1hr to start), to avoid respiratory depression

Nifedipine	Children (>1yr): <ul style="list-style-type: none">Initial: 0.125mg/kg BDMaintenance: up to 3mg/kg/day or children 120mg/day Adults: <ul style="list-style-type: none">Initial (XR): 30mg PO ODMaintenance (XR): up to 120mg/dayImmediate release (IR): 10-30mg PO q8hr	Only use extended release (XR) with children Ideally adults would only use XR for HTN Immediate release (IR): should really only be used for angina
Nitazoxanide	1-3yo: 100mg PO BD x 14 days 4-11yo: 200mg PO BD x 14 days ≥12yo and adults: 500-1000mg PO BD x 14 days	Give with food
Nitrofurantoin	Children (>1yr): 1.5 mg/kg PO q6hr Full course for UTI in children and adults is 7 days Adults: 100mg PO q6hr	
Nitroglycerine	Adults: 0.4mg SL q5min x 3 doses	prn anginal pain
Nystatin	Preterm Infants: 0.5mL to each side PO: Suspension=100,000 units/mL Term Infant: 1mL to each side of mouth q6hrs Children/Adults: <ul style="list-style-type: none">Oropharyngeal Candidiasis: 4-6ML PO q6hr	
Omeprazole	Children: 0.5-1 mg/kg/dose PO OD or BD Adults: 20-40mg PO OD	May reduce serum concentration of clopidogrel
Paracetamol/ Panadol	Children: 10-15mg/kg PO q4-6hr Adults: 650mg PO q4-6hr	Max dose: 4g/day Not given in liver failure
Paramomycin	≥ 12yo and Adults: 500mg PO QID x 14-21 days	
Pentamidine	Adults/Children: 4mg/kg IV QD	
Pethidine (Demerol)	Children: 0.5-1mg/kg q4hrs Adults: IM/PO/SQ: 50mg q3hrs	Morphine is almost always preferred if available (including for biliary issues) Not compatible with Aminophylline, Metronidazole
Phenobarbitone/ Neonates:		
Phenobarbital	<ul style="list-style-type: none">Loading: 20mg/kg IV/IMMaintenance: 5mg/kg IV/IM/PO OD Infants/Children/Adults: <ul style="list-style-type: none">Loading: 15mg/kg IV/IM (max initial loading dose 320mg)Maintenance: 5mg/kg IV/IM/PO OD	Give over 20 minutes if IV (not faster than 1 mg/kg/min)

Phenytoin	Children: <ul style="list-style-type: none">• Loading: 15-20mg/kg IV• Maintenance: 2.5-4 mg/kg IV/PO q12hrs Adults: <ul style="list-style-type: none">• Loading: 20mg/kg IV• Maintenance: 100mg IV/PO q6-8hrs	Not compatible with Aminophylline Give in NS only. Flush with NS after giving IV Push: max rate 50mg/min
Potassium	Children: 1mEq/kg/dose Adults: <ul style="list-style-type: none">• Dose based on level of hypokalemia• 10mEq raises potassium approximately 0.1• PO preferred to IV	1 mEq = 75mg (KCl) Frequency based on level of deficiency
Prednisone/ Prednisolone	Children: 1-2 mg/kg PO OD Adults: 40mg PO OD Suggested tapering schedule: Children: Decrease dose by ~10% every 2 weeks Adults: Dose \geq 20mg/day: decrease by 5mg/day every week Dose 10-20mg/day: decrease by 2.5mg/day every 2 weeks Dose \leq 10mg/day: decrease by 1mg/day every 2 weeks	Max for asthma: 60mg/day Tapering is only required if used for <u>>3 weeks</u> If any symptoms of adrenal insufficiency, return to previous dose
Propranolol	Children: 0.5-1 mg/kg/day PO \div q6-12hrs Adults: <ul style="list-style-type: none">• Initial: 40mg PO BID	Symptoms of adrenal insufficiency: abd pain, vomiting, unusual sweating, dehydration, confusion, fatigue, weakness, low BP, high HR, shock Max: 8mg/kg/day
Pyrazinamide	Children: 35mg/kg PO QD Adults: 25mg/kg PO QD	Max: 320mg PO \div q6-12hrs
Pyridoxine Pyrimethamine	Adults: 25mg PO QD Children: Initial: 0.5mg/kg/dose BD x 2-4 days and Leucovorin Maintenance: 0.25mg/kg/dose Adults: Initial: 200mg PO once Maintenance: Wt \leq 60kg: 50mg PO QD Wt > 60kg: 75mg PO QD	Given with TB treatment Given with Sulfadiazine

Quinine	Infants/Children/Adults: <ul style="list-style-type: none"> • See malaria algorithm • Loading dose: 20mg/kg IV given over 4 hours (after dilution) • Maintenance dose: 10mg/kg IV q8hrs (dilute, give over 2 hrs) 	DANGER: rapid administration is dangerous, mix with 10mL/kg of 5% dextrose & run over 2-4 hours, DO NOT exceed 5mg/kg/hr Not compatible with Phenytoin
Ranitidine	Neonates: <ul style="list-style-type: none"> • <37 weeks: 0.5mg/kg IV q12hrs • > 37 weeks: 1mg/kg IV q12hrs • PO: 1-2mg/kg q12hrs Children: 2-5 mg/kg/dose q12hrs Adults: 150mg PO BD	IV Push: minimum >5 min to prevent hypotension IV infusion: 15-20min Caution: increase risk of NEC in VLBW infants
Rifabutin	Children Treatment: 15mg/kg PO QD Prophylaxis: 5mg/kg PO QD Adults: 300mg PO QD	In severe MAC
Rifampicin	Children: 15mg/kg PO QD Adults: 10mg/kg PO QD	
Salbutamol	Nebulization ≤ 20 kg: 2.5mg/dose in 3mL NS > 20 kg: 5mg/dose in 5mL NS MDI (metered dose inhaler) 5-10 kg: 4 puffs 10-20 kg: 6 puffs > 20 kg: 8 puffs	DO NOT EVER GIVE ORALLY – not effective
Sulphadoxine/SP emetamine (SP)	• Children • 2-5yo: ½ tab monthly • 5-10yo: 1 tab monthly • 10-15yo: 2 tabs monthly • >15yo: 3 tabs monthly	Malaria prophylaxis in patients with Sickle Cell Disease
Spironolactone	Children: 0.5-1.5 mg/kg/dose BD Adults: 25mg PO OD	Max dose: 100mg/day
Valacyclovir	Children: <ul style="list-style-type: none"> • HSV: 1g PO BD • VZV: 20mg/kg/dose PO TID Adults: <ul style="list-style-type: none"> • HSV: 400mg PO TID • VZV: 1g PO TID 	
Valgancyclovir	Adults: 900mg PO BD	
Sulfadiazine	Children: 40mg/kg/dose QID Adults: 1.5g PO q6hrs	Given with Leucovorin and Pyrimethamine for PCP

Valproic Acid/ Sodium Valproate	<p>Children:</p> <ul style="list-style-type: none"> Initial: 10-15mg/kg/day PO ÷ q8-12hrs Maintenance: 30-60mg/kg/day ÷ q8-12 hrs <p>Adults:</p> <ul style="list-style-type: none"> Initial: 15mg/kg/day PO ÷ q8-12hrs Maintenance: 60mg/kg/day ÷ q8-12 hrs 	
Vitamin A	<p>< 6 months: not recommended</p> <p>6-12 months: 100,000 units PO stat</p> <p>>12 months: 200,000 units PO stat</p>	Once on admission, should not be given twice within 1 month
Vitamin D	<p>Infants:</p> <ul style="list-style-type: none"> Rickets: 2000 IU/day x 6-12 wks Maintenance: 400 IU/day <p>Children</p> <ul style="list-style-type: none"> Rickets: 2000 IU/day x 6-12 wks Maintenance: 600-1000 IU/day <p>Adults:</p> <ul style="list-style-type: none"> Deficiency: 6000 IU/day x 8 wks Maintenance: 2000 IU/day 	Children may also take 50,000 IU/week x 6 weeks
Vitamin K	<p>Neonate:</p> <ul style="list-style-type: none"> Preterm <1kg: 0.3mg/kg IM stat Preterm > 1kg: 0.5mg IM stat Term: 1mg IM stat <p>Supratherapeutic INR:</p> <ul style="list-style-type: none"> Children: 0.03 mg/kg/dose IV <ul style="list-style-type: none"> Maximum dose: 1mg Adult: <ul style="list-style-type: none"> INR 4.5-10 no bleeding: may consider 1-2.5mg PO INR >10: 2.5-5mg PO Minor bleeding & elevated INR: 2.5-5mg PO Major bleeding & elevated INR: 10mg PO 	<p>Adequate Standard Intake Daily:</p> <ul style="list-style-type: none"> 0-1 yrs: 2.5mcg 1-3 yrs: 30mcg 4-13 yrs: 60mcg 9-13 yrs: 60 mcg >14yrs female: 90mcg/day >14yrs male: 120mcg/day

Vitamin B12	<p>Infants Dietary Deficiency:</p> <ul style="list-style-type: none"> • 1mg IM/day x 5 days, then weekly x 3 more doses <p>Infants/Children Malabsorption:</p> <ul style="list-style-type: none"> • 1mg IM every other day x 6 days, then weekly for 6 weeks <p>Adults:</p> <ul style="list-style-type: none"> • Deficiency: 1mg PO QD • Severe Deficiency or Pernicious Anemia: 1mg IM every other day x 6 days, then weekly for 6 weeks 	Also known as Cyanocobalamin
Warfarin	<p>Children: 0.2mg/kg (max 10mg) PO Max 10mg/dose in OD x 2 days</p> <p>Adults: 10mg PO OD x 2 days</p>	
Zinc Sulfate	<p>Age ≤ 6 m: 10mg daily for 10-14 days</p> <p>Age > 6 m: 20mg daily for 10-14 days</p>	

Medicine Compatibility Chart (**✓**=compatible, **XXX**=incompatible)

	Rate (minutes)	AMPICILLIN	GENTAMICIN	AMINOPHYLLINE	D10%
AMPICILLIN	3-5	XXX	XXX	✓	✓
GENTAMICIN	30	XXX	XXX	✓	✓
AMINOPHYLLINE	30	✓	XXX	✓	✓
CEFTRIAXONE	30	✓	✓	✓	✓
METRONIDAZOLE	60	✓	✓	✓	✓
PHENOBARBITAL	10-15	✓	✓	XXX	✓
D10%		✓	✓	✓	
RINGERS LACTATE		✓	✓	✓	
	Rate (minutes)	CEFTRIAXONE	PHENOBARBITAL	METRONIDAZOLE	RINGERS LACTATE
AMPICILLIN	3-5	✓	✓	✓	✓
GENTAMICIN	30	✓	✓	✓	✓
AMINOPHYLLINE	30	✓	XXX	✓	✓
CEFTRIAXONE	30	XXX	✓	✓	XXX
METRONIDAZOLE	60	✓	XXX	XXX	XXX
PHENOBARBITAL	10-15	✓	XXX	XXX	✓
D10%		✓	✓	✓	✓
RINGERS LACTATE		XXX	✓	XXX	

Abbreviations

abnl – abnormal	DVT – deep vein thrombosis
ACEI – angiotensin converting enzyme inhibitor	Dx – diagnosis
ACLS – advanced cardiac life support	ECG, EKG – electrocardiogram
ACS – acute coronary syndrome	EF – ejection fraction
AKI – acute kidney injury	EGD – esophagogastroduodenoscopy
Ag - antigen	ENT – ear, nose, and throat
ARDS – acute respiratory distress syndrome	ESR – erythrocyte sedimentation rate
AS -aortic stenosis	ESRD – end-stage renal disease
ASD – atrial septal defect	EtOH – ethanol
a/w – associated with	Fe – iron (level)
BD, BID – twice daily	FHx – family history
b/c – because	FNA – fine needle aspiration
BCS – Blantyre Coma Scale	f/u – follow-up
BCx -blood culture	GCS – Glasgow coma score
bili. – bilirubin	GERD -gastroesophageal reflux disease
BMI – body mass index	GFR – glomerular filtration rate
BP – blood pressure	Gluc. – glucose
BUN – blood urea nitrogen	HA – headache
bx – biopsy	Hb, Hgb – hemoglobin
Ca – calcium	HAV – Hepatitis A virus
CAD – coronary artery disease	HBV – Hepatitis B Virus
CBC – complete blood count	Hct - hematocrit
CCB – calcium channel blocker	HCV – Hepatitis C Virus
CFU – colony forming unit	H/o – history of
CHD – congenital heart disease	HR – heart rate
CKD – chronic kidney disease	hr/hrs – hour/hours
CMP – cardiomyopathy	HSV – herpes simplex virus
CMV - cytomegalovirus	HTN – hypertension
CPAP – constant positive airway pressure	Hx – history
COPD – chronic obstructive pulmonary disease	ICP – intracranial pressure
Cr – creatinine	ICU – intensive care unit
CrCl – creatinine clearance	Ig - Immunoglobulin
CSF – cerebrospinal fluid	INH – isoniazid
CVA- cerebrovascular accident	INR – international normalized ratio
Cx – culture	ITP – idiopathic thrombocytopenic purpura
CXR – chest radiograph	IVF – intravenous fluids
ΔMS – mental status change	JVD – jugular venous distension
d/c – discontinue	LDH – lactate dehydrogenase
DDx – differential diagnosis	LFTs – liver function tests
DIC – disseminated intravascular coagulation	LOC – loss of consciousness
DKA – diabetic ketoacidosis	LP – lumbar puncture
DOE – dyspnea on exertion	MIVF – maintenance IV fluids
	RL – ringer's lactate
	LUQ – left upper quadrant
	LUSB – left upper sternal border
	LV – left ventricle

LVH – left ventricular hypertrophy	qhs – every bedtime
MAC – mycobacterium avium complex	QID – four times daily
MAM – moderate acute malnutrition	RF – rheumatic fever
MAP – mean arterial pressure	RHD – rheumatic heart disease
MAT – multifocal atrial tachycardia	RI – reticulocyte index
MCV – mean corpuscular volume	r/o – rule-out
MDI – metered dose inhaler	ROS – review of systems
MI – myocardial infarction	RR – respiratory rate
mo – month	RUQ – right upper quadrant
mod. – moderate	Rx – treatment, therapy
MTb – <i>mycobacterial tuberculosis</i>	SAM – severe acute malnutrition
MV – mitral valve	SBP – spontaneous bacterial peritonitis
n/v – nausea vomiting	sev. – severe
nL – normal	SIADH – syndrome of inappropriate antidiuretic hormone
NPO – nothing by mouth	SIRS – systemic inflammatory response syndrome
NS – normal saline	SJS – Steven-Johnson Syndrome
NSAID – nonsteroidal anti-inflammatory drug	SOB – shortness of breath
O2 sat – oxygen saturation	s/p – status post
OD, QD – daily	SPO ₂ – oxygen saturation
OGD –	STD – sexually transmitted disease
Oesophagogastroduodenoscopy	STI – sexually transmitted infection
OTC – over-the-counter	SVDK – Snake Venom Detection Kit
o/w – otherwise	sxs – symptoms
PCN – penicillin	TB – tuberculosis
PCP/PJP – <i>Pneumocystis jiroveci</i> pneumonia	TIA – transient ischemic attack
PEA – pulseless electrical activity	TIBC – total iron-binding capacity
PEEP – positive end-expiratory pressure	TID – three times daily
PFO – patent foramen ovale	TMP-SMX – trimethoprim-sulfamethoxazole
PI – protease inhibitor	TSH -thyroid stimulation hormone
PID – pelvic inflammatory disease	U/A – urinalysis
PMHx – past medical history	U/S – ultrasound
PNA – pneumonia	UCx – urine culture
PND – paroxysmal nocturnal dyspnea	UOP – urine output
PO – oral intake	URI – upper respiratory tract infection
PPD – purified protein derivative	UTI – urinary tract infection
PPI – protein pump inhibitor	VS -vital signs
PRBCs – packed red blood cells	VZV – varicella zoster virus
PSHx – past surgical history	w/ - with
PT – prothrombin time	wk – week
PTT – partial thromboplastin time	WNL – within normal limits
p/w – presents with	w/o – without
qac – before every meal	w/u – work-up

References

1. *Basic Paediatric Protocols*. Republic of Uganda Ministry of Health; 2014. <http://search.ebscohost.com/login.aspx?direct=true&db=buh&AN=6962963&site=ehost-live>.
2. de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015;132(18 Suppl 2):S526-42. doi:10.1161/CIR.0000000000000266
3. *Emergency Care Algorithms*. Emergency Medicine Kenya Foundation; 2015. <http://emergencymedicinekenya.org/algorithms>.
4. Asskaryar F, Shankar R. An Indian pediatric emergency weight estimation tool: prospective adjustment of the Broselow tape. *Int J Emerg Med*. 2015;8(1):78. doi:10.1186/s12245-015-0078-z
5. Abba K, Deeks JJ, Olliaro P, et al. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. *Cochrane database Syst Rev*. 2011;(7):CD008122. doi:10.1002/14651858.CD008122.pub2
6. Hopkins H, Bebell L, Kambale W, Dokomajilar C, Rosenthal PJ, Dorsey G. Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. *J Infect Dis*. 2008;197(4):510-518. doi:10.1086/526502
7. Nielsen MV, Amemason S, Agyekum A, et al. Clinical indicators for bacterial co-infection in Ghanaian children with P. falciparum infection. *PLoS One*. 2015;10(4):1-16. doi:10.1371/journal.pone.0122139
8. Bassat Q, Machevo S, O'Callaghan-Gordo C, et al. Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: A hospital-based study in Mozambique. *Am J Trop Med Hyg*. 2011;85(4):626-634. doi:10.4269/ajtmh.2011.11-0223
9. Gwer S, Newton CRJC, Berkley JA. Over-diagnosis and co-morbidity of severe malaria in African children: A guide for clinicians. *Am J Trop Med Hyg*. 2007;77(SUPPL. 6):6-13.
10. Church J, Maitland K. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review. *BMC Med*. 2014;12(1):31. doi:10.1186/1741-7015-12-31
11. Maltha J, Guiraud I, Kaboré B, et al. Frequency of severe malaria and invasive bacterial infections among children admitted to a rural hospital in Burkina Faso. *PLoS One*. 2014;9(2):1-8. doi:10.1371/journal.pone.0089103
12. Berkley J a, Maitland K, Mwangi I, et al. Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. *Br Med J*. 2005;330(7498):995. doi:10.1136/bmj.38408.471991.8F
13. Kibuuwa A, Byakika-Kibwika P, Achan J, et al. Bacteremia Among Febrile Ugandan Children Treated with Antimalarials Despite a Negative Malaria Test. *Am J Trop Med Hyg*. 2015;93(2):276-280. doi:10.4269/ajtmh.14-0494
14. Shanks GD. For severe malaria, artesunate is the answer. *Lancet (London, England)*. 2010;376(9753):1621-1622. doi:10.1016/S0140-6736(10)61928-9
15. Olumese P. *WHO / Guidelines for the Treatment of Malaria. Third Edition*. World Health Organization; 2016. [www. Accessed September 12, 2016.](http://www.who.int/mediacentre/news-room/12/WHO-Guidelines-for-the-Treatment-of-Malaria-Third-Edition)
16. World Health Organization. *Pocket Book of Hospital Care for Children: Second Edition Guidelines for the Management of Common Childhood Illnesses*. 2nd ed. World Health Organization; 2013.
17. World Health Organization. Department of Child and Adolescent Health and Development. *The Treatment of Diarrhoea : A Manual for Physicians and Other Senior Health Workers*. Dept. of Child and Adolescent Health and Development, World Health Organization; 2005. http://www.who.int/maternal_child_adolescent/documents/9241593180/en/. Accessed March 20, 2017.
18. World Health Organization. *Guidelines for the Control of Shigellosis, Including Epidemics Due to *Shigella Dysenteriae* Type 1*. World Health Organization; 2005. <http://www.who.int/cholera/publications/shigellosis/en/>. Accessed March 20, 2017.
19. Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence*. 2014;5(1):179-189. doi:10.4161/viru.27045
20. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med*. 2005;6(1):2-8. doi:10.1097/01.PCC.0000149131.72248.E6

21. Khilnani P, Singhi S, Lodha R, et al. Pediatric Sepsis Guidelines: Summary for resource-limited countries. *Indian J Crit Care Med.* 2010;14(1):41-52. doi:10.4103/0972-5229.63029
22. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med.* 2013;39(2):165-228. doi:10.1007/s00134-012-2769-8
23. Davies P, Maconochie I. The relationship between body temperature, heart rate and respiratory rate in children. *Emerg Med J.* 2009;26(9):641-643. doi:10.1136/emy.2008.061598
24. Thompson M, Harnden A, Perera R, et al. Deriving temperature and age appropriate heart rate centiles for children with acute infections. *Arch Dis Child.* 2009;94(5):361-365. doi:10.1136/adc.2008.145011
25. Nijman RG, Thompson M, van Veen M, Perera R, Moll HA, Oostenbrink R. Derivation and validation of age and temperature specific reference values and centile charts to predict lower respiratory tract infection in children with fever: prospective observational study. *BMJ.* 2012;345:e4224. doi:10.1136/bmj.e4224
26. *Uganda Clinical Guidelines 2016: National Guidelines for Management of Common Conditions.* 4th ed. Kampala: Ministry of Health Uganda; 2016. http://www.nda.or.ug/files/downloads/10.1007_s40264-015-0277-9.pdf. Accessed March 6, 2017.
27. Emergency Care Algorithms 2015. 2015. www.emergencymedicinekenya.org.
28. Officers PH, Tschudy MM, Arcara KM, Johns Hopkins Hospital. Children's Medical and Surgical Center. *The Harriet Lane Handbook : A Manual for Pediatric House Officers.* 19th ed. Mosby Elsevier; 2012. <https://evolve.elsevier.com/cs/product/9780323079426?role>. Accessed March 12, 2017.
29. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. *Pediatrics.* 2011;128(3):595-610. doi:10.1542/peds.2011-1330
30. Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. Antibiotics for acute pyelonephritis in children. Hodson EM, ed. *Cochrane database Syst Rev.* 2014;(7):CD003772. doi:10.1002/14651858.CD003772.pub4
31. Montini G, Toffolo A, Zucchetto P, et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. *BMJ.* 2007;335(7616):386-386. doi:10.1136/bmj.392446.692442.55
32. Nader Shaikh M, Alejandro Hoberman M. Urinary tract infections in infants older than one month and young children: Acute management, imaging, and prognosis - UpToDate. In: *UpToDate.* Waltham, MA; 2017. https://www.uptodate.com/contents/urinary-tract-infections-in-infants-older-than-one-month-and-young-children-acute-management-imaging-and-prognosis?source=search_result&search=upper%20urinary%20tract%20infection&selectedTitle=2~150#H4. Accessed March 20, 2017.
33. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. *Clin Microbiol Rev.* 2005;18(2):417-422. doi:10.1128/CMR.18.2.417-422.2005
34. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Pohl A, ed. *Cochrane database Syst Rev.* 2007;(4):CD003237. doi:10.1002/14651858.CD003237.pub2
35. Shaikh N, Craig JC, Rovers MM, et al. Identification of Children and Adolescents at Risk for Renal Scarring After a First Urinary Tract Infection. *JAMA Pediatr.* 2014;168(10):893. doi:10.1001/jamapediatrics.2014.637
36. Pollard A (GDG chair), Cloke A, Faust S, et al. Management of Bacterial Meningitis in Children and Young People. 2015:2. www.nice.org.uk/guidance/CG102. Accessed April 16, 2017.
37. Berkley JA, Versteeg AC, Mwangi I, Lowe BS, Newton CRJC. Indicators of Acute Bacterial Meningitis in Children at a Rural Kenyan District Hospital. *Pediatrics.* 2004;114(6). <http://phstwlp2.partners.org:2167/content/114/6/e713.full>. Accessed April 15, 2017.
38. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. van de Beek D, ed. *Cochrane database Syst Rev.* 2015;(9):CD004405. doi:10.1002/14651858.CD004405.pub5
39. Boyles T, Bamford C, Bateman K, et al. Guidelines: Guidelines for the management of acute meningitis in children and adults in South Africa Guidelines for the management of acute meningitis in children and adults in South Africa A von Gottberg, A Whitelaw, M Mendelson. *South Afr J Epidemiol Infect © SAJEI South Afr J Epidemiol Infect.* 2013;2828(11):5-15. http://www.fidssa.co.za/Content/Documents/Acute_Meningitis_Guidelines_May_2013.pdf. Accessed April 16, 2017.

40. Greenwood BM. Corticosteroids for Acute Bacterial Meningitis. *N Engl J Med.* 2007;357(24):2507-2509. doi:10.1056/NEJM0707474
41. Scarborough M, Gordon SB, Whitty CJM, et al. Corticosteroids for Bacterial Meningitis in Adults in Sub-Saharan Africa. *N Engl J Med.* 2007;357(24):2441-2450. doi:10.1056/NEJMoa065711
42. Hollander SA, Addonizio LJ, Chin C, et al. Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy. *Am J Emerg Med.* 2013;31(4):684-686. doi:10.1016/j.ajem.2012.12.009
43. Rakesh K Singh, MD M, TP Singh, MD Ms. Heart failure in children: Etiology, clinical manifestations, and diagnosis. In: Post TW, ed. *UpToDate*. Waltham, MA; 2017. https://www.uptodate.com/contents/heart-failure-in-children-etiology-clinical-manifestations-and-diagnosis?source=search_result&search=heart%20failure&selectedTitle=2~150#H23884780. Accessed March 21, 2017.
44. Tume SC, Schwartz SM, Bronicki RA, Klugman D, Goswami ES, Berger JT. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement. *Pediatr Crit Care Med.* 2016;17(3):S101-S108. doi:10.1097/PCC.00000000000000621
45. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography: A Scientific Statement From the American Heart Association. *Circulation.* 2015;131(20):1806-1818. doi:10.1161/CIR.0000000000000205
46. Chakravarty SD, Zabriskie JB, Gibofsky A. Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity. *Clin Rheumatol.* 2014;33(7):893-901. doi:10.1007/s10067-014-2698-8
47. Hahn RG, Knox LM, Forman TA. Evaluation of poststreptococcal illness. *Am Fam Physician.* 2005;71(10):1949-1954. <http://www.ncbi.nlm.nih.gov/pubmed/15926411>. Accessed June 9, 2017.
48. Webb RH, Grant C, Harnden A. Acute rheumatic fever. *BMJ.* 2015;351:h3443. <http://www.ncbi.nlm.nih.gov/pubmed/26175053>. Accessed June 9, 2017.
49. Evidence-based, best practice New Zealand Guidelines for Rheumatic Fever Evidence-based, best practice Guidelines on: New Zealand Guidelines for. <http://assets.heartfoundation.org.nz/shop/marketing/non-stock-resources/diagnosis-management-rheumatic-fever-guideline.pdf>. Accessed June 9, 2017.
50. Dynamed. Acute rheumatic fever. In: EBSCO Information Services. 1995, ed. *Dynamed [Internet]*. Record No. 116561. Ipswich (MA); 2015:[about 16 screens]. <http://phstwlp2.partners.org:2076/dynamed/detail?vid=2&sid=d1655d58-e244-49b7-ae66-55b8bb190d04%40sessionmgr4009&hid=4101&bdata=JnNpdGU9ZHLuYW1lZC1saXZIJnNjb3BIPXNpdGU%3D#db=dme&AN=116561&anchor=GenRef8370>. Accessed June 9, 2017.
51. Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. *Blood.* 2017;130(24):2585-2593. doi:10.1182/blood-2017-06-788935
52. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The Diagnosis and Management of Acute Otitis Media. *Pediatrics.* 2013;131(3):e964-e999. doi:10.1542/peds.2012-3488
53. These images and figures were reprinted with permission from the Pocket Book of Hospital Care for Children Guidelines for the Management of Common Illnesses with Limited Resources. Second Edition, "Other common neonatal problems", Page 65, and "Ear Infections" Page 182 and 183. World Health Organization; Copyright 2013.
54. File:Normal Left Tympanic Membrane.jpg - Wikipedia. https://en.wikipedia.org/wiki/File:Normal_Left_Tympanic_Membrane.jpg. Published 2012. Credit: Hawke M, MD. (<https://creativecommons.org/licenses/by-sa/3.0/>), from Wikimedia Commons.
55. File:Otitis media entdifferenziert2.jpg - Wikimedia Commons. https://commons.wikimedia.org/wiki/File:Otitis_media_entdifferenziert2.jpg. Published 2006. Credit: Welleschik B. (<https://creativecommons.org/licenses/by-sa/3.0/>), from Wikimedia Commons.
56. Schaefer P, Baugh RF. Acute otitis externa: an update. *Am Fam Physician.* 2012;86(11):1055-1061. <http://www.ncbi.nlm.nih.gov/pubmed/23198673>. Accessed May 19, 2017.
57. Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical Practice Guideline: Acute Otitis Externa. *Otolaryngol -- Head Neck Surg.* 2014;150(1 Suppl):S1-S24. doi:10.1177/0194599813517083
58. Kordeluk S, Kraus M, Leibovitz E. Challenges in the Management of Acute Mastoiditis in Children. *Curr Infect Dis Rep.* 2015;17(5):26. doi:10.1007/s11908-015-0479-4

59. Groth A, Enoksson F, Hultcrantz M, Stalfors J, Stenfeldt K, Hermansson A. Acute mastoiditis in children aged 0–16 years—A national study of 678 cases in Sweden comparing different age groups. *Int J Pediatr Otorhinolaryngol*. 2012;76(10):1494–1500. doi:10.1016/j.ijporl.2012.07.002
60. Chow AW, Benninger MS, Brook I, et al. Executive Summary: IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. *Clin Infect Dis*. 2012;54(8):1041–1045. doi:10.1093/cid/cir1043
61. Wald ER, Applegate KE, Bordley C, et al. Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years. *Pediatrics*. 2013. doi:10.1542/peds.2013-1071
62. Cardozo DM, Nascimento-Carvalho CMC, Souza FR, Silva NMS. Nasopharyngeal colonization and penicillin resistance among pneumococcal strains: a Worldwide 2004 update. *Brazilian J Infect Dis*. 2006;10(4):293–303. doi:10.1590/S1413-86702006000400015
63. Kisakeye A, Makumbi I, Nansera D, et al. Surveillance for *Streptococcus pneumoniae* Meningitis in Children Aged <5 Years: Implications for Immunization in Uganda. *Clin Infect Dis*. 2009;48(s2):S153–S161. doi:10.1086/596495
64. Blossom DB, Namayanja-Kaye G, Nankya-Mutyoba J, et al. Oropharyngeal colonization by *Streptococcus pneumoniae* among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. *Int J Infect Dis*. 2006;10(6):458–464. doi:10.1016/j.ijid.2006.05.010
65. Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR. High prevalence of carriage of antibiotic-resistant *Streptococcus pneumoniae* in children in Kampala Uganda. *Int J Antimicrob Agents*. 2001;17(5):395–400. <http://www.ncbi.nlm.nih.gov/pubmed/11337227>. Accessed May 21, 2017.
66. Narayan S, Mahadevan S, Serane VT. Keith Edwards score for diagnosis of tuberculosis. *Indian J Pediatr*. 2003;70(6):467–469. doi:10.1007/BF02723134
67. Sarkar S, Paul DK, Chakrabarti S, Mandal NK, Ghoshal AG. The Keith Edward scoring system: A case control study. *Lung India*. 2009;26(2):35–37. doi:10.4103/0970-2113.48894
68. Pearce EC, Woodward JF, Nyandiko WM, Vreeman RC, Ayaya SO. A Systematic Review of Clinical Diagnostic Systems Used in the Diagnosis of Tuberculosis in Children. *AIDS Res Treat*. 2012;2012:1–11. doi:10.1155/2012/401896
69. Chan P-C, Peng SS-F, Chiou M-Y, et al. Risk for Tuberculosis in Child Contacts: Development and Validation of a Predictive Score. *Am J Respir Crit Care Med*. December 2013;131204094545001. doi:10.1164/rccm.201305-0863OC
70. WHO | Global tuberculosis report 2016. *WHO*. 2016.
71. Pedrozo C, Sant’Anna CC, March M de FBP, Lucena SC, March Mde F, Lucena SC. Efficacy of the scoring system, recommended by the Brazilian National Ministry of Health, for the diagnosis of pulmonary tuberculosis in children and adolescents, regardless of their HIV status. *J Bras Pneumol*. 2010;36(1):92–98. doi:S1806-37132010000100015 [pii]
72. Sabatine MS, ed. *Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine*. Fifth. Philadelphia, PA: Wolters Kluwer | Lippincott Williams & Wilkins; 2014.
73. Grouzard V, Rigal J, Sutton M, eds. *Clinical Guidelines - Diagnosis and Treatment Manual*. 2016th ed. Médecins Sans Frontières; 2017. http://refbooks.msf.org/msf_docs/en/clinical_guide/cg_en.pdf.
74. Lawrence J, Alcock D, McGrath P, Kay J, MacMurray SB, Dulberg C. The development of a tool to assess neonatal pain. *Neonatal Netw*. 1993;12(6):59–66. <http://www.ncbi.nlm.nih.gov/pubmed/8413140>. Accessed December 5, 2017.
75. UCSF Children’s Hospital at UCSF Medical Center. Intensive Care Nursery House Staff Manual Pain Management and Sedation. https://www.ucsfbenioffchildrens.org/pdf/manuals/50_Pain.pdf. Accessed December 5, 2017.
76. MassGeneral Hospital for Children. r-FLACC Scale Face, Legs, Activity, Cry, Consolability. 2009. http://www.mghpc.org/eed_portal/Documents/Pain/Pediatric/FLACC_scale.pdf. Accessed December 5, 2017.
77. MALVIYA S, VOEPEL-LEWIS T, BURKE C, MERKEL S, TAIT AR. The revised FLACC observational pain tool: improved reliability and validity for pain assessment in children with cognitive impairment. *Pediatr Anesth*. 2006;16(3):258–265. doi:10.1111/j.1460-9592.2005.01773.x
78. Basic Paediatric Basic Paediatric for Ages up to 5 Years. 4th ed. Republic of Kenya Ministry of Health; 2016.
79. Velez L, Shepherd J, Goto C. Approach to the child with occult toxic exposure. In: Post T, ed.

- UpToDate*. Waltham, MA; 2017. https://www.uptodate.com/contents/approach-to-the-child-with-occult-toxic-exposure?source=search_result&search=ingestion&selectedTitle=1~150#H10. Accessed April 5, 2017.
80. Höjer J, Troutman WG, Hoppu K, et al. Position paper update: ipecac syrup for gastrointestinal decontamination. *Clin Toxicol (Phila)*. 2013;51(3):134-139. doi:10.3109/15563650.2013.770153
81. Pond SM, Lewis-Driver DJ, Williams GM, Green AC, Stevenson NW. Gastric emptying in acute overdose: a prospective randomised controlled trial. *Med J Aust*. 1995;163(7):345-349. <http://www.ncbi.nlm.nih.gov/pubmed/7565257>. Accessed April 4, 2017.
82. Saetta JP, Quinton DN. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study. *J R Soc Med*. 1991;84(1):35-38. doi:10.1177/014107689108400113
83. Saetta JP, March S, Gaunt ME, Quinton DN. Gastric emptying procedures in the self-poisoned patient: are we forcing gastric content beyond the pylorus? *J R Soc Med*. 1991;84(5):274-276. <http://www.ncbi.nlm.nih.gov/pubmed/1674963>. Accessed April 4, 2017.
84. Tandberg D, Diven BG, McLeod JW. Ipecac-induced emesis versus gastric lavage: a controlled study in normal adults. *Am J Emerg Med*. 1986;4(3):205-209. <http://www.ncbi.nlm.nih.gov/pubmed/2870722>. Accessed April 4, 2017.
85. Kulig K, Bar-Or D, Cantrill S V, Rosen P, Rumack BH. Management of acutely poisoned patients without gastric emptying. *Ann Emerg Med*. 1985;14(6):562-567. <http://www.ncbi.nlm.nih.gov/pubmed/2859819>. Accessed April 4, 2017.
86. Hendrickson R, Kusin S. Gastrointestinal decontamination of the poisoned patient. In: Post T, ed. *UpToDate*. Waltham, MA; 2017. <https://www.uptodate.com/contents/gastrointestinal-decontamination-of-the-poisoned-patient#H18993923>. Accessed April 4, 2017.
87. Bird S. Organophosphate and carbamate poisoning. In: Post T, ed. *UpToDate*. Waltham, MA; 2017. https://www.uptodate.com/contents/organophosphate-and-carbamate-poisoning?source=search_result&search=organophosphate&selectedTitle=1~22#H10. Accessed April 5, 2017.
88. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. *www.thelancet.com*. 2008;371(16). doi:10.1016/S0140
89. Acetaminophen poisoning. In: *Dynamed [Database Online]*. Ipswich (MA): EBSCO Information Services; 2016. <http://doi.wiley.com/10.1002/hep.20293>. Accessed May 26, 2017.
90. Janssen J, Singh-Saluja S. How much did you take? Reviewing acetaminophen toxicity. *Can Fam Physician*. 2015;61(4):347-349. <http://www.ncbi.nlm.nih.gov/pubmed/25873702>. Accessed May 26, 2017.
91. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen Hepatotoxicity and Acute Liver Failure. *J Clin Gastroenterol*. 2009;43(4):342-349. doi:10.1097/MCG.0b013e31818a3854
92. Hodgman MJ, Garrard AR. A Review of Acetaminophen Poisoning. *Crit Care Clin*. 2012;28(4):499-516. doi:10.1016/j.ccc.2012.07.006
93. Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA. Guidelines for the management of paracetamol overdose Paracetamol Treatment Nomogram. 2007. <http://www.asem.org.au/document.php/njxudmy/Paracetamol+Overdose+Treatment+Nomogr.am.pdf>. Accessed May 26, 2017.
94. Rumack Matthew nomogram with treatment (study) line.pdf - Wikipedia. [https://en.wikipedia.org/wiki/File:Rumack_Matthew_nomogram_with_treatment_\(study\)_line.pdf#file](https://en.wikipedia.org/wiki/File:Rumack_Matthew_nomogram_with_treatment_(study)_line.pdf#file). File has been cropped and colors were changed to appropriately fit size of new media. Credit: Merlin Cyrstal [CC BY-SA 3.0] (<https://creativecommons.org/licenses/by-sa/3.0/>), from Wikimedia Commons
95. Western Cape Division of Emergency Medicine. SNAKEBITE Assessment. In: Cape Town, SA: Federation of Infectious Diseases Societies of Southern Africa; 2010. [https://www.fidssa.co.za/Content/Documents/Mangement of Snakebite.pdf](https://www.fidssa.co.za/Content/Documents/Mangement%20of%20Snakebite.pdf). Accessed November 9, 2018.
96. New York Heart Association. The criteria committee of the New York Heart Association, functional capacity and objective assessment. In: *Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels*. Boston, MA: Little Brown and Company; 1994:253-255. https://professional.heart.org/professional/General/UCM_423811_Classification-of-Functional-Capacity-and-Objective-Assessment.jsp. Accessed June 4, 2017.
97. NIH Stroke Scale.; 2016. https://www.ninds.nih.gov/sites/default/files/NIH_Stroke_Scale_Booklet.pdf. Accessed

August 2, 2018.

98. Severinghaus JW. Simple, accurate equations for human blood O₂ dissociation computations. *J Appl Physiol.* 1979;46(3):599-602. <http://www.ncbi.nlm.nih.gov/pubmed/35496>. Accessed March 26, 2017.
99. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 2017. doi:10.1007/s00134-017-4683-6
100. Stanley IJ, Bwanga F, Itabangi H, Nakaye M, Bashir M, Bazira J. Prevalence and Antibiotic Susceptibility Patterns of Clinical Isolates of Methicillin- Resistant Staphylococcus aureus in a Tertiary Care Hospital in Western Uganda. <http://sciencedomain.org/abstract/5120>. 2014. <http://imsear.li.mahidol.ac.th/handle/123456789/163256>. Accessed March 27, 2017.
101. Bazira J. Trends in Antimicrobial Resistance of Staphylococcus aureus Isolated from Clinical Samples at Mbarara Regional Referral Hospital in Rural Uganda. *Br Microbiol Res J.* 2014;4(10):1084-1091. doi:10.9734/BMRJ/2014/9751
102. Andrew B, Aidah K, Bazira J, Zhi Xiang N. Prevalence of Methicillin Resistant Staphylococcus aureus among Isolates from Wounds in Surgical Wards at Kabale Regional Referral Hospital, South Western Uganda. *Br Microbiol Res J Taiwan.* 2016;17(534):1-5. doi:10.9734/BMRJ/2016/27807
103. Nalwoga J, Tirwomwe M, Onchweri AN, Maniga JN, Nyaribo CM, Miruka CO. Drug resistant *Staphylococcus aureus* in Clinical Samples at Kampala International University-teaching Hospital, Bushenyi District, Uganda. *Am J Biomed Res Vol 4, 2016, Pages 94-98.* 2016;4(4):94-98. doi:10.12691/AJBR-4-4-3
104. Seni J, Bwanga F, Najjuka CF, et al. Molecular Characterization of Staphylococcus aureus from Patients with Surgical Site Infections at Mulago Hospital in Kampala, Uganda. Smith TC, ed. *PLoS One.* 2013;8(6):e66153. doi:10.1371/journal.pone.0066153
105. Najjuka CF, Kateete DP, Kajumbula HM, Joloba ML, Essack SY. Antimicrobial susceptibility profiles of Escherichia coli and Klebsiella pneumoniae isolated from outpatients in urban and rural districts of Uganda. *BMC Res Notes.* 2016;9:235. doi:10.1186/s13104-016-2049-8
106. Seni J, Najjuka CF, Kateete DP, et al. Antimicrobial resistance in hospitalized surgical patients: a silently emerging public health concern in Uganda. *BMC Res Notes.* 2013;6(1):298. doi:10.1186/1756-0500-6-298
107. Wenzel RP, Perl TM, Kateete DP, et al. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. *J Hosp Infect.* 1995;31(1):13-24. doi:10.1016/0195-6701(95)90079-9
108. Agwu E, Ihongbe JC, Ezeonwumelu JO, Lodhi MM. Baseline burden and antimicrobial susceptibility of pathogenic bacteria recovered from oral lesions of patients with HIV/AIDS in South-Western Uganda. *Oral Sci Int.* 2015;12:59-66. doi:10.1016/S1348-8643(15)00018-X
109. Wendy Fujita A, Mbabazi O, Akampurira A, et al. 472. Antimicrobial Resistance in Uganda and the Urgent Need for Standardized Reporting and a National Surveillance Program. 2015. https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ofid/2/suppl_1/10.1093_ofid_ofv133.1025/2/ofv133.1025.pdf?Expires=1490963136&Signature=HczOuhKH-odFBsZ1~EPIt6Lx3p6fILO1M~~T7Ql-DK7I5i5x4xxdubFp5vYOAXYqkh2W23YdQzxrPQwRSrwdgdlAUWOt2vMC65mRHIUspn-KBw4-9gEccWzMYVl0y8XSnDdwSXOMoJzS63gAk9D0kGS0P26nzEqNRK4kOBhvY-z738RcgfVJ0LqUt0~5SpS7y11hEyBYtxrCTHjrVsgnA-Rs9FG6rLzFkyYf97aV9TtrY-LII~y7xZ3ocobrYw7-SPTKOKyVCA8-WIJhgyXzIop2ghKwKIVd7rQ74fnP9rlrojWZF31K3DWh9LWbDnslyFXP4PFfLN3FKZ0QHQ__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q. Accessed March 27, 2017.
110. Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis. *World J Crit care Med.* 2016;5(1):57-64. doi:10.5492/wjccm.v5.i1.57
111. McGill F, Heyderman R, Michael B, et al. Early Management of Suspected Meningitis and Meningococcal Sepsis in Immunocompetent Adults. 2016;1. doi:10.1016/j.jinf.2016.01.007
112. Bijlsma MW, Brouwer MC, Kasamkoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. *Lancet Infect Dis.* 2016;16(3):339-347. doi:10.1016/S1473-3099(15)00430-2
113. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical Features and Prognostic Factors in Adults with Bacterial Meningitis. *N Engl J Med.* 2004;351(18):1849-1859. doi:10.1056/NEJMoa040845

114. Simel DL, Rennie D, Keitz SA, eds. *The Rational Clinical Examination: Evidence-Based Clinical Diagnosis*. McGraw-Hill Medical; 2008.
115. TELISINGHE L, WAITE TD, GOBIN M, et al. Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review. *Epidemiol Infect*. 2015;143(11):2259-2268. doi:10.1017/S0950268815000849
116. Meningitis outbreak response in sub-Saharan Africa.
http://www.who.int/about/licensing/copyright_form/en/index.html. Accessed April 17, 2017.
117. Srygley FD, Gerardo CJ, Tran T, Fisher DA. Does This Patient Have a Severe Upper Gastrointestinal Bleed? *JAMA*. 2012;307(10):1072. doi:10.1001/jama.2012.253
118. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. *JAMA*. 2014;311(5):507. doi:10.1001/jama.2013.284427
119. Sass DA, Chopra KB. Portal Hypertension and Variceal Hemorrhage. *Med Clin North Am*. 2009;93(4):837-853. doi:10.1016/j.mcna.2009.03.008
120. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: An update. *Hepatology*. 2009;49(6):2087-2107. doi:10.1002/hep.22853
121. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol*. 2010;53(3):397-417. doi:10.1016/j.jhep.2010.05.004
122. Runyon BA. Management of Adult Patients with Ascites Due to Cirrhosis : Update 2012. 2012.
123. Moore, Gregory MD J, Pfaff, James A MD, FACEP F. *Assessment and Emergency Management of the Acutely Agitated or Violent Adult - UpToDate*. (Hockberger, Robert S MD F, Grayzel, Jonathan MD F, eds.). Waltham: UpToDate; 2018.
<https://www.uptodate.com/contents/assessment-and-emergency-management-of-the-acutely-agitated-or-violent-adult?search=agitated>
violant&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed May 28, 2018.
124. ECGpedia. All ECG tracings in this chapter marked with letters have been taken from the online resource ECGpedia (https://en.ecgpedia.org/index.php?title>Main_Page). They have been edited, cropped, and colors were changed to appropriately fit the size and content being presented. The original graphics for each tracing can be found at the following URLs.
a-<https://en.ecgpedia.org/index.php?title=File:LAE.png>;
b-<https://en.ecgpedia.org/index.php?title=File:LAE.png>;
c-<https://en.ecgpedia.org/index.php?title=File:RAE.png>;
d-<https://en.ecgpedia.org/index.php?title=File:RVH.png>;
e-<https://en.ecgpedia.org/index.php?title=File:LVH.png>;
f-https://en.ecgpedia.org/index.php?title=File:RBBB_inf_ML.jpg;
g-https://en.ecgpedia.org/index.php?title=File:MI_LBBB.png;
h-https://en.ecgpedia.org/index.php?title=File:Aflutte_small.svg;
i-https://en.ecgpedia.org/index.php?title=File:Afib_detail.jpg;
j-https://en.ecgpedia.org/index.php?title=File:Myocardial_Infarction;
k-<https://en.ecgpedia.org/index.php?title=File:DVA2255.jpg>;
l-<https://en.ecgpedia.org/index.php?title=File:DVA2244.jpg>;
m-<https://en.ecgpedia.org/index.php?title=File:DVA2248.jpg>;
n-<https://en.ecgpedia.org/index.php?title=File:DVA2256.jpg>;
o-<https://en.ecgpedia.org/index.php?title=File:E000002.jpg>;
p-https://en.ecgpedia.org/index.php?title=File:MI_in_LBBB_01.jpg;
q-https://en.ecgpedia.org/index.php?title=File:AMI_inferior.jpg;
r-https://en.ecgpedia.org/index.php?title=File:AMI_inferior.jpg;
s-<https://en.ecgpedia.org/index.php?title=File:Ami0005.jpg>;
t-<https://en.ecgpedia.org/index.php?title=File:Ami0005.jpg>. Main Authors: J.S.S.G. de Jong, MD PhD, P.G. Postema, MD PhD, Rob Kreuger. ECGs: A.A.M. Wilde, MD PhD, W.A. de Voogt, MD PhD, Dr. Alberto Giniger, M. Rosengarten, BEng, MD. Credit: [CC BY-SA 3.0 (<https://creativecommons.org/licenses/by-sa/3.0/>)] from Wikimedia Commons.
125. Mahler SA, Riley RF, Hiestand BC, et al. The HEART Pathway Randomized Trial: Identifying Emergency Department Patients With Acute Chest Pain for Early Discharge. *Circ Cardiovasc Qual Outcomes*. 2015;8(2):195-203. doi:10.1161/CIRCOUTCOMES.114.001384

126. Nieuwets A, Poldervaart JM, Reitsma JB, et al. Medical consumption compared for TIMI and HEART score in chest pain patients at the emergency department: a retrospective cost analysis. *BMJ Open*. 2016;6(6):e010694. doi:10.1136/bmjjopen-2015-010694
127. Poldervaart JM, Langedijk M, Backus BE, et al. Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department. *Int J Cardiol*. 2017;227:656-661. doi:10.1016/j.ijcard.2016.10.080
128. Poldervaart JM, Reitsma JB, Backus BE, et al. Effect of Using the HEART Score in Patients With Chest Pain in the Emergency Department. *Ann Intern Med*. 2017;166(10):689. doi:10.7326/M16-1600
129. Backus BE, Six AJ, Kelder JC, et al. A prospective validation of the HEART score for chest pain patients at the emergency department. *Int J Cardiol*. 2013;168(3):2153-2158. doi:10.1016/j.ijcard.2013.01.255
130. Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. *Neth Heart J*. 2008;16(6):191-196. <http://www.ncbi.nlm.nih.gov/pubmed/18665203>. Accessed May 26, 2018.
131. Backus BE, Six AJ, Kelder JC, et al. Chest Pain in the Emergency Room. *Crit Pathways Cardiol A J Evidence-Based Med*. 2010;9(3):164-169. doi:10.1097/HPC.0b013e3181ec36d8
132. *ST-Elevation Myocardial Infarction (STEMI)*. Record No. 115392. Ipswich (MA): EBSCO Information Services.; 2018. doi:10.1186/1471-2482-5-23
133. Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing Frequency of Unfractionated Heparin Thromboprophylaxis. *Chest*. 2011;140(2):374-381. doi:10.1378/chest.10-3084
134. Venkatesan A. Case 13: a man with progressive headache and confusion. *MedGenMed*. 2006;8(3):19. <http://www.ncbi.nlm.nih.gov/pubmed/17406159>. Accessed June 10, 2017.
135. Dodick D. Headache as a symptom of ominous disease. What are the warning signals? *Postgrad Med*. 1997;101(5):46-50, 55-56, 62-64. doi:10.3810/pgm.1997.05.217
136. Flow charts of algorithms for screening and diagnosing tuberculosis (TB) in adults, with modelled yields and predictive values. 2013. <https://www.ncbi.nlm.nih.gov/books/NBK294078/>. Accessed November 28, 2017.
137. Bernardo J. Diagnosis of pulmonary tuberculosis in HIV-uninfected adults. In: Post TW, ed. *UpToDate*. Waltham, MA: UpToDate; 2017. https://www.uptodate.com/contents/image?imageKey=ID%2F80879&topicKey=ID%2F111683&rank=2~150&source=see_link&search=tuberculosis. Accessed November 28, 2017.
138. Awolesi D, Naidoo M, Cassimjee MH. The profile and frequency of known risk factors or comorbidities for deep vein thrombosis in an urban district hospital in KwaZulu-Natal. *South Afr J HIV Med*. 2016;17(1):5 pages. doi:10.4102/sajhivmed.v17i1.425
139. Abah JP, Menanga A, Mbatchou BH, Minkande JZ, Akono MN, Kingue S. Pattern of venous thromboembolic diseases in a resources-limited setting in Cameroon. *Pan Afr Med J*. 2016;23. doi:10.11604/pamj.2016.23.236.7034
140. Clinical prediction of pulmonary embolism. In: *Dynamed Plus [Database Online]*. updated 2015 Dec 09. Ipswich (MA): EBSCO Information Services. <http://www.dynamed.com/topics/dmp~AN~T349949#Pulmonary-Embolism-Rule-Out-Criteria--PERC->. Accessed October 9, 2017.
141. Janelle MD J, Orrick PharmD J, Sherman PharmD E. *Opportunistic Infections (OIs) in Adults & Adolescents with HIV Infection*; 2018. <https://aidsetc.org/resource/opportunistic-infections-ois-hivads-may-2017>. Accessed November 10, 2018.
142. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_ois.pdf. Accessed (11/10/2018), Pages M1-3.
143. Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. *Lancet (London, England)*. 2011;377(9770):1011-1018. doi:10.1016/S0140-6736(10)62226-X
144. Bonafide CP, Brady PW, Keren R, Conway PH, Marsolo K, Daymont C. Development of heart and respiratory rate percentile curves for hospitalized children. *Pediatrics*. 2013;131(4):e1150-7. doi:10.1542/peds.2012-2443
145. Haque IU, Zaritsky AL. Analysis of the evidence for the lower limit of systolic and mean arterial pressure in children. *Pediatr Crit Care Med*. 2007;8(2):138-144. doi:10.1097/01.PCC.0000257039.32593.DC
146. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and

- Management of High Blood Pressure in Children and Adolescents. *Pediatrics*. 2017;140(3):e20171904. doi:10.1542/peds.2017-1904
147. Banker A, Bell C, Gupta-Malhotra M, Samuels J. Blood pressure percentile charts to identify high or low blood pressure in children. *BMC Pediatr*. 2016;16:98. doi:10.1186/s12887-016-0633-7
148. Baker C, Branca A, Chicella M, et al. *2016 Pediatric Medication Handbook*. Norfolk, VA: Children's Hospital of the King's Daughters; 2016.
http://www.chkd.org/uploadedFiles/Documents/Medical_Professionals/PedMedHandbook.pdf
149. Maguire JL, Kulik DM, Laupacis A, Kuppermann N, Uleryk EM, Parkin PC. Clinical Prediction Rules for Children: A Systematic Review. *Pediatrics*. August 2011. doi:10.1542/peds.2011-0043
150. Friedman JN, Goldman RD, Srivastava R, Parkin PC. Development of a clinical dehydration scale for use in children between 1 and 36 months of age. *J Pediatr*. 2004;145(2):201-207. doi:10.1016/j.jpeds.2004.05.035
151. Welch TR, R. T. An approach to the child with acute glomerulonephritis. *Int J Pediatr*. 2012;2012:426192. doi:10.1155/2012/426192
152. Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ. Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. *Pediatr Nephrol*. 2011;26(2):165-180. doi:10.1007/s00467-010-1554-6
153. Michael B, Menezes BF, Cunniffe J, et al. Effect of delayed lumbar punctures on the diagnosis of acute bacterial meningitis in adults. *Emerg Med J*. 2010;27(6):433-438. doi:10.1136/emj.2009.075598
154. Kanegaye JT, Soliman-Zadeh P, Bradley JS. Lumbar Puncture in Pediatric Bacterial Meningitis: Defining the Time Interval for Recovery of Cerebrospinal Fluid Pathogens After Parenteral Antibiotic Pretreatment. *Pediatrics*. 2001;108(5).
<http://pediatrics.aappublications.org/content/108/5/1169?download=true>. Accessed April 16, 2017.
155. Sadoh WE, Sadoh AE, Okposio M. Cardiovascular responses to blood transfusion in children with anemic heart failure. *Niger J Clin Pract*. 2012;15(4):424-429. doi:10.4103/1119-3077.104517
156. Kassim AA, Galadanci NA, Pruthi S, Debaun MR. How I Treat How I treat and manage strokes in sickle cell disease. doi:10.1182/blood-2014
157. Tsze DS, Valente JH. Pediatric Stroke: A Review. *Emerg Med Int*. 2011;734506(10):734506. doi:10.1155/2011/734506
158. Carden M, Morris C. *Normal Saline Bolus Use Is Associated with Worse Pain Scores in Children with Sickle Cell Disease and Vaso-Occlusive Pain Episodes: A Multicenter Experience*. Washington DC: Emergency Care Applied Research Network, Pediatric; 2018. https://www.researchgate.net/publication/325541250_Normal_Saline_Bolus_Use_is_Associated_with_Worse_Pain_Scores_in_Children_with_Sickle_Cell_Disease_and_Vaso-Occlusive_Pain_Episodes_A_Multicenter_Experience. Accessed November 13, 2018.
159. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. In: Okomo U, ed. *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2007:CD005406. doi:10.1002/14651858.CD005406.pub2
160. *Clinical Handbook for Sickle Cell Disease Vaso-Occlusive Crisis Provincial Council for Maternal and Child Health & Ministry of Health and Long-Term Care*; 2017. http://www.health.gov.on.ca/en/pro/programs/ecfa/docs/hb_sickle.pdf. Accessed November 13, 2018.
161. Jones J, Quinn R. Fluid Replacement Strategies in Sickle Cell Disease. 2017;21. doi:10.1056/NEJMra1510865
162. Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. *Haematologica*. 2006;91(1):7-10. <http://www.ncbi.nlm.nih.gov/pubmed/16434364>. Accessed April 5, 2017.
163. Heart N, Institute B. Evidence-Based Management of Sickle Cell Disease: Expert Panel, 2014. 2014.
164. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of Sickle Cell Disease. *JAMA*. 2014;311(10):1033-1048. doi:10.1001/jama.2014.10517
165. Improving Care for Children With Sickle Cell Disease/Acute Chest Syndrome. doi:10.1542/peds.2010-3099
166. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations. *Am J Med*. 2013;126(10):S1-S42.

167. Acker CG, Johnson JP, Palevsky PM, et al. Hyperkalemia in Hospitalized Patients. *Arch Intern Med.* 1998;158(8):917. doi:10.1001/archinte.158.8.917
168. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. *BMJ.* 2011;343. <http://phstwlp2.partners.org:2220/content/343/bmj.d5228>. Accessed March 30, 2017.
169. Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. *Am Fam Physician.* 2006;73(2):283-290. <http://www.ncbi.nlm.nih.gov/pubmed/16445274>. Accessed March 30, 2017.
170. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. *Texas Hear Inst J.* 2006;33(1):40-47. <http://www.ncbi.nlm.nih.gov/pubmed/16572868>. Accessed March 30, 2017.
171. Ahee P, Crowe A V. The management of hyperkalaemia in the emergency department. *J Accid Emerg Med.* 2000;17:188-191. <https://phstwlp2.partners.org:2052/pmc/articles/PMC1725366/pdf/v017p00188.pdf>. Accessed March 31, 2017.
172. Maxwell AP, Linden K, O'Donnell S, Hamilton PK, McVeigh GE. Management of hyperkalaemia. *J R Coll Physicians Edinb.* 2013;43(3):246-251. doi:10.4997/JRCPE.2013.312
173. Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. *Rev Endocr Metab Disord.* September 2016. doi:10.1007/s11154-016-9384-x
174. Mahoney B a, Smith W a D, Lo DS, Tsui K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Clase C, ed. *Cochrane Database Syst Rev.* 2005;(2):CD003235. doi:10.1002/14651858.CD003235.pub2
175. Batterink J, Ta C, Rai T, Batterink J, Cessford TA, Taylor RAI. Pharmacological interventions for the acute management of hyperkalaemia in adults (Review) Pharmacological interventions for the acute management of hyperkalaemia in adults. 2015;(10). doi:10.1002/14651858.CD010344.pub2. Copyright
176. *Clinical Practice Guidelines : Hyperkalaemia.*; 2017. http://www.rch.org.au/clinicalguide/guideline_index/Hyperkalaemia/. Accessed March 30, 2017.
177. Merriman PDA, Mwebesa DE, Katabira PE. *PALLIATIVE MEDICINE: Pain and Symptoms Control in Cancer and/or AIDS Patient in Uganda and Other African Countries.* 5th ed. Kampala, Uganda: Hospice Africa Uganda; 2012. info@hospiceafrica.or.ug.
178. Garra G, Singer AJ, Taira BR, et al. Validation of the Wong-Baker FACES Pain Rating Scale in Pediatric Emergency Department Patients. *Acad Emerg Med.* 2010;17(1):50-54. doi:10.1111/j.1553-2712.2009.00620.x
179. Savino F, Vagliano L, Ceratto S, Viviani F, Miniero R, Ricceri F. Pain assessment in children undergoing venipuncture: the Wong–Baker faces scale versus skin conductance fluctuations. *PeerJ.* 2013;1:e37. doi:10.7717/peerj.37
180. Garra G, Singer AJ, Domingo A, Thode HC. The Wong-Baker Pain FACES Scale Measures Pain, Not Fear. *Pediatr Emerg Care.* 2013;29(1):17-20. doi:10.1097/PEC.0b013e31827b2299
181. Munkres JR, James R. Guidance for national tuberculosis programmes on the management of tuberculosis in children. *Who.* 2014;2.
182. Dong X, Simon MA. The Epidemiology of Organophosphate Poisoning in Urban Zimbabwe from 1995 to 2000. *Int J Occup Environ Health.* 2001;7(4):333-338. doi:10.1179/107735201800339191
183. Z'gambo J, Siulapwa Y, Michelo C. Pattern of acute poisoning at two urban referral hospitals in Lusaka, Zambia. *BMC Emerg Med.* 2016;16(1):2. doi:10.1186/s12873-016-0068-3
184. Azab SMS, Hirshon JM, Hayes BD, et al. Epidemiology of acute poisoning in children presenting to the poisoning treatment center at Ain Shams University in Cairo, Egypt, 2009–2013. *Clin Toxicol.* 2016;54(1):20-26. doi:10.3109/15563650.2015.1112014
185. Dippenaar R, Diedericks RJ. Paediatric organophosphate poisoning--a rural hospital experience. *S Afr Med J.* 2005;95(9):678-681. <http://www.ncbi.nlm.nih.gov/pubmed/16327926>. Accessed April 5, 2017.
186. Mutiso VM, Muoki AS, Kimeu MM. PATTERNS OF POISONING AMONG PATIENTS AGED 0-13 YEARS AT A PAEDIATRIC HOSPITAL IN NAIROBI. *East Afr Med J.* 2014;91(11):379-384. <http://www.ncbi.nlm.nih.gov/pubmed/26866085>. Accessed April 5, 2017.
187. Mishara BL. Prevention of Deaths from Intentional Pesticide Poisoning. *Crisis.* 2007;28(S1):10-20. doi:10.1027/0227-5910.28.S1.10

188. Connors NJ, Harnett ZH, Hoffman RS. Comparison of Current Recommended Regimens of Atropinization in Organophosphate Poisoning. 2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057538/pdf/13181_2013_Article_324.pdf. Accessed April 5, 2017.
189. Bond GR, Pièche S, Sonicki Z, et al. A clinical decision rule for triage of children under 5 years of age with hydrocarbon (kerosene) aspiration in developing countries. *Clin Toxicol.* 2008;46(3):222-229. doi:10.1080/15563650701801218
190. Balme KH, Zar H, Swift DK, Mann MD. The efficacy of prophylactic antibiotics in the management of children with kerosene-associated pneumonitis: a double-blind randomised controlled trial. *Clin Toxicol.* 2015;3650(May 2016):1-8.
doi:10.3109/15563650.2015.1059943
191. American Psychiatric Association. *Home / APA DSM-5*. 5th ed. Washington D.C.: American Psychiatric Publishing; 2013. <http://www.dsm5.org/Pages/Default.aspx>. Accessed January 27, 2015.
192. Thomson J, ed. *Médecins sans Frontières Neonatal Care Guidelines DRAFT*. 2017th ed. Paris: Médecins Sans Frontières; 2017.
193. Brandler ES, Sharma M, Sinert RH, Levine SR. Prehospital stroke scales in urban environments: A systematic review. *Neurology.* 2014;82(24):2241-2249.
doi:10.1212/WNL.0000000000000523
194. Song B, Fang H, Zhao L, et al. Validation of the ABCD3-I Score to Predict Stroke Risk After Transient Ischemic Attack. *Stroke.* 2013;44(5):1244-1248.
doi:10.1161/STROKEAHA.113.000969
195. Merwick Á, Albers GW, Amarenco P, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. *Lancet Neurol.* 2010;9(11):1060-1069. doi:10.1016/S1474-4422(10)70240-4
196. Kiyohara T, Kamouchi M, Kumai Y, et al. ABCD3 and ABCD3-I Scores Are Superior to ABCD2 Score in the Prediction of Short- and Long-Term Risks of Stroke After Transient Ischemic Attack. *Stroke.* 2014;45(2):418-425. doi:10.1161/STROKEAHA.113.003077
197. Kiyohara T, Kamouchi M, Kumai Y, et al. ABCD3 and ABCD3-I Scores Are Superior to ABCD2 Score in the Prediction of Short- and Long-Term Risks of Stroke After Transient Ischemic Attack. *Stroke.* 2014;45(2). <http://stroke.ahajournals.org/content/45/2/418/tabs-article-info>. Accessed April 23, 2017.
198. Knoflach M, Lang W, Seyfang L, et al. Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. *Neurology.* 2016;87(9):861-869.
doi:10.1212/WNL.0000000000003033
199. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis. *JAMA.* 2016;315(8):762. doi:10.1001/jama.2016.0288
200. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA.* 2016;315(8):801-810.
doi:10.1001/jama.2016.0287
201. Huson MA, Kalkman R, Grobusch MP, van der Poll T. Predictive value of the qSOFA score in patients with suspected infection in a resource limited setting in Gabon. 2017.
doi:10.1016/j.tmaid.2016.10.014
202. McGill F, Heyderman R, Michael B, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. *J Infect.* 2016;xx:1-34. doi:10.1016/j.jinf.2016.01.007
203. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. *Gastroenterology.* 2006;131(4):1049-56; quiz 1285. doi:10.1053/j.gastro.2006.07.010
204. Krahn K, Regier L. Hypertensive Urgency (Asymptomat Severe Hypertension): Considerations for Management. In: *RxFiles Q&A Summary.* ; 2016.
<http://www.rxfiles.ca/rxfiles/uploads/documents/Hypertensive-Urgency-Management.pdf>. Accessed March 29, 2017.
205. Papadopoulos DP, Sanidas EA, Viniou NA, et al. Cardiovascular Hypertensive Emergencies. *Curr Hypertens Rep.* 2015;17(2):5. doi:10.1007/s11906-014-0515-z
206. Campia U, Chatterjee P, Varounis C, et al. Cardiovascular Hypertensive Crisis: Recent evidence and Review of the Literature. *Front Cardiovasc Med.* 2017;3(3):513389-51.
doi:10.3389/fcvm.2016.00051
207. TB DOTS Strategy Coordination ND of H. *National Tuberculosis Management Guidelines 2014*. Pretoria: Department of Health, Republic of South Africa 2014; 2014.

- http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-27.5.2014.pdf. Accessed November 28, 2017.
208. World Health Organization. *Treatment of Tuberculosis Guidelines*. Fourth. Geneva: WHO Press; 2010.
http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1. Accessed November 28, 2017.
209. Leonard JM. Central nervous system tuberculosis. In: Post TW, ed. *UpToDate*. Waltham, MA: UpToDate; 2017. https://www.uptodate.com/contents/central-nervous-system-tuberculosis?source=see_link. Accessed November 28, 2017.
210. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet*. 1997;350(9094):1795-1798. doi:10.1016/S0140-6736(97)08140-3
211. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. *Thromb Haemost*. 2000;83(3):416-420.
<http://www.ncbi.nlm.nih.gov/pubmed/10744147>. Accessed October 9, 2017.
212. Singh B, Parsaik AK, Agarwal D, Surana A, Mascarenhas SS, Chandra S. Diagnostic Accuracy of Pulmonary Embolism Rule-Out Criteria: A Systematic Review and Meta-analysis. *Ann Emerg Med*. 2012;59(6):517-520.e4. doi:10.1016/j.annemergmed.2011.10.022

Index

- Abbreviations, 160
Acetaminophen Toxicity, 32
Acute Coronary Syndromes, 123
Adult Common Clinical Complaints, 126
Advanced Cardiac Life Support, Adult, 14
Advanced Life Support, Paediatric, 13
Agitated Patient, 112
Alcohol
 CIWA Scale, 36
 Intoxication, 34
 Withdrawal, 35
Altered Mental Status, 25
 History, 26
 Neurologic Assessment, 26
Anaphylaxis, 27, 37
Anemia, 74
 Evaluation, 75
 Transfusions, 76
Asthma
 Adult, 127
 Paediatric, 53
Bacterial Vaginosis, 134
Ballard Neonatal Score, 90
Benzodiazepine Toxicity, 31
Bites, 27, 38
 Animal, 38
 Human, 38
 Mammalian, 38
 Prophylactic Treatment, 38
 Snake, 39
Bronchiolitis, 52
Carbamate Toxicity, 29
Cardiac Disease
 ACS/MI, 123
 Chest Pain, Adult, 121
 Heart Failure, Adult, 94
 Heart Failure, Paediatric, 56
 Rheumatic Fever, 58
 SVT, Adult, 125
Chancroid, 134
Chest Pain, 121
 Risk Scores, 122
Chlamydia, 134
CIWA Scale, 36
Clinical Complaints, Adults, 126
Contents, 2
Convulsions
 Adult, 101
 Paediatric, 42
COPD, Adult, 127
CPAP, Neonatal, 84
CPR
 Adult, 14
 Paediatric, 13
 Summary, 15
Deep Vein Thrombosis, 130
Dehydration
 Diarrhoea Treatment, 44
 Paediatric, 43
 Severe Acute Malnutrition, 64
Diabetic Ketoacidosis
 Adult, 105
 Paediatric, 48
Diarrhoea in Dehydration, 44
DVT, 130
Ear, Nose & Throat Infections, 68
 Mastoiditis, 69
 Otitis Externa, 69
 Otitis Media, 68
 Pharyngitis, 70
 Sinusitis, 70
Electrocardiography (ECG), 114
 A/V Enlargement, 116
 Basics, 114
 Conduction Abnormalities, 117
 Ischemia, 119
 NSTEMI, 120
 STEMI, 119
 Supraventricular Arrhythmia, 118
Electrolyte Protocols, 139
Emergency Protocols, 11
Epigastric Pain, Adult, 126
Epistaxis, 67
Essential Medications, 145

- GI Bleed, Upper, 104
Gonorrhea, 134
Headache, Adult, 126
Heart Failure
 Adult, 94
 Paediatric, 56
Herpes
 healthy patient, 134
 HIV, 138
HIV, Opportunistic Infections, 135
Human Bites, 38
Hydrocarbon Toxicity, 30
Hyperosmolar Hyperglycemic Syndrome, 105
Hyperglycemia
 Adult, 105
 Paediatric, 47
Hypertension, 106
 Emergency, 106
 Essential, 107
 Urgency, 106
Ingestions, 27
 Acetaminophen, 32
 Alcohol, 34
 Benzodiazepines, 31
 Carbamate, 29
 Hydrocarbon, 30
 Insecticide, 29
 Kerosene, 30
 Nerve Gas, 29
 Opioids, 31
 Organophosphate, 29
 Paracetamol, 32
 Paraffin, 30
Insecticide Toxicity, 29
Internal Medicine Protocols, 93
Intra-osseous Lines, 21
Jaundice
 Neonatal, 88
 Phototherapy, 88
Kerosene Toxicity, 30
Kidney Disorders
 Acute Kidney Injury, Adults, 111
 Paediatric, 49
UTI/Pyelonephritis, Paediatric, 51
Liver Failure, 108
 Work-up, 109
Malaria, 22
 Co-infection, 23
 Complications, 23
 Medications, 23
 Testing, 22
 Uncomplicated, 24
Malnutrition, 63
 Classification, 63
 Dehydration, 64
 Feeding, 66
 Severe Acute Malnutrition, 63
Mastoiditis, 69
Medications
 Compatibility Table, 159
 Formulary, 145
 Malaria, 23
 Resuscitation, 20
Meningitis
 Adult, 102
 Paediatric, 54
Myocardial Infarction, 123
National Institute of Health
 Stroke Scale, 98
Neonatal
 CPAP, 84
 Feeding, 82
 Fluid Requirements, 82
 Jaundice, 88
 Maturity Scores, 90
 Sepsis, 85
Neonatal Protocols, 81
Nerve Gas Toxicity, 29
Neurological Assessment, 26
Opioid Toxicity, 31
Opportunistic Infections in HIV, 135
 Candida, 135
 Cryptococcal meningitis, 136
 Cryptosporidiosis, 137
 Cytomegalovirus (CMV), 138
 Herpes, 138
 Histoplasmosis, 137
 Mycobacterium Avium Complex

- (MAC), 137
Pneumocystis jiroveci pneumonia (PCP), 136
Prophylaxis, 135
Toxoplasmosis, 136
Varicella, 138
Organophosphate Toxicity, 29
Otitis Externa, 69
Otitis Media, 68
Paediatric Protocols, 41
Pain Management, 77
 2 months to 7 years, 78
 4-12 Years, 79
 Neonatal, 77
 WHO Analgesic Ladder, 80
Paracetamol Toxicity, 32
Paraffin Toxicity, 30
PE, 131
Pharyngitis, 70
Physical Maturity Score, Neonatal, 91
Pneumonia
 Paediatric, 46
Poisoned Patient, 28
Potassium, 142
 Hyperkalemia, 143
 Hypokalemia, 142
Protocols
 Electrolytes, 139
 Emergency, 11
 Internal Medicine, 93
 Neonatal, 81
 Paediatric, 41
Pulmonary Embolism, 131
Reactive Airway Disease
 Paediatric, 52
References, 161
Resuscitation Medications, 20
Rheumatic Fever, 58
Sepsis
 Adult, 99
 Neonatal, 85
 Paediatric, 45
 SOFA Score, 99
Severe Acute Malnutrition, 63
 Admission Criteria, 64
 Complicated, 63
 Dehydration, 63, 64
 Feeding, 66
Sexually Transmitted Diseases, 132
Sickle Cell Disease, 59
 Acute Chest Syndrome, 62
 Acute Management, 60
 Home Medications, 59
 Stroke, 61
Sinusitis, 70
Snake Bites, 39
 Types of Envenomation, 40
Sodium, 140
 Hypernatremia, 141
 Hyponatremia, 140
Stroke, 96
 NIHealth Stroke Scale, 98
Supraventricular Tachycardia, 125
Syncope, Adult, 126
Syphilis, 134
Tetanus Prophylaxis, 38
Transfusions, 76
Transient Ischemic Attack, 96
Triage, Paediatric, 12
Tuberculosis
 Adult, 128
 Paediatric, 71
 Paediatric Scoring Systems, 71
 Paediatric Treatment, 73
Upper GI Bleed, 104
Violent Patient, 112
Vital Signs, 17
 Blood Pressure by Age,
 Female, 18
 Male, 19
 Heart Rate by Age, 17
 Respirations by Age, 17
Weight Estimation, Paediatric, 16
Wheezing Paediatric, 52